Skip to content

Please find below the online abstract Poster Walks of the last EAHP Congresses.
Please select the desired annual Congress to view the posters presented in the different topic categories.

28th Congress of the EAHP

National Poster Prize Winners

PDF DocumentPoster TitlePoster Number
PDF DocumentEXTEMPORANEOUS FLUCYTOSINE 15,5% INTRAVAGINAL GEL TO TREAT REFRACTORY CANDIDA GLABRATA VULVOVAGINTIS – CASE REPORTNP-001
MEDICATION SAFETY: STRATEGIES & OPPORTUNITIES IN CLINICAL PHARMACY PRACTICENP-002
PDF DocumentPATIENT MEDICINE GUIDES SUPPORT SAFE MEDICATION TREATMENT AND DISCHARGE FROM THE HOSPITAL IN PAEDIATRIC SPECIALISED MEDICAL CARENP-003
PDF DocumentPALL-OLU.DE: A NEW DATABASE ON THE OFF-LABEL USE OF DRUGS IN PALLIATIVE MEDICINENP-004
PDF DocumentUNAUTHORISED MEDICATION USE IN ESTONIAN HOSPITALSNP-005
PDF DocumentDRUGHOST, THE FIRST DATABASE OF UNAVAILABLE DRUGS IN EUROPE—AN ITALIAN MODEL: DATA ONE YEAR AFTER THE START OF THE PLATFORMNP-006
VALIDATION OF ANTIMICROBIAL DEFINED DAILY DOSE (DDD) FOR THE PAEDIATRIC POPULATION: FINAL RESULTS OF KIDDDS PROJECTNP-007
PDF DocumentCASE REPORT : SINGLE-USE CRANIAL DRILLS, HIGH-RISK DEVICES!NP-008
BARRIERS AND FACILITATORS TO PHARMACY PROFESSIONALS’ SPECIALIST PUBLIC HEALTH SKILLS: A MIXED METHODS UK-WIDE PHARMACEUTICAL PUBLIC HEALTH EVIDENCE REVIEWNP-009
PDF DocumentCOMPATIBILITY OF LOCAL ANESTHETIC AND CORTICOSTEROID MIXTURES IN TRANSFORAMINAL EPIDURAL STEROID INJECTIONSNP-010
LINEZOLID THERAPEUTIC DRUG MONITORING AMONG CRITICALLY ILL ADULT PATIENTS AFTER CARDIOVASCULAR SURGERYNP-011
IMPROVING THE CLINICAL PHARMACIST HANDOVER PROCESS USING AN ADAPTED ISBAR COMMUNICATION TOOL WHEN TRANSFERRING PATIENTS FROM CORK UNIVERSITY MATERNITY HOSPITAL (CUMH) TO AN INTENSIVE CARE UNIT (ICU) WITHIN CORK UNIVERSITY HOSPITAL (CUH).NP-012

Section 1: Introductory Statements and Governance

PDF DocumentPoster TitlePoster Number
PDF DocumentANALYSIS OF THE USE OF ORAL ONCOLOGY TARGETED THERAPIES IN A REGION OF SPAIN1ISG-001
PDF DocumentPHARMACIST RISK STRATIFICATION: A CHARACTERISATION OF PATIENTS WITH LOW SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR WHO DIED WITHIN 90 DAYS OF HOSPITAL DISCHARGE1ISG-002
PDF DocumentPHARMACIST RISK STRATIFICATION: A CHARACTERISATION OF PATIENTS WITH LOW SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR WHO DIED WITHIN 90 DAYS OF HOSPITAL DISCHARGE1ISG-002
PDF DocumentDIGITAL TRANSFORMATION OF THE HOSPITAL/TERRITORIAL PHARMACY – TELEPHARMACY NEW DIMENSION OF PATIENT CARE MODELS1ISG-003
PDF DocumentMULTIDISCIPLINARY MANAGEMENT OF CENTRAL VENOUS CATHETERS (CVCS) IN HEMODIALYSIS PATIENTS.1ISG-004
ASSESSMENT OF A MANAGEMENT TOOL REGARDING MEDICAL DEVICE VIGILANCE1ISG-005
PDF DocumentECONOMIC SAVING OF THE PREPARATION OF SUBCUTANEOUS FORMULATIONS COMPARED TO INTRAVENOUS: FOCUS ON DARATUMUMAB IN THREE HEALTHCARE COMPANIES1ISG-006
PDF DocumentHTA ANALYSIS FOR THE INCLUSION OF ANDEXANET ALFA (AA) WITHIN THE HOSPITAL THERAPEUTIC HANDBOOK (HTH) – THE EXPERIENCE OF AN ITALIAN CENTER SPECIALIZING IN CARDIOVASCULAR DISEASES1ISG-007
USABILITY EVALUATION OF AN INSULIN MANAGEMENT SOLUTION WITHIN AN ELECTRONIC PATIENT RECORD1ISG-008
PDF DocumentPHARMACOECONOMIC ANALYSIS OF AN ALTERNATIVE DOSAGE REGIMEN FOR PALIVIZUMAB1ISG-009
PDF DocumentECONOMIC IMPACT OF THE CLINICAL PHARMACIST ON THE REDUCTION OF DRUG-RELATED PROBLEMS BEFORE THE INITIATION OF AN ANTI-TUMOR TREATMENT – A PROSPECTIVE MULTICENTER TRIAL1ISG-010
PDF DocumentOPPORTUNITY FOR DAILY HOME-BASED MANAGEMENT OF CHRONIC PATIENTS FROM THE SAME AREA USING AN INTERPROFESSIONAL NETWORK MODEL DEVISED, SET UP AND IMPLEMENDET FOR THE COVID-191ISG-011
PDF DocumentBALANCING CLINICAL BENEFITS AND COST SAVINGS: COMPASSIONATE DRUG USE AT AN ITALIAN UNIVERSITY HOSPITAL – EVIDENCE AND INSIGHTS1ISG-012
BALANCING CLINICAL BENEFITS AND COST SAVINGS: COMPASSIONATE DRUG USE AT AN ITALIAN UNIVERSITY HOSPITAL – EVIDENCE AND INSIGHTS1ISG-012
PDF DocumentREAL-LIFE DATA OF CDK4/6 INHIBITORS PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN LOCALLY ADVANCED OR METASTATIC BREAST CANCER: EFFECTIVENESS EVALUATION1ISG-013
PDF DocumentSUSTAINABLE HEALTHCARE: AN EXAMPLE OF PHARMACEUTICAL INTERVENTION1ISG-014
PDF DocumentASSESSMENT OF PREPARATORY STAFF’S KNOWLEDGE OF CARCINOGENIC, MUTAGENIC AND REPROTOXIC (CMR) RISKS1ISG-015
PDF DocumentOCRELIZUMAB FOR THE TREATMENT OF RECAPTING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN NATIONAL HEALTH SYSTEM: A COST EFFECTIVENESS ANALYSIS1ISG-016
PDF DocumentTHE THREE HORIZONS METHOD AS A TOOL FOR DEFINING THE HOSPITAL PHARMACY RESIDENT OF THE FUTURE(HPRF)1ISG-017
TEN-YEAR DRUG SURVIVAL ANALYSIS IN MODERATE TO SEVERE PLAQUE PSORIASIS FIRST-LINE TREATMENT1ISG-018
PDF DocumentDO ALL SURGICAL SPECIALTIES HAVE AN IDENTICAL CARBON FOOTPRINT WHITIN AN AMBULATORY UNIT ?1ISG-019
PDF DocumentDRUG DAY THERAPY APPLIED TO LUSPATERCEPT: RESULTS OBTAINED IN AN ITALIAN ANTIBLASTIC DRUG UNIT1ISG-020
DRUG DAY THERAPY APPLIED TO LUSPATERCEPT: RESULTS OBTAINED IN AN ITALIAN ANTIBLASTIC DRUG UNIT1ISG-020
PDF Document1 YEAR-REVIEW OF THE EKOSONIC® ENDOVASCULAR SYSTEM (BOSTON SCIENTIFIC) IN THE MANAGEMENT OF PULMONARY EMBOLISM IN AN INTERVENTIONAL CARDIOLOGY DEPARTMENT1ISG-021
PDF DocumentHOSPITAL PHARMACISTS’ PERCEPTIONS OF THEIR PROFESSION IN TWO EUROPEAN COUNTRIES1ISG-022
PDF DocumentECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL1ISG-023
ECONOMIC IMPACT DERIVED FROM PARTICIPATION ON ANTIRETROVIRAL THERAPY CLINICAL TRIALS IN A THIRD-LEVEL HOSPITAL1ISG-023
PDF DocumentSINGLE-USE MEDICAL DEVICES IN THE TREATMENT OF CHRONIC DISEASES: WHAT IS THE ENVIRONMENTAL IMPACT?1ISG-024
PDF DocumentANALYSIS OF THE COMPLEXITY OF THE CLINICAL TRIALS CARRIED OUT IN A THIRD-LEVEL HOSPITAL1ISG-025

Section 2: Selection, Procurement and Distribution

PDF DocumentPoster TitlePoster Number
PDF DocumentCLINICAL IMPACT AND COST SAVINGS OF AN OUTPATIENT ANTIMICROBIAL THERAPY PROGRAMME: A FOCUS ON SELF-ADMINISTRATION2SPD-001
PDF DocumentEVALUATION OF THE EFFECTIVENESS AND RELATED COST OF ONCOLOGY DRUGS USED IN SPECIAL SITUATIONS, IN A THIRD-LEVEL UNIVERSITY HOSPITAL2SPD-002
PROPER MANAGEMENT AND ECONOMIC BURDEN OF UNUSED MEDICATIONS DISPOSAL IN A SUSTAINABLE LATIN AMERICAN HOSPITAL: A RETROSPECTIVE STUDY2SPD-003
BUDGETARY IMPACT OF THE INTRODUCTION OF CABOTEGRAVIR PLUS RILPIVIRINE LONG-ACTING IN A THIRD LEVEL HOSPITAL2SPD-004
PDF DocumentALTERNATIVE TO THE TREATMENT OF POOR GRAFT FUNCTION AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION: ELTROMBOPAG2SPD-005
IMPACT AND CONSEQUENCES OF THE USE OF HUMAN POLYVALENT IMMUNOGLOBULIN DURING THE COVID-19 PANDEMIC (2019-2022)2SPD-006
PDF DocumentUSE AND COST EVOLUTION OF ADALIMUMAB OVER EIGHT YEARS IN A LOCAL HOSPITAL2SPD-007
PDF DocumentSWITCHING TO A BIOSIMILAR ADALIMUMAB IN DUTCH UNIVERSITY MEDICAL CENTERS: IT IS NOT THAT HARD!2SPD-008
A FIVE-YEAR RETROSPECTIVE REPORT ON COMPREHENSIVE MEDICINE PROCUREMENT WITHIN A PUBLIC GROUP PROCUREMENT ORGANISATION2SPD-009
PDF DocumentIDENTIFYING AND QUANTIFYING DRUG-RELATED WASTE IN A HEALTHCARE ESTABLISHMENT2SPD-010
PDF DocumentAVAILABILITY OF LIQUID ANTIMICROBIALS – A NATIONAL ANALYSIS OF THE CURRENT SUPPLY SITUATION2SPD-011
PDF DocumentAPPLICATION OF FAILURE MODE AND EFFECTS ANALYSIS TO IMPROVE AUTOMATED DISPENSING CABINETS’ DRUG STOCK MANAGEMENT PROCESSES2SPD-012
PDF DocumentA COMPARATIVE LIFE CYCLE ASSESSMENT OF DIFFERENT PACKAGING OPTIONS FOR ALBUMIN DISTRIBUTION2SPD-013
PDF DocumentECO-CONSCIOUS HEALTHCARE PRODUCTS SUPPLY: INVESTIGATING THE EFFECTS OF FEWER ORDERS2SPD-014
INTEGRATED HEALTHCARE LOGISTICS: KANBAN SOLUTION FOR MANAGEMENT OF DIALYSIS WAREHOUSES PILOT CASE2SPD-015
PDF DocumentDATA-DRIVEN SELECTION OF A MEDICATION MANAGEMENT MODEL IN HOSPITALISATION WARDS2SPD-016
RISK IDENTIFICATION IN ANTIDOTE AND EMERGENCY PREPAREDNESS2SPD-017
PDF DocumentIMPACT OF INHALERS ON CO2 EMISSION IN A HEALTH AREA2SPD-018
PDF DocumentTOWARDS A SUSTAINABLE OPERATING ROOM : FEEDBACK ON ACTIONS CARRIED OUT AROUND MEDICAL DEVICES2SPD-019
DESIGN AND EVALUATION OF AN INNOVATIVE AIRBORNE TRANSPORT SYSTEM FOR BLOOD-DERIVED DRUGS UNDER EMERGENCY CONDITIONS2SPD-020

Section 3: Production and Compounding

PDF DocumentPoster TitlePoster Number
PDF DocumentTOPICAL COMPOUNDED CLINDAMYCIN SOLUTION MADE FROM ORAL DOSAGE FORMS, CONTROL AND STABILITY STUDY3PC-001
STABILITY OF TENECTEPLASE SYRINGES AFTER FRACTIONATION3PC-002
PDF DocumentSUITABILITY OF ELASTOMERIC PUMPS FOR DRUG STORAGE3PC-003
PDF DocumentDRUG WASTE OF READY-TO-ADMINISTER SYRINGES IN THE INTENSIVE CARE UNIT: ASEPTICALLY PREPARED SYRINGES VERSUS PREFILLED STERILISED SRYINGES3PC-004
PDF DocumentPREPARATION OF EPICUTANEOUS TESTS WITH MINOXIDIL AT 2% AND 5%.3PC-005
PDF DocumentSTABILITY STUDY OF CLOBAZAM LIQUID ORAL FORMS FOR PEDIATRIC PATIENTS3PC-006
PDF DocumentCONTAINMENT PERFORMANCE ASSESSMENT OF CHEMFORT® (ONGUARD®2) CLOSED SYSTEM TRANSFER DEVICE ACCORDING TO 2016 DRAFT NIOSH PROTOCOL AT FIRST AND TENTH ACTIVATIONS END OF SHELF LIFE.3PC-007
PDF DocumentSTABILITY OF PARENTERAL NUTRITION ADMIXTURES: FOCUS ON PRECIPITATION.3PC-008
PDF DocumentTHE EFFECT OF ACCELERATED LIGHT (STRESS) AND NATURAL SUNLIGHT EXPOSURES ON CETUXIMAB (ERBITUX®): EVALUATION OF AGGREGATE FORMATION AND FUNCTIONALITY3PC-009
PDF DocumentDEVELOPMENT OF A STABLE PARENTERAL SOLUTION OF TOPIRAMATE FOR EMERGENCY TREATMENT OF STATUS EPILEPTICUS3PC-010
PDF DocumentMUCOSECTOMY : FEASIBILITY STUDY OF THE AUTOMATED PREPARATION OF A STERILE SOLUTION OF 5/10% FRUCTOSE GLYCEROL.3PC-011
PDF DocumentCONTENT UNIFORMITY OF SODIUM BENZOATE CAPSULES: VALIDATION OF A METHOD USING QCPREP®3PC-012
PDF DocumentRADIOPHARMACEUTICAL SINGLE-VIAL COLD KIT FORMULATION OF FAPI-04, AN EXPERIMENTAL VECTOR FOR GALLIUM-68 PET IMAGING IN ONCOLOGY3PC-013
PDF DocumentPHYSICOCHEMICAL STABILITY OF BEVACIZUMAB 25 MG/ML CONCENTRATE (VEGZELMA®) IN ORIGINAL GLASS VIALS AFTER FIRST OPENING3PC-014
PDF DocumentMICROBIOLOGICAL PERFORMANCE QUALIFICATION OF THE ROBOTIC SYSTEMS APOTECASYRINGE AND APOTECAUNIT3PC-015
PDF DocumentPHYSICOCHEMICAL STABILITY OF MOXIFLOXACIN 1 MG/0,2 ML SYRINGES FOR INTRACAMERAL ADMINISTRATION3PC-016
PDF DocumentELABORATION OF DEFEROXAMINE EMULSION 0.5% FOR HYPERPIGMENTATION DUE TO INTRAVENOUS IRON EXTRAVASATION3PC-017
PDF DocumentGLASS AMPOULE HANDLING PRACTICES IN DUTCH HEALTHCARE: A COMPREHENSIVE ASSESSMENT3PC-018
PDF DocumentDEVELOPMENT A TOPICAL EMULSION FOR THE TREATMENT OF THIRD-DEGREE BURN PATIENTS CANDIDATES FOR SKIN GRAFT3PC-019
PDF DocumentPREVENTION OF INFECTIOUS RISK IN PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ALPHA INHIBITORS (ANTI-TNFΑ)3PC-020
PDF DocumentFORMULATION OF VORICONAZOLE OVULES AND EFFICACY IN VULVOVAGINAL CANDIDIASIS BY CANDIDA GLABRATA: A CASE REPORT.3PC-021
PDF DocumentDESIGN AND STABILITY STUDY OF AN ISONIAZID AND PYRIDOXINE ORAL LIQUID FORMULATION3PC-022
PDF DocumentNEW ACTIVITIES WITHIN A CLINICAL TRIAL MANAGEMENT UNIT: WHAT NEW RISKS FOR THE STAFF?3PC-023
PDF DocumentIMPLEMENTATION OF A STRATEGY TO OVERCOME THE POTENTIAL TOXIC EFFECTS OF PROPYLENE GLYCOL IN NEONATES3PC-024
PDF DocumentSTABILITY STUDY OF STANDARDISED FLUID THERAPY PREPARED BY THE PHARMACY DEPARTMENT TO TREAT PEDIATRIC DIABETIC KETOACIDOSIS3PC-025
PDF DocumentCOST SAVINGS ASSOCIATED WITH ROMIPLOSTIM REPACKAGING IN PATTIENT WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA3PC-026
USE OF AUTOMATED COMPOUNDING DEVICES IN PEDIATRIC PARENTERAL NUTRITION: A GOOD WAY TO ENSURE SAFETY3PC-027
FOR A MORE ECONOMICAL AND ECOLOGICAL CENTRAL STERILE SERVICES DEPARTMENT (CSSD) : BACK TO THE CONTAINER3PC-028
PDF DocumentPH MEASUREMENT: NOT AS SIMPLE AS WE THINK? A CASE OF SODIUM PERCHLORATE INJECTIONS3PC-029
PDF DocumentSTABILITY STUDY OF AN EPIDURAL ANALGESIC CONCENTRATE FOR INFUSION USED DURING CHILDBIRTH3PC-030
PDF DocumentUSABILITY OF SEMI-SOLID EXTRUSION 3D PRINTING IN HOSPITAL PHARMACY SETTINGS TO PRODUCE PERSONALISED ORAL MEDICATIONS FOR PEDIATRIC PATIENTS3PC-031
PDF DocumentOPTIMIZATION OF AN INSULIN 1 IU/ML EYE DROP FORMULATION FOR THE TREATMENT OF CORNEAL ULCERS3PC-032
KIRO ISOLATOR®: A NEW, RELIABLE, ROBOTIC DEVICE FOR THE COMPOUNDING OF INJECTABLE ANTICANCER DRUGS3PC-033
PDF DocumentFORMULATION OF KETAMINE 1% AND AMITRIPTYLINE 1% GEL IN PRURITIC EPIDERMOLYSIS BULLOSA: A CASE REPORT3PC-034
PDF DocumentPATCH TESTS WITH HAZARDOUS DRUGS: IS IT POSSIBLE TO ENSURE SAFETY DURING PRODUCTION?3PC-035
PDF DocumentRISK ANALYSIS OF THE PHARMACEUTICAL CIRCUIT FOR INJECTABLE CHEMOTHERAPIES AFTER IMPLEMENTATION OF DRUGLOG ®.3PC-036
ALUMINIUM IN PEDIATRIC PARENTERAL NUTRITION: ARE MULTICHAMBER-BAGS THE SAFER CHOICE?3PC-037
PDF DocumentAUTOLOGOUS SERUM EYE DROPS PREPARATION: APPROACH TO THE FILTRATION STEP IMPACT ON THE CONCENTRATION OF ACTIVE MOLECULES3PC-038
EARLY DE-RISKING OF THE STABILITY OF A PERSONALISED, STERILE BACTERIOPHAGE SUSPENSION ON THE BASIS OF ADVANCED KINETIC MODELING3PC-039
PDF DocumentRADIOCHEMICAL PURITY DETERMINATION OF 177LU-PSMA-617: DEVELOPMENT AND VALIDATION OF A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYTICAL METHOD3PC-040
PUBLIC PRODUCTION OF THERAPEUTIC BACTERIOPHAGES3PC-041
PDF DocumentSTERILE AND NON-STERILE COMPOUNDING: RISK ANALYSIS AND IMPROVEMENT MEASURES3PC-042
PDF DocumentINTRAVITREAL PREPARATION OF LIPOSOMAL B AMPHOTERICIN: FROM FORMULATION STUDY TO PREPARATION3PC-043
A PHYSICO-CHEMICAL STABILITY STUDY OF VANCOMYCIN EYE DROP AFTER DIFFERENT THAWING TIMES3PC-044
PDF DocumentRETROSPECTIVE STUDY OVER 6 YEARS OF THE TREND IN FUNGAL CONTAMINATION OF CONTROLLED ATMOSPHERE AREAS WITHIN A CELL THERAPY UNIT.3PC-045
PDF DocumentRISK OF PERSONNEL EXPOSURE TO HAZARDOUS DRUGS IN ROBOTIC COMPOUNDING3PC-046
PDF DocumentPEDIATRIC IV ANTIFUNGAL ADMIXTURES: CENTRALISATION’S ECONOMIC CONSEQUENCES3PC-047

Section 4: Clinical Pharmacy Services

PDF DocumentPoster TitlePoster Number
PDF DocumentCOMPARATIVE ANALYSIS OF TWO PHARMACOKINETIC PROGRAMMES FOR LITHIUM ADJUSTMENT4CPS-001
PHARMACEUTICAL CARE IN POSTOPERATIVE PAIN MANAGEMENT AT ADMISSION AND DISCHARGE4CPS-002
PDF DocumentEVALUATION OF CLINICAL VARIABLES IMPACT ON ENOXAPARIN DOSING AND ANTIXA CONCENTRATION4CPS-003
PDF DocumentIMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS4CPS-004
PDF DocumentDRUG PERSISTENCE OF JAK INHIBITORS COMPARED TO BIOLOGIC DRUGS IN REAL-WORLD PRACTICE IN PATIENTS WITH RHEUMATOID ARTHRITIS4CPS-005
PDF DocumentADHERENCE TO NEBULIZED ANTIBIOTICS IN CYSTIC FIBROSIS PATIENTS AFTER STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR4CPS-006
PDF DocumentADALIMUMAB IN THE TREATMENT OF RECALCITRANT SWEET SYNDROME: A CASE REPORT4CPS-007
PDF DocumentANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO ANTITHROMBOTIC DRUGS IN EMERGENCY DEPARTMENT4CPS-008
PDF DocumentNEONATAL DIAGNOSIS AND TREATMENT OF STIFF BABY SYNDROME: A CASE REPORT4CPS-009
CAN ERENUMAB IMPROVE QUALITY OF LIFE PERCEIVED BY PATIENTS?4CPS-010
PDF DocumentREAL-WORLD EFFECTIVENESS AND SURVIVAL OF GUSELKUMAB IN PATIENTS WITH PSORIASIS AND PSORIASIC ARTRHITIS: MULTICENTER ANALYSIS IN DAILY CLINICAL PRACTICE BY THE VALENCIAN COMMUNITY PSORIASIS GROUP.4CPS-011
PDF DocumentIMPROVING PARENTAL MEDICATION LITERACY BY PHARMACIST-LED DISCHARGE COUNSELLING IN PAEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION4CPS-012
PDF DocumentINTRAVENOUS LEVETIRACETAM SUPPLETION DURING HAEMODIALYSIS PRESERVED STABLE THERAPEUTIC SERUM CONCENTRATIONS: A CASE REPORT4CPS-013
PDF DocumentREAL WORLD DATA ON THE USE OF PCSK9 INHIBITOR TREATMENTS IN HYPERCHOLESTEROLEMIA4CPS-014
PDF DocumentASSESSMENT OF IN-HOSPITAL ANTIBIOTICS CONSUMPTION PATTERN ACCORDING TO THE WHO AWARE CLASSIFICATION IN A LOCAL HEALTH AUTHORITY4CPS-015
PDF DocumentEXPERIENCES, VIEWS AND ATTITUDES OF HOSPITAL NURSING STAFF TOWARDS THE IMPLEMENTATION OF THE UNIT DOSE DISPENSING SYSTEM FOR INPATIENTS: A QUALITATIVE INTERVIEW STUDY4CPS-016
PDF DocumentCOMPARATIVE STUDY BETWEEN TIXAGEVIMAB/CILGAVIMAB AND SOTROVIMAB IN PATIENTS WITH COVID-19: A MONOCENTRIC EXPERIENCE AT UNIVERSITY HOSPITAL4CPS-017
PDF DocumentSWITCHING BETWEEN CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN THE PROPHYLAXIS OF MIGRAINE4CPS-018
PDF DocumentDIFFERENCES IN MEROPENEM DOSE ADJUSTMENT WITH CALCULATION OF GLOMERULAR FILTRATION RATE THROUGH DIFFERENT FORMULAS.4CPS-019
PDF DocumentEVALUATION OF THE EFFECTIVENESS OF MONOCLONAL ANTIBODIES AGAINST MIGRAINE HEADACHE4CPS-020
PDF DocumentPERFORMANCE OF MULTIPLE TRIGGER TOOLS IN IDENTIFYING MEDICATION-RELATED HOSPITAL READMISSIONS4CPS-021
THE EFFECT OF DIGITAL CLINICAL DECISION SUPPORT ON PHARMACOTHERAPY IN HOSPITALISED (MORBIDLY) OBESE PATIENTS: A PROSPECTIVE INTERVENTION STUDY4CPS-022
PDF DocumentOPTIMISING BIOLOGIC THERAPY IN SEVERE UNCONTROLLED ASTHMA PATIENTS ON OMALIZUMAB TREATMENT4CPS-023
PDF DocumentANALYSIS OF POLYMEDICATION AND ADEQUACY TREATMENT RECOMMENDATIONS IN PATIENTS WITH MULTIPLE SCLEROSIS IN A TERTIARY LEVEL HOSPITAL.4CPS-024
PDF DocumentMANAGEMENT OF COVID-19 WITH NIRMATRELVIR/RITONAVIR AND TACROLIMUS MONITORING IN RENAL TRANSPLANTATION: A CASE REPORT4CPS-025
PDF DocumentACCEPTABILITY AND WILLINGNESS TO SWITCH ANTIRETROVIRAL TREATMENT IN PATIENTS WITH LONG-ACTING INJECTABLE THERAPY CRITERIA.4CPS-026
PDF DocumentANALYSIS OF CARDIOVASCULAR RISK ASSOCIATED WITH IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE TREATMENT IN PATIENTS WITH CHRONIC LYMPHOID LEUKEMIA4CPS-027
PDF DocumentANALYSIS OF INTERACTIONS DETECTED IN THE CONCOMITANT USE OF ANTINEOPLASTIC AGENTS AND PHYTOTHERAPY IN ONCOHEMATOLOGY PRACTICE AND INTERVENTIONS CARRIED OUT.4CPS-028
PDF DocumentUSE OF TOPICAL 1% CIDOFOVIR ON SKIN LESIONS IN A PATIENT WITH MONKEYPOX4CPS-029
PDF DocumentANALYSIS OF ADHERENCE TO GROWTH HORMONE TREATMENT IN PAEDIATRIC PATIENTS.4CPS-030
A POPULATION PHARMACOKINETIC MODEL OF VEDOLIZUMAB IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PRELIMINARY ANALYSIS4CPS-031
PDF DocumentPHARMACEUTICAL INTERVENTIONS FOR MEDICATION RECONCILIATION IN COMPLEX CHRONICALLY ILL PATIENTS4CPS-032
PDF DocumentREAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF SELECTIVE CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITORS UTILISATION IN METASTATIC BREAST CANCER – REVEAL STUDY4CPS-033
PDF DocumentREAL-WORLD SAFETY AND TOLERABILITY IN PATIENTS TREATED WITH ABEMACICLIB AND ENDOCRINE THERAPY: A RETROSPECTIVE OBSERVATIONAL STUDY4CPS-034
PDF DocumentIMPACT OF ANTIBIOTIC STEWARDSHIP PROGRAMME (ASP) ON ANTIBIOTIC USE AND CLINICAL OUTCOMES IN PATIENTS HOSPITALISED WITH COMMUNITYACQUIRED PNEUMONIA (CAP): RETROSPECTIVE OBSERVATIONAL BEFORE-AFTER STUDY4CPS-035
PDF DocumentEVALUATION OF THE DIAGNOSIS AND ANTIBIOTIC PRESCRIPTION PATTERN IN PATIENTS HOSPITALISED WITH URINARY TRACT INFECTIONS (UTIS)4CPS-036
PDF DocumentINTEGRATION OF THE PHARMACIST IN THE MULTIDISCIPLINARY COMMITTEE OF URO ONCOLOGICAL PATHOLOGY4CPS-037
PDF DocumentCASE REPORT ON AUTONOMIC NEUROPATHY INDUCED BY BORTEZOMIB4CPS-038
DRUG-RELATED PROBLEMS AT HOSPITAL ADMISSION IN ELDERLY PATIENTS WITH CARDIOVASCULAR DISEASES4CPS-039
PDF DocumentADHERENCE TO GUIDELINES AND PRESCRIBING TRENDS OF STATINS IN PATIENTS WITH ACUTE CORONARY SYNDROME4CPS-040
SILENCE SPEAKS LOUDER THAN WORDS: OMISSION OF PRESCRIPTION IN THE EMERGENCY ROOM4CPS-041
PDF DocumentOVERDOSE OF DARBEPOETIN IN PATIENTS WITH CHRONIC KIDNEY FAILURE. ROOM FOR IMPROVEMENT WITH PHARMACIST INTERVENTIONS4CPS-042
PDF DocumentEFFICACY AND SAFETY OF ANTI-CALCITONIN GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES FOR MIGRAINE PROPHYLAXIS: ONE-YEAR REAL-LIFE EXPERIENCE4CPS-043
PDF DocumentPRE-EXPOSURE PROPHYLAXIS DROP-OUT: FOLLOW-UP AND RELINKING THROUGH TELEPHONE CONTACT4CPS-044
PDF DocumentOPTIMISATION OF OMALIZUMAB FOR SEVERE ALLERGIC ASTHMA IN PEDIATRIC POPULATION4CPS-045
PDF DocumentEVALUATION OF HEALTH IMPACT IN INFLIXIMAB-TREATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: INCORPORATION OF PATIENT REPORTED OUTCOME MEASURES (PROMS)4CPS-046
PDF DocumentEVALUATION OF ANTIRESORPTIVE AGENT-RELATED OSTEONECROSIS THERAPY BY MEASURING CONCENTRATIONS OF PENICILLIN G IN JAWBONE4CPS-047
PDF DocumentA COMPLEX, ADHERENCE-IMPROVING PHARMACIST INTERVENTION TO REDUCE HYPERPHOSPHATEMIA IN HEMODIALYSIS PATIENTS4CPS-048
PDF DocumentTREATMENT OF ROSAI DORFMAN’S HISTIOCYTOSIS: CASE REPORT4CPS-049
PDF DocumentPRE-EXPOSURE PROPHYLAXIS FOR HIV INFECTION: PREVALENCE OF SEXUALLY TRANSMITTED INFECTIONS (STIS) AND ADHERENCE DURING THE PROGRAMME4CPS-050
PDF DocumentCOST SAVING IMPACT OF BIOSIMILAR TRASTUZUMAB FOR THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN A HOSPITAL4CPS-051
PDF DocumentEVALUATION OF USTEKINUMAB USE IN INFLAMMATORY BOWEL DISEASES4CPS-052
PDF DocumentOUTCOMES OF INFRADOSED ANTIMICROBIALS PATIENTS WITH BACTEREMIA IN THE EMERGENCY DEPARTMENT4CPS-053
PDF DocumentNETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES FOR MODERATE TO SEVERE ULCERATIVE COLITIS4CPS-054
PDF DocumentPHARMACOGENETICS AND ITS APPLICATIONS IN PERSONALISED MEDICINE: A SYSTEMATIC REVIEW4CPS-055
EFFECTIVENESS AND SAFETY OF ERIBULIN THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER.4CPS-056
PDF DocumentEFFECTIVENESS, SAFETY, AND PATIENT-REPORTED OUTCOME OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS IN CLINICAL PRACTICE4CPS-057
PDF DocumentANALYSIS OF ANTIFUNGAL CONSUMPTION IN AN INTENSIVE CARE UNIT OVER 5 YEARS4CPS-058
SEVENTEEN DRUGS, ONE SAMPLE: ANALYSING MULTIPLE ANTI-TUBERCULOSIS DRUGS SIMULTANEOUSLY USING ONE METHOD4CPS-059
PDF DocumentIMPACT OF OBESITY ON VANCOMYCIN PHARMACOKINETIC PARAMETERS IN ADULT PATIENTS4CPS-060
PDF DocumentSAFETY AND EFFECTIVENESS OF THE OFF-LABEL USE OF CANGRELOR IN PERIOPERATIVE BRIDGING: A CASE SERIES4CPS-061
PDF DocumentPOSITIVE IMPACT OF EXTENDING NATALIZUMAB DOSAGE INTERVAL FROM EVERY 4 WEEKS TO EVERY 6 WEEKS IN MULTIPLE SCLEROSIS PATIENTS4CPS-062
PDF DocumentCLINICAL PHARMACIST IN THE MULTIDISCIPLINARY TEAM IN THE INTENSIVE CARE UNIT IMPROVE THE QUALITY OF MEDICINE THROUGHOUT THE PATIENT’S HOSPITAL STAY4CPS-063
PDF DocumentREVIEW OF USE OF IMMUNOGLOBULINS IN TERTIARY HOSPITAL4CPS-064
PDF DocumentEXPERIENCE OF IMMUNOCHEMOTHERAPY VERSUS STANDARD TREATMENT IN SMALL-CELL LUNG CANCER4CPS-065
PDF DocumentTHERAPEUTIC DRUG MONITORING OF ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE.4CPS-066
EFFECTIVENESS AND SAFETY OF 1 IU/ML TOPICAL INSULIN TO TREAT PERSISTENT CORNEAL ULCERS4CPS-067
PDF DocumentTARGET THERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC): A RETROSPECTIVE ANALYSIS TO GUARANTEE THE APPROPRIATENESS OF THE PRESCRIPTIONS IN OUR HOSPITAL4CPS-068
PDF DocumentOUTPATIENT SATISFACTION IN THE TELEPHARMACY PROGRAMME OF A TERTIARY HOSPITAL PHARMACY SERVICE4CPS-069
PDF DocumentEVALUATION OF AVOIDED COST IN CLINICAL TRIALS WITH IMMUNOTHERAPY IN LUNG CANCER4CPS-070
PDF DocumentANTIBIOTIC CONSUMPTION MONITORING BY AWARE CLASSIFICATION: A SIX MONTHS ANALYSIS4CPS-071
PDF DocumentSETMELANOTIDE IN MONOGENIC OBESITY: A CASE REPORT4CPS-072
PDF DocumentANALYSIS OF THE REASONS FOR CHANGING TREATMENT IN PATJENTS WITH MULTIPLE SCLEROSIS4CPS-073
PDF DocumentDRUG CLASSES COMMONLY RELATED TO MEDICATION ERRORS AT TRANSITION OF CARE4CPS-074
PDF DocumentA SYSTEMATIC REVIEW OF THE TARGET PHARMACOKINETIC/PHARMACODYNAMIC PARAMETERS OF ANTIBIOTICS TREATING GRAM-NEGATIVE INFECTIONS4CPS-075
PDF DocumentEFFECTIVENESS AND SAFETY OF DUPILUMAB AND TRALOKINUMAB IN ATOPIC DERMATITIS IN CLINICAL PRACTICE4CPS-076
PDF DocumentPHARMACEUTICAL INTERVENTIONS AFTER DETECTION OF NON-HANDLING MEDICATIONS IN PATIENTS WITH DYSPHAGIA4CPS-077
PDF DocumentQUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES WITH MULTIPLE MYELOMA TREATEDS WITH DARATUMUMAB4CPS-078
PDF DocumentINDIRECT COMPARISON OF IL-13 INHIBITORS PLUS TOPICAL CORTICOSTEROIDS IN MODERATE TO SEVERE ATOPIC DERMATITIS4CPS-079
PDF DocumentMETASTATIC HER2-POSITIVE BREAST CARCINOMA CASE REPORT: ANTI-HER2 TREATMENT MAINTENANCE DESPITE OLIGOPROGRESSION4CPS-080
PDF DocumentCONSENSUS ON INDICATORS FOR MEDICATION-RELATED READMISSIONS: A DELPHI STUDY4CPS-081
DESCRIPTIVE STUDY OF POST-SURGERY ANALGESIC PRESCRIPTIONS4CPS-082
PDF DocumentMEDICATION RECONCILIATION INTERVENTIONS IN AN EMERGENCY DEPARTMENT AT ADMISSION4CPS-083
PDF DocumentGENOTYPING ANALYSIS OF POLYMORPHISMS IN THE DIAHYDROPYRHYDROMIDINE DEHYDROGENASE (DPYD) GENE PRIOR TO ADMINISTRATION OF FLUOROPIRMIDINES4CPS-084
LONG-TERM PERSISTENCE IN PSORIASIS PATIENTS WITH HIGH RESPONSE TO GUSELKUMAB: A REAL-WORLD RETROSPECTIVE STUDY.4CPS-085
PDF DocumentASSESSMENT OF THE CLINICAL RELEVANCE OF LEVETIRACETAM MONITORING4CPS-086
PDF DocumentADALIMUMAB PERSISTENCE IN CLINICAL PRACTICE AT A REGIONAL HOSPITAL4CPS-087
PDF DocumentFOLIC ACID, FOLINIC ACID AND HEMATOTOXIC TREATMENTS: A REVIEW AT A UNIVERSITY HOSPITAL CENTRE4CPS-088
PDF DocumentCLINICAL PHARMACIST EFFECTIVENESS IN HOSPITALISED PATIENTS: ANALYSIS OF THE INTERVENTION RECORD IN A SECONDARY ACUTE HOSPITAL4CPS-089
PDF DocumentREAL-WORLD PERSISTENCE WITH FREMANEZUMAB VERSUS ERENUMAB AMONG MIGRAINE PATIENTS4CPS-090
PDF DocumentREAL-LIFE PERSISTENCE, EFFECTIVENESS AND SAFETY OF FREMANEZUMAB IN PATIENTS WITH CHRONIC MIGRAINE4CPS-091
PDF DocumentANALYSIS OF ANTIBIOTICS CONSUMPTION AT AN ITALIAN CARDIOLOGY CENTRE: PHARMACOUSE PROFILE ACCORDING TO THE AWARE CLASSIFICATION4CPS-092
PDF DocumentANTIBIOTIC RESISTANCE IN THE HOSPITAL CONTEXT: RETROSPECTIVE ANALYSIS OF ANTIBIOGRAMS, RESISTANCE AND SENSITIVITY PROFILES AT AN ITALIAN HEART CENTER4CPS-093
RISK FACTORS FOR EMERGENCY DEPARTMENT RE-VISIT IN ELDERLY PATIENTS WITH GASTROINTESTINAL BLEEDING SECONDARY TO DIRECT ORAL ANTICOAGULANTS4CPS-094
EXPLORATORY ANALYSIS OF CARDIOVASCULAR EVENTS IN AN ASTHMATIC COHORT4CPS-095
PDF DocumentUSE OF COVID-19 ANTIVIRALS IN PATIENTS PREVIOUSLY TREATED WITH TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS: EXPERIENCE OF AN ITALIAN HOSPITAL4CPS-096
PDF DocumentREAL-WORLD STUDY OF APALUTAMIDE TREATMENT IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN NINE HOSPITALS OF VALENCIAN COMMUNITY.4CPS-097
PDF DocumentEFECTIVENESS AND SAFETY OF LONG-ACTING CABOTEGRAVIR/RILPIVIRINE IN REAL-LIFE POPULATION4CPS-098
PDF DocumentCHIMERIC ANTIGEN RECEPTOR-T CELLS (CAR-T CELLS) AND ANTIBIOTICS : A NOT-SO-INNOCENT ASSOCIATION4CPS-099
PDF DocumentTHE UTILITY OF EARLY PHARMACEUTICAL VALIDATION OF SELECTED HIGH-RISK DRUGS IN A HOSPITAL EMERGENCY DEPARTMENT4CPS-100
PDF DocumentMONITORING METABOLIC SYNDROME IN OLANZAPINE TREATED PATIENTS4CPS-101
PDF DocumentAMIODARONE AND LITHIUM-INDUCED THYROID DYSFUNCTION: WHO INITIATES THE PRESCRIBING CASCADE?4CPS-102
PDF DocumentANALYSIS OF PNEUMONIA ASSOCIATED WITH MECHANICAL VENTILATION IN CRITICALLY ILL PATIENTS UNDERGOING SELECTIVE DIGESTIVE DECONTAMINATION.4CPS-103
PDF DocumentCOMORBIDITY PATTERNS IN THE OLDER HIV PATIENT4CPS-104
PDF DocumentMEDICINES OPTIMISATION FOR PATIENTS IN A NURSING HOME4CPS-105
PDF DocumentAUC-SURVIVAL REANALYSIS OF TROPICS-02 TRIAL WITH SACITUZUMAB GOVITECAN FOR METASTATIC LUMINAL BREAST CANCER.4CPS-106
PDF DocumentADHERENCE TO DAILY ORAL TREATMENT IN MULTIPLE SCLEROSIS4CPS-107
PDF DocumentCLINICAL IMPACT OF PHARMACOKINETIC MONITORING OF INFLIXIMAB AND ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE4CPS-108
PDF DocumentSEX-RELATED DIFFERENCES IN THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS TREATMENT4CPS-109
PDF DocumentSYSTEMATIC REVIEW AND E-QUESTIONNAIRE ON THE SERVICE CHARACTERISTICS, OPERATIONS AND ACTIVITIES OF CENTRES FOR MEDICINES INFORMATION (CMI)4CPS-110
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN PATIENTS UNDER CHRONIC OPIOID TREATMENT ADMITTED TO TRAUMATOLOGY UNITS4CPS-111
PDF DocumentANTIMICROBIAL STEWARDSHIP PROGRAMME INTERVENTIONS IN INTENSIVE CARE UNIT4CPS-112
PDF DocumentTHE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS4CPS-113
PDF DocumentSUBLINGUAL ADMINISTRATION OF TACROLIMUS IN LIVER TRANSPLANT PATIENT WITH INTESTINAL MALABSORPTION: A CASE REPORT4CPS-114
PDF DocumentCHRONIC MIGRAINE REVERSION AND SYMPTOMATIC MEDICATION REDUCTION WITH FREMANEZUMAB4CPS-115
PDF DocumentREAL-WORLD EFFECTIVENESS AND COSTS OF USTEKINUMAB IN PATIENTS DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE4CPS-116
PDF DocumentUPDATE OF STOPP/START CRITERIA IN 2023: WHAT ARE THE IMPACTS ON OUR PHARMACEUTICAL INTERVENTIONS?4CPS-117
PDF DocumentMEDICATION ADHERENCE TO PSORIASIS TREATMENTS: A POPULATION-BASED STUDY4CPS-118
PDF DocumentA REAL-LIFE STUDY OF PHARMACOKINETIC MONITORING: NEPHROTOXIC IMPACT OF AMINOGLYCOSIDES AND VANCOMYCIN4CPS-119
PDF DocumentEFFICACY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY REAL-WORLD ANALYSIS AND COMPARISON WITH THE PIVOTAL STUDY (PS)4CPS-120
PDF DocumentOPTIMISING ANTIDIABETIC TREATMENT FOR ELDERLY PATIENTS ACCORDING TO THEIR FUNCTIONAL STATUS4CPS-121
PDF DocumentANALYSIS OF THE USE AND EFFECTIVENESS OF FIDAXOMICIN IN CLOSTRIDIOIDES DIFFICILE INFECTION4CPS-122
PDF DocumentSARGRAMOSTIM AND LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF CHRONIC VISCERAL LEISHMANIASIS IN HIV CO-INFECTED PATIENT: A CASE REPORT4CPS-123
PDF DocumentMONITORING OF HIGH-COST ANTIBIOTIC’S PRESCRIPTIONS IN ORDER TO ENSURE PRESCRIPTIVE APPROPRIATENESS, PATIENT SAFETY AND CONTAINING EXPENDITURE4CPS-124
PDF DocumentPHARMACEUTICAL CONSULTATIONS DEDICATED TO DIRECT ORAL ANTICOAGULANTS FOR CANCER PATIENTS: A SINGLE-CENTER PROSPECTIVE STUDY4CPS-125
ADHERENCE, PERSISTENCE, AND SWITCHING MEDICATION IN PATIENTS WITH MULTIPLE SCLEROSIS INITIATING ORAL DISEASE MODIFYING THERAPIES: A RETROSPECTIVE REAL-WORLD STUDY4CPS-126
PDF DocumentPERSISTENCE OF BIOLOGICAL DISEASE-MODIFYING DRUGS AND PHOSPHODIESTERASE-4- INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITHIS4CPS-127
PDF DocumentPOTENTIAL DRUG-DRUG INTERACTIONS IN HYPERTENSIVE PATIENTS4CPS-128
PDF DocumentEVALUATION OF THE BENEFIT OF CAROB FLOUR ON NINTEDANIB DIARRHEA IN THE TREATMENT OF DIFFUSE INTERSTITIAL LUNG DISEASE4CPS-129
PDF DocumentRISK OF HYPOKALAEMIA IN HOSPITALIZED PATIENTS ASSOCIATED WITH THE COMBINATION OF DIURETICS4CPS-130
UTILIZATION AND SAFETY PROFILE OF UPADACITINIB IN A TERTIARY HOSPITAL4CPS-131
PDF DocumentRIBOCICLIB IN METASTASIC BREAST CANCER TREATMENT: FRECUENCY AND ANALYSIS OF DIFFERENTS ADVERSE EFFECTS WHICH REQUIRED INTERVENTION4CPS-132
PDF DocumentEFFECTIVENESS AND SAFETY OF ANTI IL-5 DRUGS BENRALIZUMAB AND MEPOLIZUMAB IN SEVERE UNCONTROLLED EOSINOPHILIC ASTHMA PATIENTS4CPS-133
REAL WORLD EVIDENCE OF CEFIDEROCOL IN CLINICAL PRACTICE4CPS-134
PDF DocumentEVALUATION AND MANAGEMENT OF CONSTIPATION IN THE CRITICALLY ILL PATIENT4CPS-135
PDF DocumentANALYSIS OF THE SITUATION OF PHARMACEUTICAL CARE FOR PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES BEFORE AND AFTER THE COVID-19 PANDEMIC4CPS-136
PDF DocumentCEFIDEROCOL: UTILIZATION PROFILE IN THE TREATMENT OF MULTIDRUG-RESISTANT BACTERIA, A RETROSPECTIVE OVERVIEW.4CPS-137
PDF DocumentCEFIDEROCOL: EFFECTIVENESS AND MORTALITY OF MULTIDRUG-RESISTANT BACTERIA INFECTIONS, A RETROSPECTIVE OVERVIEW.4CPS-138
PDF DocumentVORICONAZOLE SERUM CONCENTRATIONS MONITORING4CPS-139
PDF DocumentEXPERIENCE OF USING PALBOCICLIB, RIBOCICLIB AND ABEMACICLIB IN A TERTIARY HOSPITAL4CPS-140
PDF DocumentREAL-LIFE IMPACT OF INCLUDING MONTELUKAST AS PREMEDICATION ON THE INCIDENCE OF INFUSION-RELATED REACTIONS TO ISATUXIMAB AND DESCRIPTION OF RISK FACTORS4CPS-141
COMMUNITY PHARMACY-BASED HBA1C SCREENING FOR EARLY DETECTION OF DIABETES AND PRE-DIABETES4CPS-142
PDF DocumentA DESCRIPTION OF PHARMACISTS’ INTERVENTIONS TO OPTIMISE THE TREATMENT OF ADULTS WITH ORALLY AVAILABLE COVID-DRUG PAXLOVID®4CPS-143
BIOLOGICAL TREATMENTS IN THE PREVENTION OF MIGRAINE: RESTART AND DURATION OF THERAPEUTIC REST4CPS-144
PDF DocumentCOLLABORATIVE IMPLEMENTATION OF ‘WALANT’ (LOCAL ANESTHETIC) TECHNIQUE IN A HAND SURGERY WARD4CPS-145
PDF DocumentECONOMIC IMPACT ON MULTIPLE MYELOMA CLINICAL TRIALS IN THE PHARMACY SERVICE4CPS-146
PDF DocumentOSIMERTINIB: A PROMISING TREATMENT FOR EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER4CPS-147
PDF DocumentEAVLUATION OF DAILY DOSE MANUAL DRUG DISPENSING ACCURACY4CPS-148
CENTRAL VENOUS CATHETER-RELATED BLOODSTREAM INFECTIONS IN PATIENTS ON TOTAL PARENTERAL NUTRITION4CPS-149
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN OBESE PATIENTS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION4CPS-150
PDF DocumentANALYSIS OF ANTIBIOTIC TREATMENT IN PATIENTS WITH VENTILATOR-ASSOCIATED PNEUMONIA4CPS-151
PDF DocumentTHE INCLUSION OF TRAMADOL FOR PARENTERAL USE IN THE NARCOTIC TABLE OF PHARMACOPOEIA: ANALYSIS OF EFFECTS AND CONSUMPTION IN A GENERAL HOSPITAL SETTING4CPS-152
PDF DocumentECONOMIC BENEFIT ANALYSIS ON LUNG CANCER CLINICAL TRIALS: MEDICATION AND MEDICAL TESTS4CPS-153
PDF DocumentTHERAPEUTIC DRUG MONITORING OF AMIKACIN IN NEONATES: ABOUT A NEW PROTOCOL4CPS-154
PDF DocumentPERCEPTION OF HOSPITAL PHARMACIES ABOUT TELEPHARMACY IN THE PROVISION OF HEALTHCARE FOR PEOPLE LIVING WITH HIV4CPS-155
PDF DocumentANALYSIS OF THE PRESCRIPTION PATTERN AND DAYS OF HOSPITALIZATION AVOIDED BY OUTPATIENT INTRAVENOUS ANTIBIOTIC THERAPY AND THE SAFETY OF THIS PRACTICE4CPS-156
PDF DocumentPERSPECTIVES OF PATIENTS AND MEDICAL PROVIDERS ON MULTIDISCIPLINARY MEDICATION RECONCILIATIONS SERVICE IN ADULT PATIENTS UNDERGOING THORACIC AND CARDIOVASCULAR SURGERY (MERITS STUDY)4CPS-157
PDF DocumentRELAPSED/REFRACTORY MULTIPLE MYELOMA AND NEW THERAPEUTIC OPTIONS: EXPERIENCE IN A PHASE I CLINICAL TRIALS UNIT4CPS-158
ANALYSIS OF THE INTERVENTIONS CARRIED OUT IN THE GERIATRIC SERVICE IN COLLABORATION WITH THE INTERNAL MEDICINE AND MICROBIOLOGY SERVICES4CPS-159
PDF DocumentLONG-TERM EFFECTIVENESS AND SAFETY RESULTS OF GALCANEZUMAB IN REAL-WORLD DATA IN MIGRAINE PROPHYLAXIS4CPS-160
PDF DocumentVANCOMYCIN PHARMACOKINETIC MONITORING IN CRITICALLY ILL NEONATAL PATIENTS4CPS-161
“TO ERR IS HUMAN“: PRESENTING CASES OF MEDICATION ERRORS FROM REAL CLINICAL PRACTICE4CPS-162
PDF DocumentEFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN HOSPITALISED PATIENTS WITH HYPERKALAEMIA4CPS-163
PDF DocumentANALYSIS OF USTEKINUMAB INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE ACCORDING TO LINE OF TREATMENT4CPS-164
PDF DocumentDETERMINATION OF PREDICTIVE FACTORS FOR IMMUNE-RELATED TOXICITY IN LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPY4CPS-165
PDF DocumentCOMPREHENSIVE ASSESSMENT OF PHARMACOTHERAPY IN THE COMPLEX CHRONIC PATIENT: COLLABORATION BETWEEN DIFFERENT LEVELS OF CARE4CPS-166
USE OF STANDARD- AND HIGH-DOSE LIPOSOMAL AMPHOTERICIN B AND ITS RELATIONSHIP WITH HYPOMAGNESEMIA4CPS-167
PDF DocumentEFFECTIVENESS, SAFETY AND ADHERENCE TO EVOLOCUMAB IN REAL CLINICAL PRACTICE4CPS-168
PDF DocumentEVALUATION OF ANTICHOLINERGIC DRUG PRESCRIPTION USING A CLINICAL DECISION SUPPORT SYSTEM: A PROSPECTIVE STUDY IN A GERIATRIC REHABILITATION CENTER4CPS-169
PDF DocumentCLINICAL PHARMACY PRIORITISATION ALGORITHM FOR PATIENTS IN PSYCHIATRIC LONG-TERM CARE: A PILOT STUDY4CPS-170
PDF DocumentFIXED-DOSE VERSUS WEIGHT-BASED DOSING REGIMEN OF PEMBROLIZUMAB4CPS-171
PDF DocumentIMPROVING POST-OPERATIVE ANALGESIA AND ASSOCIATED PRESCRIBING IN THE ORTHOPAEDIC SETTING4CPS-172
PDF DocumentPRESCRIPTION OF PSYCHOTROPIC DRUGS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION ON INTEGRASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY4CPS-173
PDF DocumentNASAL ESKETAMINE USE FOR MAYOR DEPRESSIVE DISORDER, FROM A THIRD LEVEL HOSPITAL TO PERIPHERAL MENTAL CENTERS4CPS-174
PDF DocumentEFFECTIVENESS OF IMMUNOTHERAPY AS A FUNCTION OF AGE: METHA-ANALYSIS OF THE APPROVED COMBINATIONS IN FIRST LINE METASTASIC NON-SMALL-CELL LUNG CANCER IN PATIENTS WITHOUT MUTATIONS.4CPS-175
PDF DocumentUSE AND PERSISTENCE OF GUSELKUMAB IN TREATMENT FOR RHEUMATIC AND DERMATOLOGICAL DISEASE4CPS-176
PDF DocumentLONG-ACTING INTRAMUSCULAR ANTIRETROVIRALS: WHAT REAL-WORLD DATA DO WE HAVE?4CPS-177
PDF DocumentEFFECT OF PCSK9 INHIBITORS ON HYPERCHOLESTEROLEMIA4CPS-178
REAL-LIFE ANALYSIS OF THE DEVELOPMENT OF ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND THERAPEUTIC APPROACH.4CPS-179
PDF DocumentSACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: COMPARISON OF OUR DATA TO THE ASCENT TRIAL AFTER TWO YEARS OF EXPERIENCE4CPS-180
PDF DocumentELECTRONIC PRESCRIBING IN THE NEONATAL INTENSIVE CARE UNIT: ANALYSIS OF PRESCRIBING ERRORS AND RISK FACTORS4CPS-181
PDF DocumentDESCRIPTION OF A CLINICAL PHARMACIST INTERVENTION FOCUSED ON MANAGEMENT OF A CHRONIC DISEASE AT HOSPITAL: THE EXAMPLE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).4CPS-182
PHARMACIST-LED OPT-OUT CESSATION TREATMENT PROTOCOL FOR COMBUSTIBLE TOBACCO SMOKING4CPS-183
PDF DocumentTHERAPIES IN ENDOMETRIAL CANCER WITH DNA MISMATCH REPAIR DEFICIENT OR MICROSATELLITE INSTABILITY: A SYSTEMATIC REVIEW4CPS-184
PDF DocumentANALYSIS OF THE USE OF MEDICATION NOT INCLUDED IN THE PHARMACOTHERAPEUTIC GUIDE OF A TERTIARY HOSPITAL4CPS-185
PDF DocumentIMPLEMENTATION OF A PATIENT STRATIFICATION MODEL IN OUTPATIENT PHARMACY FOR IMMUNE-MEDIATED DERMATOLOGICAL DISEASES4CPS-186
PDF DocumentDEVELOPMENT OF A POPULATION PHARMACOKINETIC MODEL OF CYCLOSPORINE4CPS-187
IMPLEMENTATION OF THIOPURINE PHARMACOGENETICS TO IMPROVE PEDIATRIC SAFETY AT A TERTIARY HOSPITAL4CPS-188
PDF DocumentLOCAL EXPERIENCE ON THE USE OF CANNABIDIOL FOR THE TREATMENT OF REFRACTORY EPILEPSY. SAFETY AND EFFICACY ON A 10 PATIENT’S COHORT4CPS-189
PDF DocumentDEVELOPMENT OF TRANSMURAL PHARMACEUTICAL CARE IN A GENERAL HOSPITAL4CPS-190
PDF DocumentPRE-RADIOIODINE THERAPY SURGICAL MODALITIES: COMPARION OF POST-OPERATIVE THYROGLOBULIN LEVELS IN PATIENTS UNDERGOING 1- OR 2-STEP THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER4CPS-191
PDF DocumentASTHMA AND RISK OF CARDIOVASCULAR EVENTS: A RETROSPECTIVE STUDY4CPS-192
PDF DocumentEFFECTIVENESS AND SAFETY OF INTRAVENOUS USTEKINUMAB INTENSIFICATION IN CROHN’S DISEASE WITH LOSS OF RESPONSE OR PARTIAL RESPONSE TO SUBCUTANEOUS THERAPY4CPS-193
PDF DocumentEVOLUTION OF HOSPITAL CLINICAL PHARMACY SERVICES IN FINLAND DURING YEARS 2017-2022: A FOLLOW-UP SURVEY4CPS-194
PDF DocumentCHARACTERIZATION OF INJECTABLE FORMULATIONS AND OPTIMIZATION OF THEIR DELIVERY BY ENTERAL TUBE: A PHYSICOCHEMICAL AND PHYSIOLOGICAL APPROACH4CPS-195
PDF DocumentASSESSMENT OF ORAL DRUG THERAPY REGARDING ABSORPTION DISORDERS IN PATIENTS WITH INTESTINAL OSTOMIES – AN OBSERVATIONAL STUDY4CPS-196
PDF DocumentTHE KTIA-SCORAC STUDY : SECURING THE MEDICATION MANAGEMENT OF ELDERLY PATIENTS BY THE SYSTEMATIC EVALUATION OF ANTICHOLINERGIC LOAD SCORES VIA A CLINICAL DECISION SUPPORT SYSTEM4CPS-197
EVALUATION OF PROA TEAM INTERVENTION ACCEPTANCE RATES THROUGH AN AUTOMATED MEASUREMENT SYSTEM4CPS-198
PDF DocumentCOMPARATIVE EVALUATION OF ENZYME-LINKED IMMUNOSORBENT ASSAY VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS4CPS-199
PDF DocumentTRIPLE THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS BASED ON A PHARMACOLOGICAL TREATMENT ALGORITHM4CPS-200
PDF DocumentCLINICAL EXPERIENCE OF TYROSINE-KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA4CPS-201
PDF DocumentEVALUATION OF THE EXCHANGE OF ANTICGRP MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CHRONIC REFRACTORY MIGRAINE4CPS-202
PDF DocumentDEVELOPMENT AND VALIDATION OF A DATA COLLECTION TOOL TO EVALUATE PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT4CPS-203
PDF DocumentMONITORING OF LINEZOLID IN HEMODIALYSIS: A CLINICAL CASE4CPS-204
PDF DocumentRESULTS OF ANTIBIOTIC PROPHYLAXIS IN ACUTE BRONCHOASPIRATION PNEUMONITIS4CPS-205
PDF DocumentPRE-EXPOSURE PROPHYLAXIS, ARE WE DOING IT RIGHT?4CPS-206
EVALUATION OF PROSTATIC SPECIFIC ANTIGEN DEPLETION WITH ABIRATERONE AS A PRONOSTATIVE FACTOR FOR SURVIVAL IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER4CPS-207
PDF DocumentANALYSIS OF THE IMPLEMENTATION OF A MULTIDISCIPLINARY PHARMACEUTICAL CARE PROJECT FOR GERIATRIC HEMATO-ONCOLOGY PATIENTS4CPS-208
PDF DocumentCOMPARISON OF TWO PHARMACOKINETIC/PHARMACODYNAMIC INDICES IN CRITICALLY ILL PATIENTS TREATED WITH AMIKACIN4CPS-209
PDF DocumentHOME INFUSION CHEMOTHERAPY TREATMENT FOR PATIENTS WITH MALIGNANT HAEMATOLOGICAL DISORDERS4CPS-210
PDF DocumentTITLE: ANALYSIS OF THE PRESCRIPTION OF VITAMIN D SUPPLEMENTS IN A SOCIAL HEALTH CENTER.4CPS-211
PDF DocumentMANAGEMENT OF POST CAR-T NEUROTOXICITY USING ANAKINRA. A CASE REPORT4CPS-212
PDF DocumentRESULTS OF ANTIBIOTIC TREATMENT OF AORTIC ENDOPROSTHESIS INFECTIONS IN PATIENTS NOT CANDIDATES FOR SURGERY4CPS-213
PDF DocumentMONITORING OF TACROLIMUS IN A KIDNEY TRANSPLANTED COHORT4CPS-214
PDF DocumentADJUSTMENT OF ANTIBIOTICS THROUGH THE HEMOFILTER: A CASE REPORT4CPS-215
PDF DocumentEFFICACY AND SAFETY ANALYSIS OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS: REAL-LIFE DATA.4CPS-216
PDF DocumentA COMPARATIVE EVALUATION OF THE LONG-TERM EFFECTIVENESS OF GUSELKUMAB AND RISANKIZUMAB IN THE CLINICAL MANAGEMENT OF PLAQUE PSORIASIS.4CPS-217
PDF DocumentOPIOID PRESCRIBING FOR ACUTE NON-CANCER PAIN, POST-OPERATIVE PAIN AND POST-PROCEDURE PAIN BY SURGICAL TEAMS AT A TERTIARY HOSPITAL: 1-DAY AUDIT4CPS-218
PDF DocumentBEYOND THE EXPECTED: THE ENHANCED DETECTION OF DRUG RELATED PROBLEMS, THE MOST OF A PHARMACEUTICAL DECISION SUPPORT SYSTEM4CPS-219
PDF DocumentEVALUATION OF THE IMPLEMENTATION OF A PRE-EXPOSURE PROPHYLAXIS PROGRAM. 2 YEARS EXPERIENCE IN OUR REGION4CPS-220
PDF DocumentEVALUATION OF THE RELEVANCE OF STATINS PRESCRIPTION IN THE ELDERLY : TOWARDS A DEPRESCRIPTION ?4CPS-221
THE REAL LIFE OF BENZODIAZEPINES IN GERIATRIC DEPARTMENT : CAN THE PHARMACIST HAVE AN IMPACT ?4CPS-222
PDF DocumentA STUDY ON THE PERCEPTION OF ELDERLY PATIENTS ON THE EXPIRATION DATE AND STORAGE OF PRESCRIBED MEDICATION: A QUESTIONNAIRE STUDY4CPS-223
PDF DocumentMEDICATION RECONCILIATION IN A SURGERY DEPARTMENT: 6-MONTHS EXPERIENCE4CPS-224
PDF DocumentDEFINING INTERNATIONAL CRITICAL CARE PHARMACIST ASPIRATIONS TO THE MANAGEMENT OF SEPSIS4CPS-225
PDF DocumentPHARMACEUTICAL INTERVENTION ON THE ADEQUACY OF THE INDICATION OF SEMAGLUTIDE IN DIABETES MELLITUS 24CPS-226
PDF DocumentPHARMACEUTICAL REVIEW AND PHARMACEUTICAL INTERVENTION IN A NURSING HOME TO ENHANCE THE MEDICATION MANAGEMENT OF RESIDENTS.4CPS-227
PDF DocumentIMPACT AND ACCEPTANCE OF PHARMACEUTICAL INTERVENTIONS FOR EARLY MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT4CPS-228
PDF DocumentSUSTAINABILITY: A PERSON-CENTRED, WHOLE SYSTEMS APPROACH TO MEDICINES OPTIMISATION4CPS-229
PDF DocumentCLINICAL PHARMACOGENOMICS FOR A SAFER USE OF FLUOROPYRIMIDINES4CPS-230

Section 5: Patient Safety and Quality Assurance

PDF DocumentPoster TitlePoster Number
INCIDENCE OF HEPATITIS B VIRUS REACTIVATION IN PSORIASIS PATIENTS TREATED WITH CYTOKINE INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS5PSQ-001
PRESCRIBING TREND OFFLUOROQUINOLONES FOLLOWING LATEST EMA RECOMMENDATIONS5PSQ-002
PDF DocumentIMPROVING MEDICINES MANAGEMENT OF INPATIENT PARKINSON’S DISEASE PATIENTS BY MAKING PHARMACY INTERVENTIONS5PSQ-003
COMPARISON BETWEEN BEERS 2019 CRITERIA AND THE EURO-FORTA 2018 LIST IN THE IDENTIFICATION OF POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY PATIENTS IN THE PRIMARY HEALTHCARE CONTEXT5PSQ-004
PDF DocumentUTILITY OF THE THERAPEUTIC COMPLEXITY INDEX ADAPTED TO CRITICALLY ILL PATIENTS AS A METHOD OF STRATIFICATION FOR PHARMACEUTICAL CARE5PSQ-005
PDF DocumentFREQUENCY OF CREATININE TESTING AND ACUTE KIDNEY INJURY IDENTIFICATION AND STAGING.5PSQ-006
PDF DocumentA REVIEW ON MEDICATION RECONCILIATION IN THE PERIOPERATIVE PERIOD: VARIABLES THAT LEAD TO MEDICATION ERRORS.5PSQ-007
PDF DocumentIMMUNE-MEDIATED HEPATITIS SECONDARY TO TREATMENT WITH PEMBROLIZUMAB. A CASE REPORT.5PSQ-008
PDF DocumentOFF-LABEL USE OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS ACUTE LUPUS PNEUMONITIS: A CASE REPORT5PSQ-009
PDF DocumentNATIONAL STANDARDISATION OF PRETERM PARENTERAL NUTRITION IN NEONATAL UNITS5PSQ-010
PDF DocumentTOXICITY OF IMMUNOTHERAPY TREATMENT IN CLINICAL PRACTICE5PSQ-011
PDF DocumentTOOLS OFFERED BY REGENERATIVE MEDICINE FOR THE TREATMENT OF OSTEOARTHRITIS – PLATELET RICH PLASMA (PRP).5PSQ-012
PDF DocumentNEW METHOD FOR ASSESSMENT OF ENVIRONMENTAL VIRAL CONTAMINATION OF LIQUIDS PREPARED IN CLOSED-SYSTEM DRUG TRANSFER DEVICES5PSQ-013
PDF DocumentELECTRONIC COMMUNICATION OF THE DISCONTINUATION OF HOME TREATMENT PRESCRIBED TO PATIENTS IN A TERTIARY LEVEL HOSPITAL.5PSQ-014
PDF DocumentANALYSIS OF THE OCCURRENCE OF ATRIAL FIBRILLATION WITH THE ADMINISTRATION OF IBRUTINIB: SHOULD WE BE CAREFUL WITH THIS DRUG?5PSQ-015
PDF DocumentASSESSMENT OF THE ACCREDITATION AND CONTINUOUS EDUCATION TESTS FOR PHARMACY TECHNICIANS WITHIN A CYTOTOXIC RECONSTITUTION UNIT5PSQ-016
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN ORAL AND SUBCUTANEOUS MTX PRESCRIBING ERRORS5PSQ-017
PDF DocumentANALYSIS OF ERRORS IN THE MANUAL PREPARATION OF STERILE DRUGS FROM STOCK.5PSQ-018
PDF DocumentVALIDATION PRIOR TO THE DISPENSING OF MEDICINES AS A TOOL TO IMPROVE THE QUALITY OF THE PRESCRIPTION5PSQ-019
PDF DocumentEVALUATION OF THE EFFICACY AND SAFETY OF EPCORITAMAB-BYSP IN PATIENTS WITH FOLLICULAR B LYMPHOMA: A CASE REPORT.5PSQ-020
PDF DocumentEVALUATION OF THE PREVALENCE OF MULTI-RESISTANT BACTERIA IN THE INTENSIVE CARE UNIT AFTER SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT.5PSQ-021
PDF DocumentDRUG-INDUCED APLASTIC ANAEMIA: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)5PSQ-022
PDF DocumentSAFETY AND TOLERABILITY OF VORICONAZOLE TREATMENT: A RETROSPECTIVE OBSERVATIONAL STUDY5PSQ-023
PDF DocumentENHANCING SAFETY AND EFFICIENCY IN CHEMOTHERAPY PREPARATION AND ADMINISTRATION IN A SMALL ONCOLOGY HOSPITAL5PSQ-024
PDF DocumentAUDIT ON THE CORRECT USE OF MEDICAL DEVICES FOR URINARY CATHETERISATION5PSQ-025
THE POTENTIAL OF PHARMACOVIGILANCE DATABASES TO ASSESS TOXICOLOGICAL RISK OF DIETARY SUPPLEMENTS AND OTHER UNSUPERVISED HEALTH PRODUCTS USED BY PATIENTS5PSQ-026
VARIABILITY IN VANCOMYCIN PLASMA CONCENTRATION IN NEUTROPENIC PATIENTS5PSQ-027
CASE REPORT: ANTITUMOR ACTIVITY AND TOXICITIES OF ENTRECTINIB IN A PATIENT WITH A PRIMARY CENTRAL NEUROCYTOMA5PSQ-028
THE OVERRIDING OF DRUG SAFETY ALERTS FIRED BY THE CLINICAL DECISION SUPPORT TOOL: EVALUATION OF APPROPRIATE RESPONSES AND ALERT FATIGUE SOLUTIONS5PSQ-029
PDF DocumentCONCORDANCE OF MEDICATION PRESCRIPTION RECORDS IN THE HOSPITALISED SURGICAL PATIENT5PSQ-030
“ASSESSING HEALTHCARE PROFESSIONALS “VIEWS ON DEPRESCRIPTION5PSQ-031
USE OF THE “PRECAUTIONARY ANNULMENTS” TOOL BY A HOSPITAL PHARMACY SERVICE5PSQ-032
TEMPORAL TRENDS OF ATYPICAL DRUG ACCESS AT AN ACADEMIC ONCOLOGY UNIT: THE VERONA UNIVERSITY HOSPITAL EXPERIENCE5PSQ-033
PDF DocumentCOMPARISON OF TOXICITY IN CLINICAL PRACTICE OF ANTI-PD-1/PD-L1 ANTIBODIES IN MONOTHERAPY IN NON-SMALL CELL LUNG CANCER5PSQ-034
PDF DocumentSACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: A MULTICENTER EFFECTIVENESS AND SAFETY STUDY5PSQ-035
PDF DocumentANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON ANTIMICROBIAL PRESCRIPTIONS IN THE POSTOPERATIVE RESUSCITATION UNIT5PSQ-036
PDF DocumentPERIPHERAL BLOOD BIOMARKERS DYNAMICS PREDICT CLINICAL RESPONSE TO PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL CELL LUNG CANCER5PSQ-037
PDF DocumentREAL-WORLD SAFETY OF IBRUTINIB IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA5PSQ-038
PDF DocumentIMPACT OF TAILORED SCREENING INTERVALS ON THE BURDEN OF DRUG-DRUG INTERACTION ALERTS: AN INTERRUPTED TIME SERIES ANALYSIS5PSQ-039
PDF DocumentVOLUNTARY MEDICATION ERRORS REPORTING SYSTEM IN AN ORTHOPEDIC SURGERY AND TRAUMATOLOGY UNIT5PSQ-040
PDF DocumentIMPACT OF INTRODUCING PREFILLED ATROPINE SYRINGES IN OCULAR SURGERY: PROACTIVE ASSESSMENT OF DRUG COSTS AND MEDICATION SAFETY5PSQ-041
PDF DocumentFOCUS ON MEDICATION ERRORS ON HIGH-RISK MEDICATIONS IN A HOSPITAL’S ELECTRONIC INCIDENT REPORTING SYSTEM5PSQ-042
PDF DocumentDESCRIPTIVE STUDY OF MARKETED MEDICINES CONTAINING ASPARTAME5PSQ-043
PDF DocumentSAFETY OF PEMBROLIZUMAB +/- CHEMOTHERAPY IN FIRST-LINE METASTATIC NON-SMALL-CELL LUNG CARCINOMA IN REAL-WORLD PRACTICE5PSQ-044
PDF DocumentANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS WITH DEMENTIA AND IN TREATMENT WITH HIGH ANTICHOLINERGIC ACTIVITY DRUGS5PSQ-045
SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE INDUCED BY ALPRAZOLAM: A CASE REPORT5PSQ-046
PDF DocumentTHE PERCEIVED IMPACT ON PATIENT SAFETY AND QUALITY OF CARE OF PHARMACEUTICAL TECHNICAL ASSISTANTS ON NURSING WARDS: A QUALITATIVE STUDY5PSQ-047
PDF DocumentCOST-SAVING IMPACT OF USING NUSINERSEN BY CLINICAL TRIALS FOR SPINAL MUSCULAR ATROPHY5PSQ-048
PDF DocumentMEDICATION PRESCRIBING ERRORS PROSPECTIVE OBSERVATIONAL STUDY IN AN INTENSIVE CARE UNIT5PSQ-049
PDF DocumentIT IS POSSIBLE TO IMPROVE THE HIPOPOTASEMIC MANAGMENT IN THE HOSPITAL?5PSQ-050
PDF DocumentEFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN OLDER PATIENTS AT NURSING HOME WITH COVID-19.5PSQ-051
PDF DocumentANALYSIS OF POTENTIAL PROGNOSTIC FACTORS OF EFFICACY IN TISAGENLECLEUCEL TREATMENT IN A COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA5PSQ-052
EFFECTIVENESS AND SAFETY OF GALCANEZUMAB. REAL-LIFE RESULTS.5PSQ-053
PDF DocumentEVALUATION OF AN APPLICATION TO HELP FOR THE ADEQUACY OF THE DOSAGE OF ANTIBIOTICS IN RENAL FAILURE5PSQ-054
PDF DocumentEFFICACY AND SAFETY OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS TREATMENT5PSQ-055
PDF DocumentVACCINATION COVERAGE AGAINST PENUMOCOCCUS FOR PEOPLE LIVING WITH HIV BEFORE AND AFTER THE COVI-19 PANDEMIC5PSQ-056
PDF DocumentANTICHOLINERGIC BURDEN ASSESSMENT IN INSTITUTIONALIZED PATIENTS5PSQ-057
PDF DocumentEFFICACY EVALUATION OF ANTI-PCSK9 DRUGS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA.5PSQ-058
PDF DocumentSTUDY OF THE USE OF CEFTAZIDIME/AVIBACTAM IN A FIRST LEVEL HOSPITAL5PSQ-059
PDF DocumentREAL-LIFE DATA ON THE EFFECTIVENESS AND SAFETY OF CABOTEGRAVIR/RILPIVIRINE IN A THIRD-LEVEL HOSPITAL5PSQ-060
PDF DocumentCURRENT PRACTICE OF PEDIATRIC OFF-LABEL PRESCRIPTIONS IN A PEDIATRIC HOSPITAL5PSQ-061
SAFETY EVALUATION OF PEMBROLIZUMAB IN MONOTHERAPY5PSQ-062
PDF DocumentADJUVANTE ANALGESICS INTERACTIONS: HOW TO MANAGE PAIN IN PATIENTS RECEIVING ORAL THERAPY FOR BREAST CANCER TREATMENT5PSQ-063
PDF DocumentANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON DIRECT ACTING ORAL ANTICOAGULANTS IN A TERTIARY CARE HOSPITAL.5PSQ-064
PDF DocumentINTESTINAL PERFORATION AFTER CRS AND ICANS IN A CAR-T TREATED PATIENT: A CLINICAL CASE REPORT.5PSQ-065
PDF DocumentSURVIVAL ANALYSIS OF REGORAFENIB IN PATIENTS WITH COLORECTAL CANCER. FIRST RESULTS OF REGORAFENIB USE IN REAL CLINICAL PRACTICE5PSQ-066
PDF DocumentDRUG UTILIZATION PROFILES OF ADVANCED THERAPY MEDICINAL PRODUCTS: A REAL WORLD EVIDENCE STUDY5PSQ-067
PDF DocumentTHE HOSPITAL PHARMACIST’S INTERVENTIONS IN THE POST-MARKETING PHARMACOVIGILANCE OF ANTI-ASTHMATIC BIOLOGICS: A REAL LIFE ANALYSIS5PSQ-068
PDF DocumentCOMPARISON OF RENAL GLOMERULAR FILTRATION ESTIMATION FORMULAS IN VANCOMYCIN PHARMACOKINETIC MONITORING5PSQ-069
PDF DocumentDUPILUMAB IS A MONOCLONAL ANTIBODY USED FOR THE TREATMENT OF ATOPIC DERMATITIS. THIS STUDY EVALUATES THE EFFECTIVENESS AND PERSISTENCE. DUPILUMAB PRESENTS GOOD EFFECTIVENESS AND PERSISTENCE.5PSQ-070
PDF DocumentMULTIDISCIPLINARY MANAGEMENT OF DRESS SYNDROME: A CASE REPORT5PSQ-071
PDF DocumentTREATMENT WITH GALCANEZUMAB IN REAL WORLD DATA: SAFETY.5PSQ-072
PDF DocumentRISK SCORE FOR DRUG DISCREPANCY AND ADHERENCE IN CLINICAL TRIAL PATIENTS5PSQ-073
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN PAIN MANAGEMENT5PSQ-074
PDF DocumentADHERENCE TO LOCAL ANTIBIOTIC PRESCRIBING GUIDELINES WITHIN 48 HOURS OF INPATIENT ADMISSION5PSQ-075
PDF DocumentEFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY VS NIVOLUMAB PLUS IPILIMUMAB IN RENAL CELL CARCINOMA IN CLINICAL PRACTICE5PSQ-076
PDF DocumentADEQUATE NUTRITIONAL THERAPY IN CRITICAL PATIENTS WITH CORONAVIRUS DISEASE (COVID-19)5PSQ-077
PDF DocumentHYPOPHOSPHATEMIA AFTER FERRIC CARBOXYMALTOSE ADMINISTRATION IN A COHORT OF ELDERLY PATIENTS WITH HIP FRACTURE5PSQ-078
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN A HEALTH MANAGEMENT AREA5PSQ-079
PDF DocumentCLINICAL INTERVENTIONS IN PATIENTS UNDERGOING ANTIPARKINSONIAN TREATMENT: THE IMPORTANCE OF CORRECT RECONCILIATION5PSQ-080
PDF DocumentSATISFACTION OF PHYSICIANS AND HOSPITAL PHARMACISTS OF A HYPERSENSITIVITY DOCUMENTATION TOOL WITH DE-LABELING FEATURE IN CLINICAL PRACTICE5PSQ-081
PDF DocumentTHIRD-GENERATION HOSPITAL-EXCLUSIVE CEPHALOSPORINS: DIFFERENT SAFETY PROFILES?5PSQ-082
PDF DocumentMARIBAVIR-INDUCED TOXIC EPIDERMAL NECROLYSIS IN A LIVER TRANSPLANT PATIENT: A CASE REPORT.5PSQ-083
PDF DocumentEROSIVE BALANITIS AS A POSSIBLE ADVERSE EFFECT TO TREATMENT WITH TOFACITINIB. A CASE REPORT.5PSQ-084
PDF DocumentSAFETY ASSESSMENT OF JANUS KINASE INHIBITORS IN CLINICAL PRACTICE5PSQ-085
ADMINISTRATION OF TYROSINE KINASE INHIBITOR DRUGS IN PATIENTS WITH ENTERAL FEEDING TUBES5PSQ-086
PDF DocumentANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS5PSQ-087
PDF DocumentADHERENCE TO ANTIRETROVIRAL THERAPY IN VIH PATIENTS5PSQ-088
PDF DocumentOUTCOME OF MOLNUPIRAVIR TREATMENT IN RENAL TRANSPLANT PATIENTS WITH COVID-195PSQ-089
PDF DocumentCAPSAICIN 8% PATCH IN TREATMENT OF PERIPHERAL NEUROPATHIC PAIN5PSQ-090
PDF DocumentSUITABILITY OF TERIPARATIDE AND LEVEL OF ACCEPTANCE OF PHARMACOTHERAPEUTIC RECOMMENDATIONS IN AN AREA OF HEALTH MANAGEMENT5PSQ-091
ALTERED PHARMACOKINETICS PARAMETERS OF VANCOMYCIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY WITH FEBRILE NEUTROPENIA, A BAYESIAN SOFTWARE ESTIMATION5PSQ-092
PDF DocumentDOES EXPOSURE TO ANTIBIOTICS PRIOR TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AFFECT THEIR EFFECTIVENESS?5PSQ-093
INCIDENCE OF HYPERSENSITIVITY REACTIONS IN PACLITAXEL INFUSIONS FOLLOWING THE DISCONTINUATION OF RANITIDINE.5PSQ-094
PDF DocumentHOSPITAL PHARMACISTS ENGAGEMENT IN PHARMACOVIGILANCE PRACTICES DURING COVID-19 IN THE NORTH MACEDONIA5PSQ-095
PDF DocumentDESCRIPTION OF INMMUNOGLOBULIN REPLACEMENT THERAPY IN MULTIPLE MYELOMA PATIENTS WITH ANTI-BCMA CART5PSQ-096
PDF DocumentAN APPROACH TO THE USE OF MACHINE LEARNING TOOLS FOR THE PREDICTION OF ADVERSE EVENTS IN CANCER PATIENTS ON IMMUNOTHERAPY5PSQ-097
PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: OPTIMIZATION OF ACCESS TO THERAPY IN ACCORDANCE WITH EUROPEAN GUIDELINES5PSQ-098
DRUG-RELATED PROBLEMS ASSOCIATED WITH THE TREATMENT OF POLYCYSTIC OVARY SYNDROME5PSQ-099
PDF DocumentSURVEY OF PATIENT INVOLVEMENT IN ADVERSE DRUG REACTION MONITORING: THEIR INFORMATION SOURCES AND NEEDS5PSQ-100
MEDICAL DEVICES INCIDENT REPORTS: AN ITALIAN EXPERIENCE5PSQ-101
PDF DocumentANALYSIS OF REPEATED EMERGENCY DEPARTMENT VISITS AND THEIR RELATIONSHIP TO MEDICATION5PSQ-102
PDF DocumentVANCOMYCIN-INDUCED RENAL TOXICITY THROUGH THERAPEUTIC DRUG MONITORING IN DAILY PRACTICE5PSQ-103
PDF DocumentREAL WORLD EVIDENCE: IS IBRUTINIB AS SAFE AS EVIDENCE TELLS?5PSQ-104
PATTERNS OF USE AND APPROPRIATENESS OF ANTICOAGULATION IN ATRIAL FIBRILLATION: AN OBSERVATIONAL STUDY AMONG GERIATRIC INPATIENTS5PSQ-105
PDF DocumentFALL-INCREASING RISK DRUGS (FRIDS) AND FALL-RELATED FRACTURES5PSQ-106
PDF DocumentCOMPLIANCE OF FLUOROQUINOLONES PRESCRIPTIONS : A HOSPITAL ACQUIRED RESISTANCE ?5PSQ-107
PDF DocumentEFFICACY AND SAFETY OF INFLIXIMAB IN NF-KB ESSENTIAL MODULATOR DELETED EXON 5 AUTO-INFLAMMATORY SYNDROME: A CASE REPORT5PSQ-108
PDF DocumentHAEMOASSIST: A DIGITAL BRIDGE BETWEEN HAEMOPHILIA PATIENTS AND PHARMACISTS5PSQ-109
PDF DocumentDESENSITIZATION TO MONOCLONAL ANTIBODIES IN ONCOHEMATOLOGICAL PATIENTS5PSQ-110
PDF DocumentSODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AFTER HEART TRANSPLANTATION5PSQ-111
PDF DocumentA SURVEY OF HOME STORAGE TEMPERATURE OF IN-USE INSULINS AND ANALYSIS OF THEIR STABILITIES UNDER THE SIMULATED HIGHEST HOME TEMPERATURE5PSQ-112
PDF DocumentROOT CAUSE ANALYSIS: STATEGY FOR A SUSTAINABLE ANTIBLASTIC THERAPY MANAGEMENT SYSTEM5PSQ-113
PDF DocumentHEAD AND NECK ERYTHEMA ASSOCIATED WITH THE USE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS5PSQ-114
EVALUATION OF HYPOTHYROIDISM ASSOCIATED WITH APALUTAMIDE AND ENZALUTAMIDE TREATMENT IN METASTATIC PROSTATE CANCER USING THE EUROPEAN ADVERSE EFFECT DATABASE (EUDRAVIGILANCE)5PSQ-115
PDF DocumentREAL-WORLD PERSISTENCE WITH GUSELKUMAB AMONG ADULTS WITH PSORIATIC ARTHRITIS5PSQ-116
PDF DocumentTRACEABILITY OF IMPLANTABLE MEDICAL DEVICES / PATIENT INFORMATION: WHERE DO WE STAND?5PSQ-117
PDF DocumentNON-ACTIVE PRESCRIPTIONS IN AMBULATORY PATIENTS: ANALYSIS AND EFFECT IN CONSULTATION WAITING TIME5PSQ-118
PDF DocumentREVIEW OF REAL-WORLD MANAGEMENT OF NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS: A DOUBLE-EDGED WEAPON5PSQ-119
PDF DocumentPEMBROLIZUMAB IMMUNE-MEDIATED TOXICITY5PSQ-120
PDF DocumentA REVIEW OF THE EXPOSURE TO POTENTIALLY HARMFUL EXCIPIENTS THROUGH ORAL LIQUID FORMS IN PEDIATRIC INPATIENTS IN FRANCE5PSQ-121
SEQUENTIAL CHANGE OF DOSING INTERVAL OF PALIPERIDONE PALMITATE BASED ON PLASMA CONCENTRATION MONITORING5PSQ-122
SIMUALTION OF A DISCHARGE CONTROL: AN EFFECTIVE TOOL FOR QUALIFYING STAFF5PSQ-123
PDF DocumentTHE TREATMENT OF PRESSURE ULCERS WITH BACTERIA BINDING MEDICATION AS A VALID THERAPEUTIC OPPORTUNITY5PSQ-124
ANALYSIS OF INTRODUCING PROBIOTICS FOR THE PREVENTION OF NECROTIZING ENTEROCOLITIS IN PREMATURE NEONATES IN A NEONATAL UNIT5PSQ-125
PDF DocumentTHE ANALYSIS OF INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN HOSPITALIZED SENIORS5PSQ-126
PDF DocumentMEDICATION-RELATED FALLS IN A NURSING HOME: IDENTIFICATION AND HOSPITAL PHARMACY INTERVENTIONS5PSQ-127
PDF DocumentCOST-EFFECTIVENESS OF PHARMACEUTICAL PREOPERATIVE CONSULTATIONS: A FIVE-YEAR ANALYSIS5PSQ-128

Section 6: Education and Research

PDF DocumentPoster TitlePoster Number
INCIDENCE OF HEPATITIS B VIRUS REACTIVATION IN PSORIASIS PATIENTS TREATED WITH CYTOKINE INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS5PSQ-001
PRESCRIBING TREND OFFLUOROQUINOLONES FOLLOWING LATEST EMA RECOMMENDATIONS5PSQ-002
PDF DocumentIMPROVING MEDICINES MANAGEMENT OF INPATIENT PARKINSON’S DISEASE PATIENTS BY MAKING PHARMACY INTERVENTIONS5PSQ-003
COMPARISON BETWEEN BEERS 2019 CRITERIA AND THE EURO-FORTA 2018 LIST IN THE IDENTIFICATION OF POTENTIALLY INAPPROPRIATE MEDICATION IN ELDERLY PATIENTS IN THE PRIMARY HEALTHCARE CONTEXT5PSQ-004
PDF DocumentUTILITY OF THE THERAPEUTIC COMPLEXITY INDEX ADAPTED TO CRITICALLY ILL PATIENTS AS A METHOD OF STRATIFICATION FOR PHARMACEUTICAL CARE5PSQ-005
PDF DocumentFREQUENCY OF CREATININE TESTING AND ACUTE KIDNEY INJURY IDENTIFICATION AND STAGING.5PSQ-006
PDF DocumentA REVIEW ON MEDICATION RECONCILIATION IN THE PERIOPERATIVE PERIOD: VARIABLES THAT LEAD TO MEDICATION ERRORS.5PSQ-007
PDF DocumentIMMUNE-MEDIATED HEPATITIS SECONDARY TO TREATMENT WITH PEMBROLIZUMAB. A CASE REPORT.5PSQ-008
PDF DocumentOFF-LABEL USE OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS ACUTE LUPUS PNEUMONITIS: A CASE REPORT5PSQ-009
PDF DocumentNATIONAL STANDARDISATION OF PRETERM PARENTERAL NUTRITION IN NEONATAL UNITS5PSQ-010
PDF DocumentTOXICITY OF IMMUNOTHERAPY TREATMENT IN CLINICAL PRACTICE5PSQ-011
PDF DocumentTOOLS OFFERED BY REGENERATIVE MEDICINE FOR THE TREATMENT OF OSTEOARTHRITIS – PLATELET RICH PLASMA (PRP).5PSQ-012
PDF DocumentNEW METHOD FOR ASSESSMENT OF ENVIRONMENTAL VIRAL CONTAMINATION OF LIQUIDS PREPARED IN CLOSED-SYSTEM DRUG TRANSFER DEVICES5PSQ-013
PDF DocumentELECTRONIC COMMUNICATION OF THE DISCONTINUATION OF HOME TREATMENT PRESCRIBED TO PATIENTS IN A TERTIARY LEVEL HOSPITAL.5PSQ-014
PDF DocumentANALYSIS OF THE OCCURRENCE OF ATRIAL FIBRILLATION WITH THE ADMINISTRATION OF IBRUTINIB: SHOULD WE BE CAREFUL WITH THIS DRUG?5PSQ-015
PDF DocumentASSESSMENT OF THE ACCREDITATION AND CONTINUOUS EDUCATION TESTS FOR PHARMACY TECHNICIANS WITHIN A CYTOTOXIC RECONSTITUTION UNIT5PSQ-016
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN ORAL AND SUBCUTANEOUS MTX PRESCRIBING ERRORS5PSQ-017
PDF DocumentANALYSIS OF ERRORS IN THE MANUAL PREPARATION OF STERILE DRUGS FROM STOCK.5PSQ-018
PDF DocumentVALIDATION PRIOR TO THE DISPENSING OF MEDICINES AS A TOOL TO IMPROVE THE QUALITY OF THE PRESCRIPTION5PSQ-019
PDF DocumentEVALUATION OF THE EFFICACY AND SAFETY OF EPCORITAMAB-BYSP IN PATIENTS WITH FOLLICULAR B LYMPHOMA: A CASE REPORT.5PSQ-020
PDF DocumentEVALUATION OF THE PREVALENCE OF MULTI-RESISTANT BACTERIA IN THE INTENSIVE CARE UNIT AFTER SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT.5PSQ-021
PDF DocumentDRUG-INDUCED APLASTIC ANAEMIA: AN ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)5PSQ-022
PDF DocumentSAFETY AND TOLERABILITY OF VORICONAZOLE TREATMENT: A RETROSPECTIVE OBSERVATIONAL STUDY5PSQ-023
PDF DocumentENHANCING SAFETY AND EFFICIENCY IN CHEMOTHERAPY PREPARATION AND ADMINISTRATION IN A SMALL ONCOLOGY HOSPITAL5PSQ-024
PDF DocumentAUDIT ON THE CORRECT USE OF MEDICAL DEVICES FOR URINARY CATHETERISATION5PSQ-025
THE POTENTIAL OF PHARMACOVIGILANCE DATABASES TO ASSESS TOXICOLOGICAL RISK OF DIETARY SUPPLEMENTS AND OTHER UNSUPERVISED HEALTH PRODUCTS USED BY PATIENTS5PSQ-026
VARIABILITY IN VANCOMYCIN PLASMA CONCENTRATION IN NEUTROPENIC PATIENTS5PSQ-027
CASE REPORT: ANTITUMOR ACTIVITY AND TOXICITIES OF ENTRECTINIB IN A PATIENT WITH A PRIMARY CENTRAL NEUROCYTOMA5PSQ-028
THE OVERRIDING OF DRUG SAFETY ALERTS FIRED BY THE CLINICAL DECISION SUPPORT TOOL: EVALUATION OF APPROPRIATE RESPONSES AND ALERT FATIGUE SOLUTIONS5PSQ-029
PDF DocumentCONCORDANCE OF MEDICATION PRESCRIPTION RECORDS IN THE HOSPITALISED SURGICAL PATIENT5PSQ-030
“ASSESSING HEALTHCARE PROFESSIONALS “VIEWS ON DEPRESCRIPTION5PSQ-031
USE OF THE “PRECAUTIONARY ANNULMENTS” TOOL BY A HOSPITAL PHARMACY SERVICE5PSQ-032
TEMPORAL TRENDS OF ATYPICAL DRUG ACCESS AT AN ACADEMIC ONCOLOGY UNIT: THE VERONA UNIVERSITY HOSPITAL EXPERIENCE5PSQ-033
PDF DocumentCOMPARISON OF TOXICITY IN CLINICAL PRACTICE OF ANTI-PD-1/PD-L1 ANTIBODIES IN MONOTHERAPY IN NON-SMALL CELL LUNG CANCER5PSQ-034
PDF DocumentSACITUZUMAB-GOVITECAN IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: A MULTICENTER EFFECTIVENESS AND SAFETY STUDY5PSQ-035
PDF DocumentANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON ANTIMICROBIAL PRESCRIPTIONS IN THE POSTOPERATIVE RESUSCITATION UNIT5PSQ-036
PDF DocumentPERIPHERAL BLOOD BIOMARKERS DYNAMICS PREDICT CLINICAL RESPONSE TO PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL CELL LUNG CANCER5PSQ-037
PDF DocumentREAL-WORLD SAFETY OF IBRUTINIB IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA5PSQ-038
PDF DocumentIMPACT OF TAILORED SCREENING INTERVALS ON THE BURDEN OF DRUG-DRUG INTERACTION ALERTS: AN INTERRUPTED TIME SERIES ANALYSIS5PSQ-039
PDF DocumentVOLUNTARY MEDICATION ERRORS REPORTING SYSTEM IN AN ORTHOPEDIC SURGERY AND TRAUMATOLOGY UNIT5PSQ-040
PDF DocumentIMPACT OF INTRODUCING PREFILLED ATROPINE SYRINGES IN OCULAR SURGERY: PROACTIVE ASSESSMENT OF DRUG COSTS AND MEDICATION SAFETY5PSQ-041
PDF DocumentFOCUS ON MEDICATION ERRORS ON HIGH-RISK MEDICATIONS IN A HOSPITAL’S ELECTRONIC INCIDENT REPORTING SYSTEM5PSQ-042
PDF DocumentDESCRIPTIVE STUDY OF MARKETED MEDICINES CONTAINING ASPARTAME5PSQ-043
PDF DocumentSAFETY OF PEMBROLIZUMAB +/- CHEMOTHERAPY IN FIRST-LINE METASTATIC NON-SMALL-CELL LUNG CARCINOMA IN REAL-WORLD PRACTICE5PSQ-044
PDF DocumentANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS WITH DEMENTIA AND IN TREATMENT WITH HIGH ANTICHOLINERGIC ACTIVITY DRUGS5PSQ-045
SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE INDUCED BY ALPRAZOLAM: A CASE REPORT5PSQ-046
PDF DocumentTHE PERCEIVED IMPACT ON PATIENT SAFETY AND QUALITY OF CARE OF PHARMACEUTICAL TECHNICAL ASSISTANTS ON NURSING WARDS: A QUALITATIVE STUDY5PSQ-047
PDF DocumentCOST-SAVING IMPACT OF USING NUSINERSEN BY CLINICAL TRIALS FOR SPINAL MUSCULAR ATROPHY5PSQ-048
PDF DocumentMEDICATION PRESCRIBING ERRORS PROSPECTIVE OBSERVATIONAL STUDY IN AN INTENSIVE CARE UNIT5PSQ-049
PDF DocumentIT IS POSSIBLE TO IMPROVE THE HIPOPOTASEMIC MANAGMENT IN THE HOSPITAL?5PSQ-050
PDF DocumentEFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN OLDER PATIENTS AT NURSING HOME WITH COVID-19.5PSQ-051
PDF DocumentANALYSIS OF POTENTIAL PROGNOSTIC FACTORS OF EFFICACY IN TISAGENLECLEUCEL TREATMENT IN A COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA5PSQ-052
EFFECTIVENESS AND SAFETY OF GALCANEZUMAB. REAL-LIFE RESULTS.5PSQ-053
PDF DocumentEVALUATION OF AN APPLICATION TO HELP FOR THE ADEQUACY OF THE DOSAGE OF ANTIBIOTICS IN RENAL FAILURE5PSQ-054
PDF DocumentEFFICACY AND SAFETY OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS TREATMENT5PSQ-055
PDF DocumentVACCINATION COVERAGE AGAINST PENUMOCOCCUS FOR PEOPLE LIVING WITH HIV BEFORE AND AFTER THE COVI-19 PANDEMIC5PSQ-056
PDF DocumentANTICHOLINERGIC BURDEN ASSESSMENT IN INSTITUTIONALIZED PATIENTS5PSQ-057
PDF DocumentEFFICACY EVALUATION OF ANTI-PCSK9 DRUGS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA.5PSQ-058
PDF DocumentSTUDY OF THE USE OF CEFTAZIDIME/AVIBACTAM IN A FIRST LEVEL HOSPITAL5PSQ-059
PDF DocumentREAL-LIFE DATA ON THE EFFECTIVENESS AND SAFETY OF CABOTEGRAVIR/RILPIVIRINE IN A THIRD-LEVEL HOSPITAL5PSQ-060
PDF DocumentCURRENT PRACTICE OF PEDIATRIC OFF-LABEL PRESCRIPTIONS IN A PEDIATRIC HOSPITAL5PSQ-061
SAFETY EVALUATION OF PEMBROLIZUMAB IN MONOTHERAPY5PSQ-062
PDF DocumentADJUVANTE ANALGESICS INTERACTIONS: HOW TO MANAGE PAIN IN PATIENTS RECEIVING ORAL THERAPY FOR BREAST CANCER TREATMENT5PSQ-063
PDF DocumentANALYSIS OF PHARMACEUTICAL INTERVENTIONS ON DIRECT ACTING ORAL ANTICOAGULANTS IN A TERTIARY CARE HOSPITAL.5PSQ-064
PDF DocumentINTESTINAL PERFORATION AFTER CRS AND ICANS IN A CAR-T TREATED PATIENT: A CLINICAL CASE REPORT.5PSQ-065
PDF DocumentSURVIVAL ANALYSIS OF REGORAFENIB IN PATIENTS WITH COLORECTAL CANCER. FIRST RESULTS OF REGORAFENIB USE IN REAL CLINICAL PRACTICE5PSQ-066
PDF DocumentDRUG UTILIZATION PROFILES OF ADVANCED THERAPY MEDICINAL PRODUCTS: A REAL WORLD EVIDENCE STUDY5PSQ-067
PDF DocumentTHE HOSPITAL PHARMACIST’S INTERVENTIONS IN THE POST-MARKETING PHARMACOVIGILANCE OF ANTI-ASTHMATIC BIOLOGICS: A REAL LIFE ANALYSIS5PSQ-068
PDF DocumentCOMPARISON OF RENAL GLOMERULAR FILTRATION ESTIMATION FORMULAS IN VANCOMYCIN PHARMACOKINETIC MONITORING5PSQ-069
PDF DocumentDUPILUMAB IS A MONOCLONAL ANTIBODY USED FOR THE TREATMENT OF ATOPIC DERMATITIS. THIS STUDY EVALUATES THE EFFECTIVENESS AND PERSISTENCE. DUPILUMAB PRESENTS GOOD EFFECTIVENESS AND PERSISTENCE.5PSQ-070
PDF DocumentMULTIDISCIPLINARY MANAGEMENT OF DRESS SYNDROME: A CASE REPORT5PSQ-071
PDF DocumentTREATMENT WITH GALCANEZUMAB IN REAL WORLD DATA: SAFETY.5PSQ-072
PDF DocumentRISK SCORE FOR DRUG DISCREPANCY AND ADHERENCE IN CLINICAL TRIAL PATIENTS5PSQ-073
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN PAIN MANAGEMENT5PSQ-074
PDF DocumentADHERENCE TO LOCAL ANTIBIOTIC PRESCRIBING GUIDELINES WITHIN 48 HOURS OF INPATIENT ADMISSION5PSQ-075
PDF DocumentEFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY VS NIVOLUMAB PLUS IPILIMUMAB IN RENAL CELL CARCINOMA IN CLINICAL PRACTICE5PSQ-076
PDF DocumentADEQUATE NUTRITIONAL THERAPY IN CRITICAL PATIENTS WITH CORONAVIRUS DISEASE (COVID-19)5PSQ-077
PDF DocumentHYPOPHOSPHATEMIA AFTER FERRIC CARBOXYMALTOSE ADMINISTRATION IN A COHORT OF ELDERLY PATIENTS WITH HIP FRACTURE5PSQ-078
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN A HEALTH MANAGEMENT AREA5PSQ-079
PDF DocumentCLINICAL INTERVENTIONS IN PATIENTS UNDERGOING ANTIPARKINSONIAN TREATMENT: THE IMPORTANCE OF CORRECT RECONCILIATION5PSQ-080
PDF DocumentSATISFACTION OF PHYSICIANS AND HOSPITAL PHARMACISTS OF A HYPERSENSITIVITY DOCUMENTATION TOOL WITH DE-LABELING FEATURE IN CLINICAL PRACTICE5PSQ-081
PDF DocumentTHIRD-GENERATION HOSPITAL-EXCLUSIVE CEPHALOSPORINS: DIFFERENT SAFETY PROFILES?5PSQ-082
PDF DocumentMARIBAVIR-INDUCED TOXIC EPIDERMAL NECROLYSIS IN A LIVER TRANSPLANT PATIENT: A CASE REPORT.5PSQ-083
PDF DocumentEROSIVE BALANITIS AS A POSSIBLE ADVERSE EFFECT TO TREATMENT WITH TOFACITINIB. A CASE REPORT.5PSQ-084
PDF DocumentSAFETY ASSESSMENT OF JANUS KINASE INHIBITORS IN CLINICAL PRACTICE5PSQ-085
ADMINISTRATION OF TYROSINE KINASE INHIBITOR DRUGS IN PATIENTS WITH ENTERAL FEEDING TUBES5PSQ-086
PDF DocumentANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS5PSQ-087
PDF DocumentADHERENCE TO ANTIRETROVIRAL THERAPY IN VIH PATIENTS5PSQ-088
PDF DocumentOUTCOME OF MOLNUPIRAVIR TREATMENT IN RENAL TRANSPLANT PATIENTS WITH COVID-195PSQ-089
PDF DocumentCAPSAICIN 8% PATCH IN TREATMENT OF PERIPHERAL NEUROPATHIC PAIN5PSQ-090
PDF DocumentSUITABILITY OF TERIPARATIDE AND LEVEL OF ACCEPTANCE OF PHARMACOTHERAPEUTIC RECOMMENDATIONS IN AN AREA OF HEALTH MANAGEMENT5PSQ-091
ALTERED PHARMACOKINETICS PARAMETERS OF VANCOMYCIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY WITH FEBRILE NEUTROPENIA, A BAYESIAN SOFTWARE ESTIMATION5PSQ-092
PDF DocumentDOES EXPOSURE TO ANTIBIOTICS PRIOR TO TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AFFECT THEIR EFFECTIVENESS?5PSQ-093
INCIDENCE OF HYPERSENSITIVITY REACTIONS IN PACLITAXEL INFUSIONS FOLLOWING THE DISCONTINUATION OF RANITIDINE.5PSQ-094
PDF DocumentHOSPITAL PHARMACISTS ENGAGEMENT IN PHARMACOVIGILANCE PRACTICES DURING COVID-19 IN THE NORTH MACEDONIA5PSQ-095
PDF DocumentDESCRIPTION OF INMMUNOGLOBULIN REPLACEMENT THERAPY IN MULTIPLE MYELOMA PATIENTS WITH ANTI-BCMA CART5PSQ-096
PDF DocumentAN APPROACH TO THE USE OF MACHINE LEARNING TOOLS FOR THE PREDICTION OF ADVERSE EVENTS IN CANCER PATIENTS ON IMMUNOTHERAPY5PSQ-097
PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: OPTIMIZATION OF ACCESS TO THERAPY IN ACCORDANCE WITH EUROPEAN GUIDELINES5PSQ-098
DRUG-RELATED PROBLEMS ASSOCIATED WITH THE TREATMENT OF POLYCYSTIC OVARY SYNDROME5PSQ-099
PDF DocumentSURVEY OF PATIENT INVOLVEMENT IN ADVERSE DRUG REACTION MONITORING: THEIR INFORMATION SOURCES AND NEEDS5PSQ-100
MEDICAL DEVICES INCIDENT REPORTS: AN ITALIAN EXPERIENCE5PSQ-101
PDF DocumentANALYSIS OF REPEATED EMERGENCY DEPARTMENT VISITS AND THEIR RELATIONSHIP TO MEDICATION5PSQ-102
PDF DocumentVANCOMYCIN-INDUCED RENAL TOXICITY THROUGH THERAPEUTIC DRUG MONITORING IN DAILY PRACTICE5PSQ-103
PDF DocumentREAL WORLD EVIDENCE: IS IBRUTINIB AS SAFE AS EVIDENCE TELLS?5PSQ-104
PATTERNS OF USE AND APPROPRIATENESS OF ANTICOAGULATION IN ATRIAL FIBRILLATION: AN OBSERVATIONAL STUDY AMONG GERIATRIC INPATIENTS5PSQ-105
PDF DocumentFALL-INCREASING RISK DRUGS (FRIDS) AND FALL-RELATED FRACTURES5PSQ-106
PDF DocumentCOMPLIANCE OF FLUOROQUINOLONES PRESCRIPTIONS : A HOSPITAL ACQUIRED RESISTANCE ?5PSQ-107
PDF DocumentEFFICACY AND SAFETY OF INFLIXIMAB IN NF-KB ESSENTIAL MODULATOR DELETED EXON 5 AUTO-INFLAMMATORY SYNDROME: A CASE REPORT5PSQ-108
PDF DocumentHAEMOASSIST: A DIGITAL BRIDGE BETWEEN HAEMOPHILIA PATIENTS AND PHARMACISTS5PSQ-109
PDF DocumentDESENSITIZATION TO MONOCLONAL ANTIBODIES IN ONCOHEMATOLOGICAL PATIENTS5PSQ-110
PDF DocumentSODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AFTER HEART TRANSPLANTATION5PSQ-111
PDF DocumentA SURVEY OF HOME STORAGE TEMPERATURE OF IN-USE INSULINS AND ANALYSIS OF THEIR STABILITIES UNDER THE SIMULATED HIGHEST HOME TEMPERATURE5PSQ-112
PDF DocumentROOT CAUSE ANALYSIS: STATEGY FOR A SUSTAINABLE ANTIBLASTIC THERAPY MANAGEMENT SYSTEM5PSQ-113
PDF DocumentHEAD AND NECK ERYTHEMA ASSOCIATED WITH THE USE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS5PSQ-114
EVALUATION OF HYPOTHYROIDISM ASSOCIATED WITH APALUTAMIDE AND ENZALUTAMIDE TREATMENT IN METASTATIC PROSTATE CANCER USING THE EUROPEAN ADVERSE EFFECT DATABASE (EUDRAVIGILANCE)5PSQ-115
PDF DocumentREAL-WORLD PERSISTENCE WITH GUSELKUMAB AMONG ADULTS WITH PSORIATIC ARTHRITIS5PSQ-116
PDF DocumentTRACEABILITY OF IMPLANTABLE MEDICAL DEVICES / PATIENT INFORMATION: WHERE DO WE STAND?5PSQ-117
PDF DocumentNON-ACTIVE PRESCRIPTIONS IN AMBULATORY PATIENTS: ANALYSIS AND EFFECT IN CONSULTATION WAITING TIME5PSQ-118
PDF DocumentREVIEW OF REAL-WORLD MANAGEMENT OF NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS: A DOUBLE-EDGED WEAPON5PSQ-119
PDF DocumentPEMBROLIZUMAB IMMUNE-MEDIATED TOXICITY5PSQ-120
PDF DocumentA REVIEW OF THE EXPOSURE TO POTENTIALLY HARMFUL EXCIPIENTS THROUGH ORAL LIQUID FORMS IN PEDIATRIC INPATIENTS IN FRANCE5PSQ-121
SEQUENTIAL CHANGE OF DOSING INTERVAL OF PALIPERIDONE PALMITATE BASED ON PLASMA CONCENTRATION MONITORING5PSQ-122
SIMUALTION OF A DISCHARGE CONTROL: AN EFFECTIVE TOOL FOR QUALIFYING STAFF5PSQ-123
PDF DocumentTHE TREATMENT OF PRESSURE ULCERS WITH BACTERIA BINDING MEDICATION AS A VALID THERAPEUTIC OPPORTUNITY5PSQ-124
ANALYSIS OF INTRODUCING PROBIOTICS FOR THE PREVENTION OF NECROTIZING ENTEROCOLITIS IN PREMATURE NEONATES IN A NEONATAL UNIT5PSQ-125
PDF DocumentTHE ANALYSIS OF INTERACTIONS AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN HOSPITALIZED SENIORS5PSQ-126
PDF DocumentMEDICATION-RELATED FALLS IN A NURSING HOME: IDENTIFICATION AND HOSPITAL PHARMACY INTERVENTIONS5PSQ-127
PDF DocumentCOST-EFFECTIVENESS OF PHARMACEUTICAL PREOPERATIVE CONSULTATIONS: A FIVE-YEAR ANALYSIS5PSQ-128

27th Congress of the EAHP

National Poster Prize Winners

PDF DocumentPoster TitlePoster Number
PDF DocumentDEVELOPING THE ROLE OF PRIMARY CARE CLINICAL PHARMACISTNP-001
PDF Document“CAPSULE PHARMA”, AN INNOVATIVE DIGITAL TRAINING TOOL TO LEARN ABOUT IMPORTANT STERILE MEDICAL DEVICE (SMD) CONCEPTSNP-002
PHARMACEUTICAL INFUSION SCHEDULES AS A TOOL TO IMPROVE FLUID RESTRICTION IN PICU PATIENTSNP-003
PDF DocumentRETROSPECTIVE STUDY ON INDIVIDUALISED MEDICATION OF DEMENTIA PATIENTS RECEIVING CHRONIC HOSPITAL CARESNP-004
PDF DocumentSELF-ASSESSMENT ON THE IMPLEMENTATION OF RECOMMENDATIONS OF THE PERIOPERATIVE PROCESS: INFECTIOUS RISK MANAGEMENT IN SURGERY SETTINGNP-005
PDF DocumentIMMUNOTHERAPY IN SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCERNP-006
PDF DocumentRECOMMENDATIONS FOR ADMINISTRATION OF IMMUNOSUPPRESSANTS VIA ENTERAL FEEDING TUBE ACCORDING TO THEIR IN-VITRO ADMINISTRATIONNP-007
PDF DocumentEMERGENCY DEPARTMENT REVISIT SOCORE BASED ON PHARMACOTHERPAYNP-008
PDF DocumentASSESSMENT OF MEDICATION DISCREPANCIES BY PHARMACIST-LED MEDICATION RECONCILIATION AT ADMISSION : A PROSPECTIVE STUDY IN TRAUMATOLOGYNP-009
PDF DocumentDEVELOPMENT OF A 2% LIDOCAINE GEL FOR LOCAL ANAESTHESIA OF THE EYE PRIOR TO INTRAVITREAL INJECTIONNP-010
PDF DocumentAround one-third of people with diabetes will develop foot ulcers in their lifetimeStudent Science Award

Section 1: Introductory Statements and Governance

PDF DocumentPoster TitlePoster Number
PDF DocumentECONOMIC IMPACT GENERATED BY NATALIZUMAB OPTIMIZATION1ISG-001
PDF DocumentMEDICATION WASTE IN AN ORTHOPAEDIC DEPARTMENT: EFFECT OF PATIENT’S OWN MEDICATION USE AND SELF-ADMINISTRATION DURING HOSPITALISATION AND THE VIEWS OF PATIENTS AND HOSPITAL STAFF1ISG-002
PDF DocumentPROTOCOL FOR THE OPTIMISATION OF PHARMACEUTICAL VALIDATION IN HOSPITALIZED PATIENTS1ISG-003
HOME DELIVERY – EFFICIENCY, ECONOMY AND CUSTOMER SATISFACTION OUTCOMES – COMPARISON OF ASSISTANCE MODELS1ISG-004
DEPARTMENT COMPUTERISED PHARMACEUTICAL CABINET: RESULTS OF DEMATERIALIZATION AND TRACEABILITY OF DRUGS IN OBSTETRICS AND GYNECOLOGY1ISG-005
OPPORTUNITY TO STUDY ADHERENCE AND PERSISTENCE WITH HOME DELIVERY (HD) – REAL WORLD DATA (RWD) AND REAL WORLD EVIDENCE (RWE) ANALYSIS1ISG-006
OPPORTUNITIES FOR LOGISTIC REORGANISATION OF THE HOSPITAL PHARMACY WITH NEW CARE MODES: STOCK MANAGEMENT (SM) AND HOME DELIVERY (HD)1ISG-007
PDF DocumentTHE MULTIDISCIPLINARY ASSESSMENT OF RAPID ANTIGEN TESTS FOR THE DETECTION OF THE OMICRON VARIANT: THE ROLE OF THE HOSPITAL PHARMACIST IN A UNIVERSITY HOSPITAL1ISG-008
PDF DocumentA FRAMEWORK FACILITATING ACCESS TO MEDICINES IN THE EUROPEAN UNION1ISG-009
PDF DocumentPHARMACY STAFF SATISFACTION AND OPINION OF NEW WEBSITE APPLICATION FOR OUTPATIENT CARE1ISG-010
PDF DocumentMANAGEMENT OF UNADMINISTERED THERAPIES: IMPACT OF PHARMACIST-DOCTOR COLLABORATION TO OPTIMIZE THE PROCESS OF PREPARING CANCER THERAPIES1ISG-011
PDF DocumentCOST-MINIMISATION ANALYSIS: PROPHYLACTIC TREATMENT OF HAEMOPHILIA TYPE A, WHAT TO CHOOSE BETWEEN FACTOR VIII, RECOMBINANT FACTORS VIII (MOROCTOCOG-ALFA AND OCTOCOG) AND EMICIZUMAB?1ISG-012

Section 2: Selection, Procurement and Distribution

PDF DocumentPoster TitlePoster Number
PDF DocumentUSE AND COST EVOLUTION OF INFLIXIMAB AND ADALIMUMAB OVER 8 YEARS IN A TERTIARY HOSPITAL2SPD-001
COST SAVINGS IMPACT OF GENERICS: A LOCAL EXPERIENCE ON LENALIDOMIDE2SPD-002
PDF DocumentERRORS DETECTED IN THE TELEPHARMACY PROCEDURE2SPD-003
PDF DocumentECONOMIC EVALUATION AND BUDGET IMPACT FOR A REGIONAL HEALTH SERVICE ASSOCIATED WITH THE INCLUSION OF THE FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN A REGIONAL PHARMACOTHERAPEUTIC GUIDELINE2SPD-004
PDF DocumentNEW CLOSED SYSTEM TRANSFER DEVICE CONTAINS REAL DRUG VAPOURS FOR UP TO 28 DAYS2SPD-005
PDF DocumentARE ALL BIOLOGIC AGENTS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS EQUIVALENT ALTERNATIVES?2SPD-006
PDF DocumentUSE OF DRUGS IN SPECIAL SITUATIONS2SPD-007
BUDGETARY IMPACT DUE TO THE REPLACEMENT OF ORIGINAL LENALIDOMIDE INTO GENERIC LENALIDOMIDE2SPD-008
PDF DocumentAVOIDED COSTS FROM THE INCLUSION OF BREAST CANCER PATIENTS IN CLINICAL TRIALS2SPD-009
PDF DocumentREVIEW OF THE ENVIRONMENTAL CRITERIA INTRODUCED IN THE TENDERING OF DRUGS, MEDICAL DEVICES AND NON-MEDICAL EQUIPMENT IN A HEALTH GROUP PROCUREMENT ORGANIZATION2SPD-010
PDF DocumentCOMPARATIVE EFFICACY OF EPTINEZUMAB, GALCANEZUMAB, FREMANEZUMAB AND ERENUMAB IN THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE2SPD-011
PDF DocumentCOMPARATIVE EFFICACY OF ABROCITINIB, BARICITINIB AND UPADACITINIB IN MONOTHERAPY FOR THE TREATMENT OF ATOPIC DERMATITIS2SPD-012
PDF DocumentINTERVENTIONAL CARDIOLOGY: ANALYSIS OF STERILE MEDICAL DEVICE’S CONSUMPTION AND ASSESSMENT OF DIFFERING PRACTICES2SPD-013
PDF DocumentCOST STUDY: REUSABLE FLEXIBLE URETEROSCOPES VERSUS SINGLE-USE IN A HEALTHCARE FACILITY2SPD-014
INDIRECT COMPARISON OF ANIFROLUMAB VS BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS2SPD-015
COMPARATIVE EFFICACY OF BIMEKIZUMAB, IXEKIZUMAB AND BRODALUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS2SPD-016
PDF DocumentTELEPHARMACY AND HOME DELIVERY PROGRAMME FOR OUTPATIENTS THROUGH THE COMMUNITY PHARMACY2SPD-017
PDF DocumentBEZLOTOXUMAB: STRATEGIES TO REDUCE ECONOMIC IMPACT2SPD-018
PDF DocumentEXPLORING ECONOMIC AND QUALITATIVE ASPECTS OF DRUG USE IN A PENITENTIARY INSTITUTE2SPD-019
PDF DocumentIMPACT OF COVID-19 TREATMENT OPTIONS ON HOSPITAL PHARMACY’S WORKLOAD: LESSONS LEARNED2SPD-020

Section 3: Production and Compounding

PDF DocumentPoster TitlePoster Number
PDF DocumentPREPACKED BOXES FOR OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT) – A QUESTIONNAIRE SURVEY ON KNOWLEDGE, OPINION AND WISHES3PC-001
PDF DocumentHAZARDOUS DRUG AND ANTIBIOTIC RESIDUE SURFACE CONTAMINATION – IS THERE A NEED TO REDUCE EXPOSURE?3PC-002
99m-Tc- HMPAO LABELED LEUKOCITES: STUDYING ACUTE INFECTION OUTBREAKS – NUCLEAR PHARMACIST IN NUCLEAR MEDICINE3PC-003
PDF DocumentECONOMIC SAVINGS OF ERENUMAB REDOSING IN A THIRD LEVEL HOSPITAL3PC-004
PDF DocumentCLOSED SYSTEM TRANSFER DEVICE (CSTD) EXTENDS PRACTICAL IN-USE SHELF LIFE TO 28 DAYS AFTER FIRST PUNCTURE OF NON-PRESERVED SINGLE-USE-VIALS IN BOTH CONTROLLED AND UNCONTROLLED ENVIRONMENTS3PC-005
PDF DocumentCONTAINER CLOSURE INTEGRITY TESTING AND PROCES VALIDATION OF CLOSED SYSTEM TRANSFER DEVICES FOR ASEPTIC RECONSTITUTION OF DRUG VIALS CONNECTED TO FLUID BAGS3PC-006
IMPACT OF A SUSTAINABILITY STRATEGY IN THE DEVELOPMENT OF STANDARDIZED NEONATAL PARENTERAL NUTRITION ON DEMAND3PC-007
PDF DocumentSLOW ANAKINRA DESENSITIZATION PROTOCOL DESIGN FOR DELAYED HYPERSENSIBILITY REACTION3PC-008
PDF DocumentCYCLOPHOSPHAMIDE SURFACE CONTAMINATION IN A ROBOTIC CHEMOTHERAPY COMPOUNDING PROCESS3PC-009
PDF DocumentFORMULATION OF TACROLIMUS SOLUTION FOR SUBLINGUAL USE3PC-010
PDF DocumentA VIRTUAL STERILISATION AREA : AN INTERACTIVE TRAINING TOOL3PC-011
PDF DocumentIMPACT AND SATISFACTION IN DRUG ADDICTS ATTENTION CENTERS AFTER INCREASING THE STABILITY OF METHADONE ORAL SOLUTION3PC-012
PDF DocumentFORMULATION AND ELABORATION OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF A MENINGEAL CARCINOMATOSIS3PC-013
PDF DocumentMETAMORPHINE INSTEAD OF POLYSUBSTANCE USE?3PC-014
PDF DocumentIN-USE STABILITY OF COMIRNATY AND SPIKEVAX CLINICAL SOLUTIONS: PFIZER-BIONTECH AND MODERNA COVID-19 VACCINES. A COMPARATIVE STUDY FROM A HOSPITAL PHARMACY PERSPECTIVE3PC-015
PDF DocumentDOES A HOSPITAL COMPRESSOR SYSTEM CONTINOUSLY DELIVER MEDICINAL AIR ACCORDING TO THE EUROPEAN PHARMACOPAEIA?3PC-016
PDF DocumentIMPACT OF AGITATION ON PEMBROLIZUMAB (KEYTRUDA®) SAFETY AND EFFICACY: AGGREGATION AND FUNCTIONALITY.3PC-017
TIME TO AVAILABILITY OF INJECTABLE ANTICANCER DRUGS FOR OUTPATIENTS: REASSESSMENT IN A FRENCH COMPREHENSIVE CANCER CENTER3PC-018
PDF DocumentINDIGO CARMINE SOLUTION AND ADRENALINE IN SUBMUCOSAL CHROMOENDOSCOPY3PC-019
PDF DocumentCLOBETASOL PETROLATUM OINTMENT 0.015% FOR THE TREATMENT OF CUTANEOUS GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS: A CASE REPORT.3PC-020
PDF DocumentAMPHOTERICIN AND COLISTIN GELS FOR NECROTIZING WOUNDS: GALENIC AND MICROBIOLOGICAL VALIDATION.3PC-021
PDF DocumentFORMULATION AND QUALITY CONTROL OF A BISOPROLOL 0.5 MG/ML ORAL SOLUTION FOR PAEDIATRIC USE3PC-022
PDF DocumentPATCH TESTS WITH ETHAMBUTOL 10%, ISONIAZID 15% AND PYRAZINAMIDE 25%: A CASE REPORT.3PC-023
PDF DocumentTHE PREPARATION PERSONALIZED OF IMMUNOGLOBULIN BAGS TO IMPROVE THE TREATMENT PATH OF NEUROLOGICAL PATIENTS3PC-024
OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT): AN EXAMPLE DURING THE COVID-19 HEALTH EMERGENCY.3PC-025
PDF DocumentEFFECTIVENESS AND SAFETY OF INSULIN 1UI/ml EYE DROPS3PC-026
PDF DocumentSTABILITY OF TACROLIMUS ORAL SUSPENSION IN DISPOSABLE POLYPROPYLENE SYRINGE3PC-027
PDF DocumentFORMULATION OF AN ORAL PLATELET LYSATE GEL TO TREAT CHRONIC GRAFT VERSUS HOST DISEASE ASSOCIATED ORAL MUCOSITIS. EFFECTIVENESS IN A SERIES OF CASES3PC-028
PDF DocumentMANAGEMENT OF A CHEMOTHERAPY PRODUCTION AFTER A CYBER-ATTACK IN A PUBLIC HOSPITAL3PC-029
PDF DocumentEVALUATION OF EXCIPIENTS USED IN PAEDIATRIC COMPOUNDED FORMULATIONS PRESCRIBED IN A NEONATAL INTENSIVE CARE UNIT3PC-030
PDF DocumentA DELPHI METHOD TO STANDARDIZE THE PREPARATION OF AUTOLOGOUS SERUM EYE DROPS ?3PC-031
USE OF ORAL KETAMINE FORMULATION IN PATIENTS WITH CHRONIC REFRACTORY PAIN3PC-032
PDF DocumentECONOMIC IMPACT OF CENTRALIZING PEDIATRIC INTRAVENOUS ADMIXTURES3PC-033
USE OF A MIXTURE OF BLEOMYCIN, LIDOCAINE AND EPINEPHRINE IN THE TREATMENT OF KELOID SCARS.ON THE SUBJECT OF A CASE.3PC-034
PDF DocumentGALENIC DEVELOPMENT OF A GENERIC SPECIALTY WITH CONVENTIONAL RELEASE BASED ON ACARBOSE3PC-035
PDF DocumentCENTRALIZED AND PERSONALIZED PREPARATION OF INTRAVENOUS KETAMINE FOR PATIENTS WITH RESISTANT DEPRESSION3PC-036
PDF DocumentLIQUID CHROMATOGRAPY MASS SPECTROMETRY ANALYSIS OF DOXORUBICIN AND EPIRUBICIN AFTER FREEZING3PC-037

Section 4: Clinical Pharmacy Services

PDF DocumentPoster TitlePoster Number
PDF DocumentEMICIZUMAB IN ACQUIRED HAEMOPHILIA TYPE A: A CASE REPORT.4CPS-001
PDF DocumentSAFETY AND EFFECTIVENESS OF MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION AFTER TWO AND A HALF YEARS OF CLINICAL EXPERIENCE4CPS-002
PDF DocumentEXPERIENCES WITH A BEST POSSIBLE MEDICATION HISTORY (BPMH) CONDUCTED BY PHARMACY STUDENTS IN THE HOSPITAL SETTING: A SCOPING REVIEW4CPS-003
PDF DocumentTRENDS IN TREATMENTS DURING COVID-19 PANDEMIA IN A UNIVERSITY TERTIARY HOSPITAL4CPS-004
PDF DocumentSUCCESSFUL TREATMENT OF OSTEOMYELITIS CAUSED BY DIFFICULT-TO-TREAT RESISTANT PSEUDOMONAS AERUGINOSA WITH CEFIDEROCOL AS MONOTHERAPY: A CASE REPORT4CPS-005
PDF DocumentCOMPLETE CLINICAL RESPONSE IN METASTATIC BREAST CANCER AFTER FRONT-LINE TREATMENT WITH RIBOCICLIB/TAMOXIFEN4CPS-006
PDF DocumentTARGETING PATIENTS WITH PNEUMONIA BY COVID-19 THAT COULD BE BENEFICIATED BY COLCHICINE.4CPS-007
PDF DocumentDOES COMORBIDITY AFFECT ADHERENCE TO INHALERS IN SEVERE ASTHMA PATIENTS TREATED WITH BIOLOGICS?4CPS-008
PDF DocumentΔ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY : EVALUATION OF EFFECTIVENESS AND SAFETY4CPS-009
PDF DocumentDUPILUMAB FOR THE TREATMENT OF ATOPIC DERMATITIS: EVALUATION OF EFFECTIVENESS AND SAFETY4CPS-010
PDF DocumentCLINICAL AND ECONOMIC IMPACT OF PHARMACIST ANTIMICROBIAL INTERVENTIONS IN A SMALL HOSPITAL4CPS-011
PDF DocumentPLATELET TO LYMPHOCYTE RATIO (PLR) AS BIOLOGICAL MARKER OF INTEREST IN INMUNOTHERAPY4CPS-012
TREOSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE. EFFICACY AND SAFETY.4CPS-013
PDF DocumentCOMPARISON OF TWO PROTOCOLS FOR THE ADMINISTRATION OF LEUCOVORIN RESCUES AFTER HIGH DOSE METHOTREXATE INFUSION OF 24 HOURS4CPS-014
PDF DocumentROLE OF CLINICAL PHARMACIST IN THE OPTIMISATION OF NIRMATRELVIR/RITONAVIR PRESCRIPTION IN THE EMERGENCY DEPARTMENT4CPS-015
PDF DocumentPREDICTIVE PERFORMANCE OF GLOMERULAR FILTRATION RATE EQUATIONS BASED ON CYSTATIN C, CREATININE AND THEIR COMBINATION IN CRITICALLY ILL PATIENTS4CPS-016
PDF DocumentREAL-WORLD EVIDENCE ON RHEUMATOID ARTHRITIS TREATMENT PERSISTENCE: JANUS KINASE INHIBITORS VERSUS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS.4CPS-017
PDF DocumentEVOLUTION OF ANTIMICROBIAL USE IN COVID-19 PATIENTS4CPS-018
PDF DocumentQUALITY ASSESSMENT OF THE EVIDENCE UNDERPINNING PHARMACIST-LED ANTIMICROBIAL STEWARDSHIPS INTERVENTIONS4CPS-019
PDF DocumentTREATMENT PERSISTENCE AND DISCONTINUATION REASONS OF JANUS KINASE INHIBITORS IN A REAL-WORLD SETTING OF RHEUMATOID ARTHRITIS PATIENTS.4CPS-020
EFFECTIVENESS, PERSISTENCE, AND ADHERENCE OF BARICITINIB IN RHEUMATOID ARTHRITIS: LONG-TERM REAL-WORLD EVIDENCE STUDY4CPS-021
PDF DocumentADHERENCE TO EVOLOCUMAB AND ITS IMPACT ON LDL CHOLESTEROL REDUCTION4CPS-022
PDF DocumentTOPICAL RAPAMYCIN IN RARE TUBEROUS SCLEROSIS DISEASE: LIPOSOMAL FORMULATION STABILITY4CPS-023
PDF DocumentCOMPARISON OF CHANGES IN CLINICAL VALUES OF INTENSIVE CARE PATIENTS AT VETERANS HOSPITAL ACCORDING TO VARIOUS FAT EMULSIONS FOR PARENTERAL NUTRITION4CPS-024
FREMANEZUMAB UTILISATION STUDY AND EFFECTIVENESS IN THE ‘REAL WORLD’4CPS-025
PDF DocumentEFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN REDUCING POTASSIUM CONCENTRATIONS IN HOSPITALISED PATIENTS4CPS-026
PDF DocumentCOST SAVINGS IMPACT AND EFFECTIVENESS OF OMALIZUMAB OPTIMISATION IN REFRACTORY CHRONIC URTICARIA.4CPS-027
DRUG BURDEN INDEX EVALUATION IN INSTITUTIONALIZED GERIATRIC PATIENTS AS A DEPRESCRIPTION STRATEGY4CPS-028
PDF DocumentECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES4CPS-029
PDF DocumentIMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES4CPS-030
PDF DocumentTHERAPEUTIC DRUG MONITORING OF CEFTAZIDIME/AVIBACTAM ADMINISTERED BY CONTINUOUS INFUSION: PK/PD TARGET ACHIEVEMENT AND CLINICAL OUTCOMES4CPS-031
THE USE OF LEAN METHODOLOGY IN CLINICAL PHARMACOKINETICS – A RETROSPECTIVE ANALYSIS4CPS-032
PDF DocumentEVALUATION OF THE EFFECTIVENESS OF REINDUCTION OR INTENSIFICATION WITH USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE4CPS-033
PDF DocumentANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-194CPS-034
PDF DocumentASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE4CPS-035
PDF DocumentSUCCESSFUL TREATMENT OF POSTSURGICAL MENINGITIS CAUSED BY BACILLUS CEREUS: A CASE REPORT4CPS-036
PDF DocumentINDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN PSORIATIC ARTHRITIS4CPS-037
PDF DocumentCHALLENGES RELATED TO TRANSITIONING FROM HOSPITAL TO TEMPORARY CARE AT A SKILLED NURSING FACILITY4CPS-038
PDF DocumentCLINICAL AND ECONOMIC IMPACT OF MULTISWITCHING FROM ORIGINAL ADALIMUMAB TO BIOSIMILARS.4CPS-039
PDF DocumentELECTRONIC CLINICAL DECISION SUPPORT FOR PHARMACOTHERAPEUTIC INTERVENTIONS TO REDUCE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS4CPS-040
PDF DocumentASSESSMENT OF QUALITY OF LIFE IN PATIENTS UNDERGOING ANTIMIGRAINE TREATMENT4CPS-041
PDF DocumentOFF-LABEL USE OF USTEKINUMAB IN NONBULLOUS CONGENITAL ICHTHYOSIFORM ERYTHRODERMA: A CASE REPORT4CPS-042
PDF DocumentDRUG-DRUG INTERACTIONS WITH NIRMATRELVIR/RITONAVIR FOR COVID-19 AND THE ROLE OF HOSPITAL PHARMACISTS4CPS-043
PDF DocumentEFFECTIVENESS AND SAFETY OF DIFFERENT INITIAL DOSES OF ARIPIPRAZOLE INTRAMUSCULAR DEPOT4CPS-044
ECOLOGICAL AND CLINICAL IMPACT OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME ON THE INCIDENCE OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE4CPS-045
A QUALITATIVE STUDY OF FEASABILITY AND ACCEPTABILITY OF A PHARMACY PRIORITISATION TOOLKIT BY A FRAILTY FOCUSED MULTIDICIPLINARY TEAM IN AN ACUTE HOSPITAL EMERGECY DEPARTMENT4CPS-046
PDF DocumentIMPACT OF CORTICOSTEROID ON THE EFFECTIVENESS OF IMMUNOTHERAPY4CPS-047
PDF DocumentANALYSIS OF PAXLOVID® FOR THE TREATMENT OF COVID-19 IN ARAGÓN, SPAIN4CPS-048
PDF DocumentTELEPHARMACY AND NEW HEALTHCARE MODELS: CLOSER TO PATIENTS4CPS-049
PDF DocumentANALYSIS OF REAL-LIFE USE OF IBRUTINIB AFTER RELAPSE TO CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA4CPS-050
IMPACT OF THE NEW ANTIEPILEPTIC DRUG MONITORING PROGRAMME ON THE ACTIVITY OF THE PHARMACY AND NEUROLOGY DEPARTMENTS4CPS-051
PDF DocumentLONG-TERM MONITORING OF UREA AS TREATMENT FOR HYPONATREMIA ASSOCIATED TO INADEQUATE SECRETION OF ANTIDIURETIC HORMONE (ISADH)4CPS-052
PDF DocumentKOUNIS SYNDROME SECONDARY TO METAMIZOLE: A CASE REPORT4CPS-053
PDF DocumentUSE OF INTRATHECAL LIPOSOMAL-AMPHOTERICIN B FOR CANDIDA MENINGITIS: A CASE REPORT.4CPS-054
PDF DocumentEFFECTIVENESS AND SAFETY OF RIBOCICLIB IN THE FIRST LINE OF LUMINAL METASTATIC BREAST CANCER.4CPS-055
A CLINICAL AND COST ANALYSIS OF MEDICINES RECONCILIATION BY CLINICAL PHARMACISTS ON HOSPITAL DISCHARGE4CPS-056
PDF DocumentSEARCHING FOR A TREATMENT FOR PERIPHERAL TISSUE ISCHEMIA IN NEWBORNS. A CASE REPORT.4CPS-057
PDF DocumentSYMBALOO AS DIGITAL TOOL FOR HEMOPHILIA4CPS-058
EFFICACY AND SAFETY OF EARLY SWITCH TO ORAL ANTIBIOTHERAPY IN PNEUMOLOGY: PROPENSITY SCORE-MATCHED ANALYSIS4CPS-059
PDF DocumentEFFECTIVENESS AND ECONOMIC ANALYSIS OF WEIGHT-BASED VERSUS FIXED DOSING OF PEMBROLIZUMAB IN NON SMALL CELL LUNG CANCER4CPS-060
PDF DocumentAPPLICATION OF PROPORTION OF DAY COVERED (PDC) TO EVALUATE ADHERENCE AND PERSISTENCE TO TREATMENT WITH FINGOLIMOD IN PATIENTS WITH MULTIPLE SCLEROSIS4CPS-061
PDF DocumentEVALUATION AND FOLOW-UP OF PEDIATRIC PATIENT WITH SHORT BOWEL SYNDROME ON TREATMENT WITH TEDUGLUTIDE: CASE REPORT4CPS-062
PDF DocumentUSING MACHINE LEARNING TO PREDICT PHARMACEUTICAL INTERVENTIONS IN A HOSPITAL SETTING4CPS-063
PDF DocumentEFFECTIVENESS OF RIBOCICLIB AND ABEMACICLIB AS FIRST LINE TREATMENT FOR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN.4CPS-064
SIMULATION OF THE IMPACT OF PHARMACOGENETIC MONITORING OF CYTOCHROME P450 2C19 IN PATIENTS ON CLOPIDOGREL TREATMENT4CPS-065
PDF DocumentBIOLOGICAL TREATMENTS USED TO TREAT HIDRADENITIS SUPPURATIVA IN A TERTIARY HOSPITAL4CPS-066
PDF DocumentA CROSS-SECTORAL PHARMACIST INTERVENTION FOR PATIENTS IN TRANSITION BETWEEN HOSPITAL AND GENERAL PRACTICE: A PILOT STUDY4CPS-067
PDF DocumentCONDUCTION OF AN AUDIT TO REDUCE THE ECONOMIC LOSS DUE TO UNUTILIZED ONCOLOGICAL DRUG PREPARATIONS4CPS-068
PDF DocumentEXPERIENCE OF ONCOHEMATOLOGY PATIENTS IN OUTPATIENT THERAPY WITH COMPREHENSIVE MEDICATION MANAGEMENT IN THE CONTEXT OF A COVID 19 PANDEMIC4CPS-069
PDF DocumentTHE CLINICAL PHARMACIST : AN ESSENTIAL ACTOR IN TIMES OF CRISIS4CPS-070
IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS4CPS-071
PDF DocumentREAL-WORLD EXPERIENCE IN HEMOPHILLIA B PATIENTS AFTER SWITCHING TO FIX EXTENDED HALF LIFE USING PHARMACOKINETIC POBLACIONAL SOFTWARE AND MONOCOMPARTIMENTAL MODEL4CPS-072
PDF DocumentANALYSIS OF EFFECTIVENESS AND POSITIVE PREDICTIVE VALUE OF ANTIMICROBIAL STEWARDSHIP ALERTS USING A CLINICAL-DECISSION SUPPORT SYSTEM4CPS-073
PDF DocumentEFFICACY AND SAFETY OF SOTROVIMAB: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY IN A FRENCH HOSPITAL4CPS-074
PDF DocumentPERSISTENCE AND COST ANALYSIS OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIASIS4CPS-075
PDF DocumentEFFECTIVENESS AND TOLERABILITY OF CYCLIN-DEPENDENT KINASE INHIBITOR TREATMENT IN METASTATIC BREAST CANCER: REAL-LIFE DATA.4CPS-076
PDF DocumentCLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS TREATED WITH DORAVIRINE4CPS-077
PDF DocumentASSESSMENT OF THE QUALITY OF A HOSPITAL’S CLINICAL TRIAL INITIATION VISIT4CPS-078
PDF DocumentCOMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM ADMINISTERED BY INTERMITTENT INFUSION VERSUS CONTINUOUS INFUSION4CPS-079
PDF DocumentOPTIMIZATION OF ANTIRETROVIRAL THERAPY: RESULTS AFTER SIMPLIFICATION TO BITHERAPY WITH DOLUTEGRAVIR/LAMIVUDINE OR DOLUTEGRAVIR/RILPIVIRINE.4CPS-080
EVALUATION OF EFFECTIVENESS, SAFETY AND ADHERENCE OF PRE-EXPOSURE PROPHYLAXIS AGAISNT HIV4CPS-081
PDF DocumentMOST FREQUENT ERRORS IN THE INHALATION TECHNIQUE OF ASTHMATIC CHILDREN4CPS-082
PDF DocumentCREATININE AND CYSTATIN-BASED ESTIMATED RENAL FUNCTION IN VANCOMYCIN MONITORING4CPS-083
PDF DocumentEFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH VERY HIGH VS HIGH PD-L1 EXPRESSION4CPS-084
PHARMACEUTICAL INTERVENTIONS IN A NEONATOLOGY UNIT4CPS-085
COMPARISON OF A TRADITIONAL ELISA TECHNIQUE VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.4CPS-086
PDF DocumentPERSISTENCE IN THE METHADONE MAINTENANCE PROGRAMME AND ITS RELATIONSHIP WITH THE MEDICATION REGIMEN COMPLEXITY INDEX IN OPIOID DEPENDENT PATIENTS4CPS-087
PDF DocumentCORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY IN NON-SMALL CELL LUNG CANCER TREATED WITH NIVOLUMAB4CPS-088
PDF DocumentCURRENT STATUS OF HEPATITIS C VIRUS INFECTION4CPS-089
A REVIEW OF PHARMACY HOMECARE SERVICES WITHIN A GROUP OF UK HOSPITAL PHARMACIES4CPS-090
PDF DocumentWHAT YOU NEED TO KNOW ABOUT BRUGADA SYNDROME IF YOU ARE A HOSPITAL PHARMACIST4CPS-091
PDF DocumentSTATISTICAL RELATIONSHIP BETWEEN BIOMARKERS WITH PROGNOSTIC VALUE IN ANTI-PDL1 TREATMENTS IN CANCER PATIENTS4CPS-092
PDF DocumentPOLYPHARMACY AND INAPPROPRIATE DRUGS IN PATIENTS WITH OROPHARYNGEAL DYSPHAGIA4CPS-093
PDF DocumentANALYSIS OF INTERVENTIONS ON ANTIBIOTIC PRESCRIPTIONS BY THE ANTIMICROBIAL STEWARDSHIP PROGRAMS AT THE EMERGENCY DEPARTMENT4CPS-094
PDF DocumentINFUSION AUDIT IN HEMATOLOGY: IMPORTANCE OF EVALUATION AND OPTIMIZATION OF PROFESSIONAL PRACTICES4CPS-095
EVOLUTION OF SELECTIVE IMMUNOMODULATE THERAPY IN SPECIAL SITUATIONS4CPS-096
PDF DocumentCOMPARATIVE EFFECTIVENESS OF RISANKIZUMAB AND SECUKINUMAB IN MODERATE TO SERIOUS PSORIASIS.4CPS-097
PDF DocumentNIRMATRELVIR-RITONAVIR EFFECTIVENESS ANALYSIS AND INTERACTION PROFILE ANALYSIS4CPS-098
PDF DocumentNINTEDANIB AND PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS: COMPARATIVE EFFECTIVENESS AND SAFETY IN A THIRD-LEVEL HOSPITAL4CPS-099
PDF DocumentVALIDITY, RELIABILITY AND USER-PRACTICABILITY OF A CLASSIFICATION TOOL FOR DRUG-RELATED PROBLEMS AND PHARMACIST INTERVENTIONS WITHIN AN UPPER AUSTRIAN HOSPITAL TRUST4CPS-100
PDF DocumentCAUSALITY OF ADVERSE DRUG REACTIONS IN HIV-PATIENTS TREATED WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE4CPS-101
PDF DocumentDRUG RELATED PROBLEMS SECONDARY TO HEPARIN TREATMENT IN PATIENTS DISCHARGED FROM THE EMERGENCY DEPARTMENT4CPS-102
PDF DocumentPHARMACOKINETIC INTERACTION STUDY OF OSIMERTINIB AND DIGOXIN: A CASE REPORT4CPS-103
PDF DocumentANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN A UNIT DOSE AREA4CPS-104
PDF DocumentCEFIDEROCOL TREATMENT IN COVID-19 POSITIVE PATIENTS CO-INFECTED WITH PAN-RESISTANT PSEUDOMONAS AERUGINOSA4CPS-105
PDF DocumentBEDSIDE CHECK OF MEDICATION APPROPRIATENESS (BED-CMA) AS A RISK-BASED TOOL FOR BEDSIDE CLINICAL PHARMACY SERVICES: A PROOF-OF-CONCEPT STUDY AT THE TRAUMA SURGERY WARD4CPS-106
PDF DocumentEFFECT OF PATIENT BODY WEIGHT ON THE PHARMACOKINETIC BEHAVIOR OF AMIKACIN4CPS-107
PDF DocumentPATIENT AND PHYSICIANS’S SATISFACTION WITH CLINICAL PHARMACY SERVICES ON A HEMATOLOGY WARD IN A LARGE TERTIARY CARE HOSPITAL4CPS-108
PDF DocumentTHERAPEUTIC DRUG MONITORING OF VANCOMYCIN IN ONCOLOGIC AND HEMATOLOGIC PATIENTS: REAL-WORLD DATA4CPS-109
PDF DocumentASSOCIATION BETWEEN BASELINE CHARACTERISTICSTS AND FIRST LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER PATIENTS4CPS-110
PDF DocumentIMPORTANCE OF IMPLEMENTING A CLINICAL PHARMACOKINETIC UNIT IN HOSPITAL PHARMACY SERVICE4CPS-111
PDF DocumentSURVEY OF DIETARY SUPPLEMENT USE AND VACCINATION STATUS AMONG RHEUMATOID ARTHRITIS PATIENTS DURING THE COVID-19 PANDEMIC4CPS-112
PDF DocumentANALYSIS OF PHARMACEUTICAL INTERVENTIONS AND ACTIVITY IN THE ARTHROPATHY PHARMACEUTICAL CARE PRACTICE IN A REGIONAL HOSPITAL4CPS-113
PDF DocumentDEVELOPMENT AND PROSPECTIVE VALIDATION OF A PREDICTION MODEL TO IDENTIFY CLINICALLY RELEVANT MEDICATION DISCREPANCIES AT THE EMERGENCY DEPARTMENT4CPS-114
PDF DocumentDEVELOPMENT AND IMPLEMENTATION OF A REVIEW PROGRAMME ASSISTED BY THE PHARMACIST TO IMPROVE THE ADEQUACY OF TREATMENT IN POLYMEDICATED PATIENTS IN HOSPITAL OUTPATIENT SETTING4CPS-115
PDF DocumentTHE EFFICIENCY AND COST-EFFECTIVENESS OF HEALTHCARE AND NUTRITIONAL INTERVENTIONS IN THE MANAGEMENT OF POST-STROKE OROPHARYNGEAL DYSPHAGIA, RESULTS OF A SYSTEMATIC REVIEW4CPS-116
PDF DocumentUSE OF ERYTHROMYCIN AS PROKINETIC IN CRITICALLY HOSPITALIZED PATIENTS4CPS-117
PDF DocumentHEALTH OUTCOMES IN A COHORT OF HIV+ PATIENTS STRATIFIED USING THE KAISER PERMANENTE PYRAMID POPULATION-BASED RISK STRATIFICATION MODEL4CPS-118
PDF DocumentPNEUMONOLOGY-PHARMACY COLLABORATION IN THE PHARMACOTHERAPEUTIC OPTIMIZATION OF MONOCLONAL ANTIBODIES IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA4CPS-119
PDF DocumentADVERSE EFFECTS OF ANTIRETROVIRALS: EXPERIENCE OF PATIENTS. «TALK ABOUT IT TO BETTER MANAGE IT»4CPS-120
PDF DocumentANALYSIS OF THE USE OF INTRAVENOUS IRON IN OUTPATIENTS4CPS-121
PDF DocumentCLINICAL FOLLOW-UP IN PATIENTS WITH MIGRAINE AFTER DISCONTINUATION OF PROPHYLACTIC BIOLOGICAL TREATMENT: A REAL-WORLD EXPERIENCE4CPS-122
PDF DocumentCASE-CONTROL STUDY ON THE ASSOCIATION BETWEEN NOSOCOMIAL BLOODSTREAM INFECTIONS AND GLUCOCORTICOIDS, TOCILIZUMAB, SYSTEMIC ANTIBIOTICS, MECHANICAL VENTILATION AND LENGTH OF HOSPITAL STAY IN COVID-19 HOSPITALISED PATIENTS4CPS-123
PDF DocumentEFFICACY AND SAFETY OF ERENUMAB IN A SECOND-LEVEL HOSPITAL4CPS-124
PDF DocumentPREEXPOSURE PROPHYLAXIS IN MEN AT HIGH RISK FOR HIV-1 INFECTION4CPS-125
PDF DocumentLINEZOLID STUDY USE AND ASSESSMENT THE APPROPRIATENESS OF ITS PRESCRIPTION IN A REGIONAL HOSPITAL4CPS-126
PDF DocumentPHARMACOKINETIC MONITORING OF VANCOMYCIN, GENTAMICIN AND AMIKACIN IN PAEDIATRIC POPULATION4CPS-127
PDF DocumentCLINICAL PRACTICE: ANTI-VEGF THERAPY FOR RESISTANT MACULAR EDEMA.4CPS-128
PDF DocumentREAL-LIFE EFFECTIVENESS AND SAFETY OF NIRAPARIB AND OLAPARIB IN HIGH-GRADE OVARIAN CANCER4CPS-129
PDF DocumentEVALUATION OF TIXAGEVIMAB-CILGAVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-194CPS-130
PDF DocumentSOCIAL FUNCTION OF THE TELEPHARMACY: A SOCIOECONOMIC ANALYSIS4CPS-131
PDF DocumentANALYSIS OF PHARMACEUTICAL INTERVENTIONS REGARDING ADMISSION RECONCILIATION4CPS-132
PDF DocumentSAFETY AND EFFECTIVENESS OF GUSELKUMAB ON MODERATE TO SEVERE PLAQUE PSORIASIS4CPS-133
PERSISTENCE AND SHIFT IN THE TREATMENT OF PSORIASIS IN THE PERIOD 2019 – 20214CPS-134
PDF DocumentMELANOMA ADJUVANT THERAPY: from trials to clinical practice2154CPS-135
PDF DocumentSTANDARD FIRST DAY OF LIFE CENTRAL PARENTERAL NUTRITION, EXPERIENCE IN REAL CLINICAL PRACTICE4CPS-136
PDF DocumentEVALUATING THE POTENTIAL CLINICAL AND ECONOMIC IMPACT OF CHEMOTHERAPY PRESCRIBING BY PHARMACISTS AT A UNIVERSITY TEACHING HOSPITAL4CPS-137
PDF DocumentUSE OF SODIUM ZIRCONIUM CYCLOSILICATE IN HYPERKALEMIC EMERGENCIES4CPS-138
PDF DocumentTHE PHARMACEUTICAL NEWSLETTER AS AN INFORMATION TOOL: USEFUL OR FUTILE ?4CPS-139
MEDICAL CANNABIS: PRESCRIPTION ANALYSIS IN TERMS OF FORMULATION AND THERAPEUTIC NEED IN AN HOSPITAL PHARMACY4CPS-140
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN A MEDICAL EMERGENCY DEPARTMENT: 6-MONTHS EXPERIENCE4CPS-141
PDF DocumentEVALUATION OF PREMEDICATION USE IN ADVERSE DRUG REACTIONS OCCURENCE IN PATIENTS WHO RECEIVED INFLIXIMAB TO TREAT INFLAMMATORY BOWEL DISEASE4CPS-142
PDF DocumentCORE BINDING FACTOR ACUTE MYELOID LEUKEMIA FOLLOWING IMMUNE CHECKPOINT INHIBITION FOR SOLID TUMORS: TWO CASE REPORTS AND LITERATURE STATE OF THE ART.4CPS-143
PDF DocumentEXPERIENCE OF USING REMDESIVIR IN THE TREATMENT OF PATIENTS WITH SARS-COV2 INFECTION4CPS-144
PDF DocumentCONSENSUS VALIDATION OF A SCREENING TOOL FOR CARDIOVASCULAR PHARMACOTHERAPY IN GERIATRIC PATIENTS: THE RASP_CARDIO LIST4CPS-145
PDF Document‘REAL WORLD’ EXPERIENCE OFELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN THE TREATMENT OF CYSTIC FIBROSIS: EFFECTIVENESS AND SAFETY EVALUATION4CPS-146
PDF DocumentREAL WORLD DATA (RWD) ANALYSIS ON USE OF IMMUNECHECKPOINT INHIBITORS (ICI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)4CPS-147
USE OF ANTIVIRALS AUTHORIZED FOR THE TREATMENT OF COVID-19 IN PATIENTS NOT SUBJECT TO HOSPITAL ADMISSION4CPS-148
PDF DocumentPAIN MANAGEMENT IN MENTAL HEALTH.4CPS-149
PDF DocumentTHE ROLE OF CLINICAL PHARMACIST IN EMERGENCY DEPARTMENT4CPS-150
PDF DocumentACETYLSALICYLIC ACID DESENSITIZATION IN PATIENTS WITH CORONARY ARTERY SYNDROME: LITERATURE REVIEW, RETROSPECTIVE ANALYSIS AND PATIENT FOLLOW-UP PROCEDURE IN AN ITALIAN CARDIOLOGICAL CENTER4CPS-151
PDF DocumentPERSISTENT CYTOPENIA AFTER CAR-T CELLS: TREATMENT WITH ELTROMBOPAG. A CASE REPORT.4CPS-152
PDF DocumentOFF-LABEL USE OF KETAMINE FOR RESISTANT DEPRESSION: ROLE OF THE HOSPITAL PHARMACIST4CPS-153
PDF DocumentIFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITS: INCIDENCE IN A PATIENT SAMPLE AND POSSIBLE CHEMIOTHERAPY PROTOCOL REVIEW4CPS-154
PDF DocumentCREATION AND VALIDATION OF A MEDICATION REVIEW SUPPORT TOOL FOR POTASSIUM CHLORIDE INJECTION (KCl-inj) PRESCRIPTIONS4CPS-155
PDF DocumentANALYSIS OF EFECTIVENESS AND COSTS OF DRUG THERAPY PRESCRIBED IN SPECIAL SITUATIONS IN OUR HOSPITAL4CPS-156
PDF DocumentCOMPARISON OF THE EFFECTIVENESS BETWEEN INTERLEUKIN-23 INHIBITORS FOR TREATMENT OF PSORIASIS IN A THIRD LEVEL HOSPITAL4CPS-157
PDF DocumentIMPROVEMENT IN PATIENT CARE BY PHARMACIST PHONE CALL AFTER STARTING TREATMENT4CPS-158
PDF DocumentESTIMATING RENAL FUNCTION FOR DRUG DOSING: CORRELATION BETWEEN CKD-EPI AND COCKCROFT-GAULT IN AN ELDERLY POPULATION4CPS-159
PDF DocumentREAL-WORLD PERSISTENCE WITH DOLUTEGRAVIR/LAMIVUDINE VERSUS BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE AMONG HUMAN IMMUNODEFICIENCY VIRUS PATIENTS4CPS-160
PDF DocumentNEGATIVE PRESSURE WOUND THERAPY IMPORTANCE IN WOUND CARE4CPS-161
PDF DocumentTRIPLE WHAMMY DRUG-DRUG INTERACTION: CLINICAL RELEVANCE AND RESULTS OF PHARMACEUTICAL INTERVENTION.4CPS-162
PDF DocumentCYTOCHROME P450 2C19 GENOTYPING FOR PERSONALISATION OF PROTON PUMP INHIBITOR THERAPY4CPS-163
PDF DocumentADEQUACY REVIEW IN THE USE OF DAPAGLIFLOZIN FOR THE TREATMENT OF HEART FAILURE.4CPS-164
PDF DocumentADAPTATION OF MARKETED PARENTERAL NUTRITION TO THE NEEDS OF A HOSPITAL.4CPS-165
PDF DocumentIMPLEMENTATION OF A LINEZOLID PHARMACOKINETIC MONITORING PROGRAMME4CPS-166
PDF DocumentCURRENT TRENDS IN THE USE OF CHECK-POINT INHIBITORS FOR NON-SMALL CELL LUNG CANCER4CPS-167
PDF DocumentRESULTS OF THE USE OF GALCANEZUMAB IN ROUTINE CLINICAL PRACTICE4CPS-168
PDF DocumentPHYSICOCHEMICAL CHARACTERIZATION OF ORAL LIQUID FORMS AND REVIEW OF THE LITERATURE FOR SAFE AND EFFECTIVE ADMINISTRATION BY ENTERAL FEEDING TUBES4CPS-169
THE HOSPITAL PHARMACIST ROLE IN MULTIDISCIPLINARY TEAM DURING THE VACCINATION CAMPAIGN4CPS-170
PDF DocumentMETHADONE DRUG-DRUG INTERACTIONS POTENTIALLY RELATED TO CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE4CPS-171
PDF DocumentBRODALUMAB’S EFFECTIVENESS ON MODERATE TO SEVERE PLAQUE PSORIASIS IN REAL PRACTISE4CPS-172
PDF DocumentEVALUATION OF INCLUSION CRITERIA OF OUTPATIENTS INCLUDED AT HOSPITAL MEDICATION DISPENSING PROGRAMME THROUGH COMMUNITY PHARMACIES4CPS-173
EFFECTIVITY AND SAFETY OF CYCLIN-DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER PATIENTS4CPS-174
PDF DocumentSEPSIS CODE: IMPROVING OUTCOMES FOR PATIENTS WITH SEPSIS4CPS-175
PDF DocumentEVALUATION OF NIRMATRELVIR/RITONAVIR USE AND EFFECTIVENESS4CPS-176
PDF DocumentOPTIMIZATION OF THE THERAPEUTIC MANAGEMENT OF PATIENTS ON ECMO IN THE PEDIATRIC INTENSIVE CARE UNIT4CPS-177
PDF DocumentDURABILITY OF TREATMENT AND REASONS FOR DISCONTINUATION OF DIMETHYL FUMARATE AND TERIFLUNOMIDE IN PATIENTS WITH MULTIPLE SCLEROSIS4CPS-178
REVERSAL OF ANTICOAGULATION IN ORTHOGERIATRIC PATIENTS WITH HIP FRACTURE REQUIRING EARLY SURGICAL INTERVENTION4CPS-179
PDF DocumentVANCOMYCIN: CONCORDANCE OF DOSAGE ADJUSTMENT ACCORDING TO MINIMUM PLASMA CONCENTRATION AND AREA UNDER THE CURVE/MINIMUM INHIBITORY CONCENTRATION4CPS-180
PDF DocumentFOLLOW-UP OF EXPOSED NEWBORNS TO HIV IN PREGNANCY IN A TERTIARY HOSPITAL4CPS-181
PDF DocumentEXPERIENCE OF DISCONTINUATION TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE4CPS-182
PDF DocumentEFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN REAL LIFE SETTING4CPS-183
PDF DocumentWHAT IS THE ADDITIONNAL VALUE OF PHARMACEUTICAL INTERVENTIONS ON [123I]-METAIODOBENZYLGUANIDINE SCINTIGRAPHY?4CPS-184
COMPOUNDED INSULIN EYE DROPS: POPULATION CHARACTERISTICS, USE IN CLINICAL PRACTICE AND SAFETY4CPS-185
PDF DocumentEFFECTIVENESS AND SAFETY OF CILGAVIMAB/TIXAGEVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-194CPS-186
PDF DocumentPATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH MONOCLONAL ANTIBODIES FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-194CPS-187
PDF DocumentQUALITY OF LIFE IN PATIENTS ON GALCANEZUMAB LONG TERM TREATMENT4CPS-188
PDF DocumentANALYSIS OF MEDICATION PERSISTANCE IN MIGRAINE PATIENTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES4CPS-189
PDF DocumentANALYSIS OF IBRUTINIB DOSE REDUCTION IN PATIENTS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA. ARE WE DOING IT RIGHT?4CPS-190
PDF DocumentIMPACT OF THE COVID-19 PANDEMIC ON THE ADHERENCE OF HIV PATIENTS4CPS-191
PDF DocumentANALYSIS OF ADHERENCE AND ASSOCIATED RISK FACTORS IN MULTIPLE SCLEROSIS PATIENTS UNDER DISEASE-MODIFYING THERAPY4CPS-192
PDF DocumentSUITABILITY OF THE DUAL ANTIPLATELET THERAPY TO THE GUIDELINES OF EUROPEAN SOCIETY OF CARDIOLOGY IN ACUTE CORONARY SYNDROME4CPS-193
PDF DocumentBASELINE AUDIT OF POTENTIAL TO OPTIMISE THERAPY THROUGH USE OF SGLT2i IN A COHORT OF PATIENT ADMITTED WITH AN ACUTE MYOCARDIAL INFARCTION4CPS-194
PDF DocumentE-LUNGING: EVALUATION OF AN E-LEARNING PROGRAM INTENDED FOR HEALTHCARE PROFESSIONALS REGARDING THE MEDICATION OF LUNG TRANSPLANT PATIENTS4CPS-195
PDF DocumentPOTENTIALLY INAPPROPIATE MEDICATIONS AND POTENTIALLY PRESCRIBING OMISSIONS IN OLDER PEOPLE LIVING WITH HIV4CPS-196
PDF DocumentCONCOMITANT USE OF PROTON PUMP INHIBITORS AND PALBOCICLIB: ¿IS THERE A REAL IMPACT ON RESPONSE?4CPS-197
PDF DocumentANALYSIS OF ANTIPSYCHOTIC DRUGS USE AT A SPANISH TERTIARY HOSPITAL4CPS-198
PDF DocumentPHARMACO-ECONOMIC IMPACT OF DRUG INTOXICATIONS IN CHILDREN4CPS-199
PDF DocumentSUSTAINING A PHARMACEUTICAL DECISION SUPPORT SYSTEM BY DETERMINING THE CLINICAL RISK’S LEVEL OF DETECTED DRUG-RELATED PROBLEMS4CPS-200
PDF DocumentPHARMACEUTICAL CARE TO OPTIMIZE TREATMENT FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A PRISON4CPS-201
PDF DocumentTHE USEFULNESS OF A PHARMACY RESIDENT STAGE IN THE CRITICAL CARE UNIT4CPS-202
PDF DocumentANTIBIOTIC STEWARDSHIP PROGRAMME INTERVENTIONS IN A THIRD LEVEL HOSPITAL IN SPAIN: A ONE-YEAR REVIEW4CPS-203
PDF DocumentNATIONAL SURVEY ON CLONIDINE PRESCRIBING PRACTICES IN COMPLEX TRAUMA IN CHILD PSYCHIATRY4CPS-204
PDF DocumentPHARMACIST’S INTERVENTION IN THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH HEART FAILURE – AN OPPORTUNITY FOR IMPROVEMENT4CPS-205
PDF DocumentEVALUATION OF IRON CARBOXYMALTOSE VS IRON SUCROSE ADMINISTRATION FOR THE CONTROL OF ANAEMIA IN HOSPITALISED PATIENTS4CPS-206
PHARMACEUTlCAL INTERVENTIONS IN AN INTENSIVE CARE UNIT OF EMERGENCY TRAUMA4CPS-207
PDF DocumentTELEPHARMACY INTERVENTIONS IN PATIENTS WITH CHRONIC DISEASES4CPS-208
PDF DocumentEXPERIENCE OF THE NOCEBO EFFECT IN PATIENTS WITH SWITCH TO BIOSIMILARS IN RHEUMATOID ARTHRITIS.4CPS-209
PDF DocumentEFFICACY OF MONOCLONAL ANTIBODIES TO PREVENT PROGRESSION TO SEVERE COVID-19 DISEASE: REAL-LIFE DATA OF A UNIVERSITY HOSPITAL4CPS-210
DESIGN AND VALIDATION OF A QUESTIONNAIRE IN ARABIC LANGUAGE EVALUATING CHRONIC RENAL FAILURE PATIENTS’S KNOWLEDGE4CPS-211
PDF DocumentSPECIALIST PHARMACIST-LED MULTIDISCIPLINARY CARE PATHWAY FOR OPTIMISING LIPID THERAPY – SIX MONTHS INTERIM ANALYSIS4CPS-212
PDF DocumentCHARACTERISTICS OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN VERSUS KAWAZAKI ON CLINICAL ASPECTS, SPECIFICITIES AND TREATMENT4CPS-213
PDF DocumentREAL-LIFE RESULTS ON THE USE OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER4CPS-214
PDF DocumentDESCRIPTION OF THE PRE-EXPOSURE PROPHYLAXIS COVERAGE AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS.4CPS-215
OFF-LABEL USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN JEHOVAH’S WITNESS PATIENTS WITH HIP FRACTURE SUBJECTED TO MAJOR ORTHOPAEDIC SURGERY: A THREE CASES REPORT4CPS-216
PDF DocumentTHE USE OF CYSTIC FIBROSIS CONDUCTANCE REGULATOR MODULATORS IN PATIENTS WITH RARE MUTATION4CPS-217
TNF GENE POLYMORPHISMS PREDICTORS OF RESPONSE TO ANTI-TNF DRUGS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS4CPS-218
PDF DocumentAGAMENON-SEOM MODEL FOR THE PREDICTION OF SURVIVAL IN PATIENTS WITH HER2-POSITIVE ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA RECEIVING TRASTUZUMAB-BASED FIRST-LINE TREATMENT4CPS-219
PDF DocumentCOMPARATIVE ANALYSIS OF SKIN TOXICITY ON PATIENTS WITH METASTATIC COLON CANCER TREATED WITH EPIDERMAL GROWTH RECEPTOR BLOCKING DRUGS.4CPS-220
PDF DocumentASSESSMENT OF CLINICAL BENEFIT OF CANCER TREATMENTS ACCORDING TO THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SCALE4CPS-221
PDF DocumentHAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED > 55 YEARS WITH ACUTE MYELOID LEUKAEMIA4CPS-222
PDF DocumentBOTULINUM TOXIN TYPE A: THE NON-INVASIVE SUCCESS FOR OVERACTIVE BLADDERS4CPS-223
PDF DocumentIMPACT OF AUGMENTED RENAL CLEARANCE ON ANTIMICROBIAL DOSING IN SEVERELY BURNED PATIENTS4CPS-224
PDF DocumentHEALTH IMPACT OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH BIOLOGICAL AGENTS FROM THE PATIENT’S PERSPECTIVE: A CROSS-SECTIONAL STUDY USING PATIENT REPORTED OUTCOME MEASURES (PROMs)4CPS-225
PDF DocumentCONTINUOUS INFUSION OF VANCOMICYN: WHO ARE THE PATIENT CANDIDATES AND HOW SAFE IT IS?4CPS-226
PDF DocumentREAL WORLD EVIDENCE OF THE USE OF DEFIBROTIDE FOR PROPHYLAXIS OF VENO-OCCLUSIVE DISEASE AFTER POST-HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN4CPS-227
PDF DocumentHIGH DOSE PHENOBARBITAL COMA IN PAEDIATRIC REFRACTORY STATUS EPILEPTICUS4CPS-228
PDF DocumentTHE ADDED VALUE OF A NATIONAL ELECTRONIC HEALTH RECORD FOR THE BEST POSSIBLE MEDICATION HISTORY OBTAINED BY A CLINICAL PHARMACIST4CPS-229
PDF DocumentALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED <60 YEARS WITH ACUTE MYELOID LEUKEMIA4CPS-230
EVALUATION OF CLINICAL DATA OF PATIENTS TREATED WITH ANTI-PCSK9 DRUGS IN TWO HEALTH DISTRICTS4CPS-231
PDF DocumentCOMPARATIVE EFFICACY OF RISANKIZUMAB AND GUSELKUMAB IN MODERATE TO SEVERE PLAQUE PSORIASIS4CPS-232
PDF DocumentPD-L1 EXPRESSION AND HISTOLOGICAL TYPE AS PREDICTORS OF RESPONSE IN METASTASIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PEMBROLIZUMAB IN FIRST LINE4CPS-233
PDF DocumentDEVELOPMENT AND VALIDATION OF A RAPID HIGH PERFORMANCE CHROMATOGRAPHY METHOD (HPLC) FOR THE DETERMINATION OF LINEZOLID IN HUMAN PLASMA4CPS-234
IMPACT OF TELEPHARMACY ON BIOLOGIC THERAPIES ADHERENCE AND CLINICAL OUTCOMES IN PATIENTS WITH PSORIASIS4CPS-235
PDF DocumentLOSS TO FOLLOW-UP FACTORS OF PEOPLE LIVING WITH HIV4CPS-236
PDF DocumentHYPERKALEMIA AND RISK FACTORS: SCREENING AND ASSESSSMENT IN HOSPITAL PATIENTS.4CPS-237
PDF DocumentPROFILE OF ELDERLY PATIENTS AT HIGH FALL RISK AND POLYPHARMACY IN THE EMERGENCY DEPARTMENT.4CPS-238
PDF DocumentPOPULATION PHARMACOKINETICS OF ISAVUCONAZOLE BASED ON PHAMACOGENETICS IN IMMUNOSUPPRESSED PATIENTS4CPS-239
FINGOLIMOD: ANALYSIS OF USE AND SAFETY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS4CPS-240
PDF DocumentFINAL VALIDITY OF A TOOL FOR RATING SIGNIFICANCE OF PHARMACISTS’ CLINICAL CONTRIBUTIONS IN HOSPITAL4CPS-241
PDF DocumentISAVUCONAZOLE TREATMENT IN TWO PEDIATRIC PATIENTS DURING EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: THE ROLE OF THERAPEUTIC DRUG MONITORING.4CPS-242
PDF DocumentDELAYED HIV TREATMENT AND FACTORS ASSOCIATED4CPS-243
PDF DocumentANALYSIS AND COMPARISON OF OLANZAPINE ADMINISTRATION IN SMOKING AND NON-SMOKING PATIENTS4CPS-244
PDF DocumentPREVENTION OF REFEEDING SYNDROME IN PATIENTS ON PARENTERAL NUTRITION: A REVIEW OF APPROPRIATENESS4CPS-245
PDF DocumentTREATMENT AND NURSING CARE OF MUCORMYCOSIS IN PAEDIATRICS: A CASE REPORT4CPS-246
PDF DocumentINITIATIVES TO IMPROVE THE MANAGEMENT OF PATIENTS WITH HEREDITARY ANGIOEDEMA BY HOSPITAL PHARMACY4CPS-247
PDF DocumentTHERAPEUTIC DRUG MONITORING OF LINEZOLID IN SOFT-TISSUE AND OSTEOARTICULAR INFECTIONS: A RETROSPECTIVE ANALYSIS4CPS-248
PDF DocumentRELATIONSHIP BETWEEN RENAL FUNCTION AND ERTAPENEM PLASMA CONCENTRATION IN ADULT PATIENTS.4CPS-249
PDF DocumentEXPERIENCE OF TECOVIRIMAT AND CIDOFOVIR USE IN A PATIENT WITH MONKEYPOX: A CASE REPORT4CPS-250
PDF DocumentHEREDITARY ANGIOEDEMA: IMPACT OF THE BURDEN OF DISEASE IN SPAIN4CPS-251
PDF DocumentOPTIMIZATION OF ERTAPENEM POSOLOGY IN A CRITICALLY ILL PATIENT BY THERAPEUTIC DRUG MONITORING: A CASE REPORT4CPS-252
DESCRIPTIVE STUDY OF THE ONCOLOGY AND HAEMATOLOGY POPULATION, DIAGNOSIS, AND IMMUNOTHERAPY IN PATIENTS OVER 65 YEARS OLD IN A THIRD LEVEL HOSPITAL4CPS-253
PDF DocumentDAPAGLIFOZIN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE4CPS-254
PDF DocumentANTIPARKINSONIAN MEDICATION RECONCILIATION: HOW PREVENTING MEDICATION ERRORS PROMOTES THERAPEUTIC QUALITY AND SAFETY4CPS-255
PDF DocumentENHANCING THE SAFETY OF INJECTABLE CYTOTOXIC CHEMOTHERAPY AT A TERTIARY CARE HOSPITAL: A RETROSPECTIVE ANALYSIS OF PHARMACISTS’ INTERVENTIONS IN CHEMOTHERAPY PREPARATION SERVICES4CPS-256
PDF DocumentPREOPERATIVE INTRAVENOUS IRON TO TREAT ANEMIA BEFORE MAJOR ORTHOPEDIC SURGERY4CPS-257
PDF DocumentPHARMACOKINETICS ALTERATIONS IN FIVE CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL4CPS-258
PDF DocumentMANAGEMENT OF VORICONAZOLE-INDUCED LIVER TOXICITY IN A PEDIATRIC PATIENT4CPS-259
PDF DocumentPERSISTENCE, SAFETY AND ASSOCIATED LYMPHOPENIA OF DIMETHYL FUMARATE IN RELAPSING REMITTING MULTIPLE SCLEROSIS, REAL WORLD DATA4CPS-260
ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ONCOLOGICAL TREATMENT OF PROSTATE CANCER AND CHRONIC MEDICATION.4CPS-261
PDF DocumentA NOVEL ARTIFICIAL INTELLIGENCE-BASED TOOL TO ASSESS ANTICHOLINERGIC BURDEN: A SURVEY4CPS-262
PDF DocumentTHE PHARMACIST’S ROLE IN OPTIMIZING SURGICAL ANTIBACTERIAL PROPHYLAXIS (SAP)4CPS-263

Section 5: Patient Safety and Quality Assurance

PDF DocumentPoster TitlePoster Number
PDF DocumentEFFICACY AND SAFETY OF THE COMBINATION OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA: A CASE REPORT5PSQ-001
PDF DocumentPHARMACIST IN SECURING DRUG CIRCUIT : FROM PRESCRIPTION TO ADMINISTRATION (ANALYSIS AND ACTIONS)5PSQ-002
PDF DocumentPERFORMANCE OF A COLD MAINTENANCE DEVICE DURING THE IMPLEMENTATION OF A PNEUMATIC CIRCUIT5PSQ-003
PDF DocumentEPCLUSA RELATED SLEEPINESS: A CASE REPORT 5PSQ-004
PDF DocumentANALYSIS OF ANTI-ANGIOGENESIS-RELATED ADVERSE EVENTS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (VEGFR-TKIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA 5PSQ-005
PDF DocumentIMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: A 7-MONTHS ANALYSIS5PSQ-006
PDF DocumentIMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: WHAT’S NEW AND WHAT’S LEFT?5PSQ-007
PDF DocumentA DIGITAL ASSISTANT TO SUPPORT PATIENTS IN PREPARING MEDICATION RECONCILIATION: PATIENT EXPERIENCES.5PSQ-008
PDF DocumentEFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY SWITCHING IN MIGRAINE PATIENTS5PSQ-009
PDF DocumentDIGOXIN ADJUSTMENT: COMPARATIVE ANALYSIS OF THREE PHARMACOKINETIC SOFTWARE5PSQ-010
PDF DocumentPHARMACOKINETIC EVALUATION OF DRUGS WITH A NARROW THERAPEUTIC RANGE AND THEIR INFLUENCE ON CLINICAL DECISION5PSQ-011
PDF DocumentCASE REPORT: INHALED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR MILD-TO-MODERATE AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS – 24 MONTHS OF FOLLOW-UP5PSQ-012
PDF DocumentPALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: NEUTROPENIA MANAGEMENT IN CLINICAL PRACTICE.5PSQ-013
PDF DocumentIMPACT OF HISTAMINE-2 ANTAGONIST SHORTAGE ON THE INCIDENCE OF HYPERSENSITIVITY REACTIONS TO PACLITAXEL – TOWARDS CRISIS MANAGEMENT AND A PREMEDICATION RECONSIDERATION IN FRANCE (PACLIREACT STUDY)5PSQ-014
PDF DocumentPERSISTENCE OF TREATMENT WITH JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN PATIENTS ALREADY TREATED WITH THEM5PSQ-015
PDF DocumentHUMAN FACTORS ROLE IN MEDICATION ERRORS: DILUTING INTRAVENOUS MEDICATIONS AT HOSPITAL WARDS – A STUDY BASED ON INCIDENT REPORTS5PSQ-016
PDF DocumentIMMUNE-MEDIATED ADVERSE EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) THERAPY IN REAL LIFE POPULATION: WE CONTINUE TO LEARN.5PSQ-017
PDF DocumentPRESCRIBING ERRORS IN CHILDREN: WHAT IS THE IMPACT OF A COMPUTERIZED PHYSICIAN ORDER ENTRY?5PSQ-018
PDF DocumentANALYSIS OF THE USE OF IDARUCIZUMAB IN A TERTIARY HOSPITAL5PSQ-019
ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS TO INCREASE THE SAFETY AND ADEQUACY OF THEIR TREATMENT5PSQ-020
PDF DocumentAUTOMATION MEETS TRACEABILITY TO OPTIMIZE DRUGS AND MEDICAL DEVICES LOGISTICS GUARANTEEING PATIENT SAFETY AND HOSPITAL STAFF WELL-BEING5PSQ-021
PDF DocumentANALYSIS OF HEALTHCARE VISITS TO EMERGENCY SERVICES FROM PATIENTS WITH PAINFUL VASCULAR ULCERS TREATED WITH TOPICAL SEVOFLURANE5PSQ-022
PDF DocumentSEVERE PHOTOTOXICITY REACTION ASSOCIATED WITH VANDETANIB: A CASE REPORT5PSQ-023
PDF DocumentHAZARD VULNERABILITY ANALYSIS (HVA): EVALUATION OF RISK IN EXPERIMENTAL ONCOLOGICAL DRUGS COMPOUNDING5PSQ-024
PDF DocumentIMPACT AND EVALUATION OF PHARMACOKINETIC MONITORING IN PRIMARY CARE.5PSQ-025
PDF DocumentMEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND CDK4/6 INHIBITORS5PSQ-026
PDF DocumentAPPROPRIATENESS OF PRESCRIPTION OF TRICYCLIC ANTIDEPRESSANTS ACCORDING TO STOPP CRITERIA5PSQ-027
PDF DocumentCDK 4/6 INHIBITORS – ANALYSIS OF POTENTIAL DRUG INTERACTIONS5PSQ-028
PDF DocumentPERCEIVED EXPERIENCE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AFTER IMPLEMENTING A TELEPHARMACY PROGRAMME5PSQ-029
PDF DocumentSAFETY AND SECURITY OF CICLOSPORIN EYE DROPS IN PATIENTS WITH XEROPHTHALMIA5PSQ-030
PDF DocumentANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED5PSQ-031
PDF DocumentPHARMACIST INTEGRATION IN THE MULTIDISCIPLINARY EMERGENCY TEAM5PSQ-032
PDF DocumentANTIVIRAL TREATMENT DISCONTINUATION IN PATIENTS WITH HEPATITIS B5PSQ-033
PDF DocumentFIXED VS WEIGHT-BASED DOSING OF PEMBROLIZUMAB FOR PATIENTS UNDER 80 KG, BASED ON OBSERVED ADRS IN ONE CANCER SETTING5PSQ-034
PDF DocumentMASS UNIFORMITY OF HARD CAPSULES: ROYAL SPANISH PHARMACOPOEIA VS UNITED STATES PHARMACOPOEIA5PSQ-035
PDF DocumentMEDICATION ERRORS RELATED TO HIGH-ALERT MEDICATIONS IN A TERTIARY CARE PEDIATRIC HOSPITAL – AN ANALYSIS OF REGISTER-BASED DATA5PSQ-036
PDF DocumentIMPORTANCE AND IMPACT OF PHARMACEUTICAL RECONCILIATION AT DISCHARGE IN THE ELDERLY PATIENT WITH POLYMEDICATION5PSQ-037
PDF DocumentDRUG RELATED VISITS TO THE EMERGENCY DEPARTMENT IN NURSING HOME PATIENTS5PSQ-038
PDF DocumentRAF-KINASI PATHWAY INHIBITORS IN TREATMENT OF METASTATIC MELANOMA: WHEN COMPLIANCE DOESN’T MATCH WITH TOLERANCE.5PSQ-039
ANALYSIS OF THE IMPACT OF THE COVID-19 PANDEMIC ON PSYCHOTROPIC DRUG USE5PSQ-040
PDF DocumentSTERILE INTRAOCULAR INFLAMMATION AFTER INTRAVITREAL AFLIBERCEPT5PSQ-041
PDF DocumentPREVALENCE OF MEDICATION PRESCRIPTION WITH A POTENTIAL NEGATIVE EFFECT ON SWALLOWING IN OUTPATIENTS WITH COGNITIVE IMPAIRMENT AND A DIAGNOSIS OF DYSPHAGIA.5PSQ-042
UNSUPPORTED PRESCRIPTION OF POLYVALENT IMMUNOGLOBULINS IN A UNIVERSITY HOSPITAL CENTER: FREQUENCY AND COST5PSQ-043
PDF DocumentREAL-LIFE SAFETY AND SATISFACTION OF CFTR PROTEIN MODULATORS IN CYSTIC FIBROSIS5PSQ-044
PDF DocumentIMPACT OF PHARMACEUTICAL INTERVENTIONS IN CRITICAL PATIENTS5PSQ-045
PDF DocumentFMEA (FAILURE MODE AND EFFECT ANALYSIS) APPLICATION TO PARENTERAL NUTRITION BAGS MANUFACTURING PROCESS: ROLE OF HOSPITAL PHARMACIST5PSQ-046
PDF DocumentPRECAUTIONARY CANCELLATION: TOOL TO IMPROVE PATIENT SAFETY5PSQ-047
PDF DocumentWHAT DO ONCOLOGISTS AND PHARMACISTS THINK AND WANT FROM A CAHM-DRUG INTERACTION CHECKER? A BROADSCALE SURVEY TO ASSESS EXPECTATIONS.5PSQ-048
PDF DocumentASSESSMENT AND OPTIMISATION OF THE MANAGEMENT OF HIGH RISK MEDICINES IN A GENERAL HOSPITAL5PSQ-049
PDF DocumentANALYSIS OF THE USE OF USTEKINUMAB FOR CROHN DISEASE IN THE REAL CLINICAL PRACTICE5PSQ-050
PDF DocumentPARKINSONISM INDUCED BY TAKING TRAZODONE AS A HYPNOTIC: A CASE REPORT5PSQ-051
PDF DocumentCHANGES IN POLYMEDICATED PATIENTS’ PRESCRIPTIONS AFTER OUTPATIENT HOSPITAL CONSULTATIONS IN REAL LIFE SITUATIONS5PSQ-052
PDF DocumentDESIGN OF A PRIORIZATION SYSTEM BY COMPLEXITY OF THE REVIEW IN POLYMEDICATED PATIENTS: POTENTIAL INADECUACY INDEX5PSQ-053
PDF DocumentASSESSEMENT OF OCCUPATIONAL PRACTICES: ANALYSIS OF THE PRESCRIPTIONS OF TRANSCATHETER AORTICVALVE IMPLANTATION (TAVI)5PSQ-054
SAFETY TESTING ASSESSMENT FOR THE ADHERENCE OF DOSE REDUCTION IN ONCOLOGY TREATMENT FOLLOWING CLINICAL GUIDELINES RECOMMENDATIONS IN PATIENTS PRIOR RECEIVING FLUOROPYRIMIDINES (5-FLUOROURACIL, CAPECITABINE AND TEGAFUR)5PSQ-055
PDF DocumentHETEROGENEITY OF DEXMEDETOMIDINE TREATMENT EFFECT ON MORTALITY ACCORDING TO AGE5PSQ-056
PDF DocumentEFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF INFLAMMATORY FACIAL GRANULOMA SECONDARY TO SILICONE5PSQ-057
PDF DocumentMANAGEMENT OF SOLID ORAL PHARMACEUTICAL FORMS WITH UNIT DOSE5PSQ-058
PDF DocumentREAL-WORLD CLINICAL DATA OF PALBOCICLIB AND RIBOCICLIB IN BREAST CANCER PATIENT5PSQ-059
PDF DocumentGLUTEN IN MEDICINES. A PRESCRIPTION HELPING TOOL.5PSQ-060
PDF DocumentNEW-ONSET MULTIPLE SCLEROSIS ASSOCIATED WITH ADALIMUMAB TREATMENT: ABOUT TWO CASE REPORTS5PSQ-061
PDF DocumentREVIEW AND DEPRESCRIPTION OF MEDICATION IN POLYMEDICATED PATIENTS WITH PSYCHOACTIVE DRUGS.5PSQ-062
PDF DocumentA CROSS-SECTIONAL STUDY ON THE POTENTIALLY INAPROPIATE PRESCRIBED AND CONTRAINDICATED HIGH-RISK MEDICATION IN HOSPITALIZED CHRONIC COMPLEX PATIENTS5PSQ-063
PDF DocumentCONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT5PSQ-064
PDF DocumentBE A HUMAN, NOT A CASE REPORT! HOSPITAL PHARMACISTS MAKE THE DIFFERENCE5PSQ-065
PDF DocumentADEQUACY TO PROTOCOL OF USE OF TOCILIZUMAB FOR MANAGEMENT OF COVD-19 DISEASE5PSQ-066
TRACKING THE OVERAL IN USE AND STRESS STABILITY OF ROMIPLISTIM (N-PLATE®) BY THE EVALUATION OF A SELECTED SET OF CRITICAL QUALITY ATTRIBUTES5PSQ-067
PDF DocumentDIARRHEA OCCURRENCE ANALYSIS IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS5PSQ-068
PDF DocumentANALYSIS AND MONITORING OF ERRORS ASSOCIATED WITH ELECTRONIC PRESCRIPTION SYSTEMS: PRESCRIPTIONS WITH INCORRECT DRUG SCHEDULES.5PSQ-069
PDF DocumentPHARMACEUTICAL CARE IN AN ONCO-HEMATOLOGICAL CLINICAL TRIALS UNIT5PSQ-070
PDF DocumentANALYSIS OF MEDICATION PROVIDED BY PATIENTS5PSQ-071
PDF DocumentANALYSIS OF THE DURATION AND COMPLICATIONS ASSOCIATED WITH PERIPHERAL PARENTERAL NUTRITION: A COHORT STUDY.5PSQ-072
PDF DocumentIS THERE A SAFETY DIFFERENCE? JANUS KINASE INHIBITORS IN REAL CLINICAL PRACTICE5PSQ-073
PDF DocumentINTERACTIONS DETECTED WITH THE USE OF NIRMATRELVIR/RITONAVIR IN A TERTIARY HOSPITAL5PSQ-074
PDF DocumentPROPOSAL FOR THE ADJUSTMENT AND OPTIMISATION OF THE MEDICATION PROVIDED BY THE PATIENT5PSQ-075
PDF DocumentPATIENTS’ SATISFACTION AFTER CHANGING FROM 150MG TO 300MG SECUKINUMAB PEN PRESENTATION5PSQ-076
CYCLIN DEPENDENT KINASES 4 AND 6 INHIBITORS – REAL-WORLD DATA ANALYSIS5PSQ-077
PDF DocumentANALYSIS OF CASIRIVIMAB AND IMDEVIMAB USE IN OUTPATIENTS WITH COVID-195PSQ-078
PDF DocumentFONDAPARINUX IN AN INFANT WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA. A CASE REPORT.5PSQ-079
PDF DocumentIDENTIFICATION OF PHARMACOLOGICAL INTERACTIONS BETWEEN IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND DIETARY SUPPLEMENTS/HERBS IN PATIENTS WITH CYSTIC FIBROSIS IN AN OUTPATIENT PHARMACEUTICAL CARE UNIT5PSQ-080
PDF DocumentASSESSMENT OF THE IMPACT OF THE PHARMACEUTICAL INTERVENTION IN MEDICATION RECONCILIATION AT PATIENT ADMISSION IN A SURGICAL PRE-HOSPITALIZATION CLINIC5PSQ-081
GRAVIMETRIC CONTROL OF PARENTERAL NUTRITION IN NEONATOLOGY AND PEDIATRICS.5PSQ-082
PDF DocumentFOUR YEARS OF A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY5PSQ-083
PDF DocumentASSESSING QUALITY OF LIFE OF PATIENTS WITH SEVERE ASTHMA MEASURED BY PATIENT REPORTED OUTCOMES5PSQ-084
PDF DocumentMEDICATION ADMINISTRATION IN PATIENTS WITH DYSPHAGIA: SEARCHING FOR THE BEST PHARMACEUTICAL FORM5PSQ-085
PDF DocumentANALYSIS OF POTENCIALLY INAPPROPRIATE PRESCRIPTION IN A NURSING HOME5PSQ-086
PDF DocumentEVALUATION OF THE EFFECTIVENESS OF LAMIVUDINE IN THE PROPHYLAXIS OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL DISEASES5PSQ-087
PDF DocumentEXPLORING THE NEED FOR A CHECK OF COMPOUNDING APPROPRIATENESS SERVICE: EVALUATION OF SPONTANEOUS CHECKS BEFORE COMPOUNDING AT A LARGE TERTIARY CARE HOSPITAL5PSQ-088
CHRONIC NON-CANCER PAIN, WHAT ABOUT THIS PATIENTS?5PSQ-089
PDF DocumentSTUDY OF THE USE OF RESTRICTED ANTIBIOTICS DURING COVID-19 PANDEMIC: CEFTAROLINE, CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM.5PSQ-090
PDF DocumentTRIFECTA™ BIOPROSTHESES : EVALUATION OF THE SAFETY BASED ON THE STUDY OF DEGENERATIONS ACCORDING TO THE VARC-3 CLASSIFICATION5PSQ-091
PDF DocumentPHARMACOVIGILANCE OF BIOLOGICAL THERAPIES FROM THE OUTPATIENT DEPARTMENT5PSQ-092
PDF DocumentPHARMACEUTICAL INTERVENTION AFTER INAPPROPRIATE PRESCRIPTION OF ZOLPIDEM5PSQ-093
PDF DocumentTOXICITY IN PATIENTS TREATED WITH VENETOCLAX. A SAFETY STUDY IN REAL-WORLD PRACTICE5PSQ-094
CARDIAC CONDUCTION DISORDERS ASSOCIATED WITH THE USE OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY5PSQ-095
PDF DocumentA PROSPECTIVE OBSERVATIONAL STUDY OF MEDICATION PRESCRIBING ERRORS IN AN EMERGENCY DEPARTMENT.5PSQ-096
PDF DocumentHEALTH ALERT OF TOFACITINIB AND PHARMACEUTICAL INTERVENTION5PSQ-097
PDF DocumentSAFETY AND PERSISTENCE OF ANTI-FIBROTIC DRUGS IN INTERSTITIAL LUNG DISEASES5PSQ-098
PDF DocumentADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARS-CoV-2 INFECTION IN A UNIVERSITY HOSPITAL5PSQ-099
PDF DocumentUTILITY OF SOCIAL MEDIA AS A SOURCE OF PAEDIATRIC DRUG SAFETY, A SYSTEMATIC REVIEW5PSQ-100
ANALYSIS OF HIP PROSTHESES OVER A YEAR5PSQ-101
PDF DocumentSAFETY EVALUATION OF MIDLINE CATHETERS USED FOR ANTIBIOTIC THERAPY5PSQ-102
PDF DocumentPARENTAL UNMET NEEDS ON PAEDIATRIC DRUGS EXPRESSED IN FORUMS5PSQ-103
PDF DocumentERRORS IN ACENOCOUMAROL RECONCILIATION IN PATIENTS ADMITTED FROM THE EMERGENCY DEPARTMENT5PSQ-104
PDF DocumentDEVELOPMENT OF HYPOMAGNESEMIA IN CRITICAL PATIENTS TREATED WITH ISAVUCONAZOLE5PSQ-105
PDF DocumentSAFETY PERCEIVED BY PROFESSIONALS AFTER THE INNOVATION OF THE MEDICATION USE CIRCUIT IN A NEONATAL INTENSIVE CARE UNIT5PSQ-106
PDF DocumentSAFETY ASSESSMENT OF ERENUMAB AND GALCANEZUMAB IN CLINICAL PRACTICE5PSQ-107
PDF DocumentCOMPUTERIZED PHYSICIAN ORDER ENTRY WITH CLINICAL DECISION SUPPORT IN PREVENTING WRONG DOSE ERRORS IN PEDIATRIC MEDICATION ORDERS: A SYSTEMATIC REVIEW5PSQ-108
PDF DocumentRANSOMWARE ATTACK ON A CYTOTOXIC PREPARATION UNIT (CPU): WHAT NOW?5PSQ-109
IMPACT OF THE USE OF TRANSPARENT ADHESIVE DRESSINGS ON INFECTIONS IN PERITONEAL DIALYSIS5PSQ-110
PDF DocumentMEDICATION ERRORS, THEIR PERCEPTION, ANALYSIS, AND PROPOSAL OF SOLUTIONS IN A PUBLIC HOSPITAL5PSQ-111
PDF DocumentRELATIONSHIP BETWEEN EFFECTIVENESS AND IMMUNE-MEDIATED TOXICITY OF IMMUNE CHECK-POINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER5PSQ-112
PDF DocumentREAL-LIFE EFFECTIVENESS, SAFETY AND ADHERENCE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS5PSQ-113
PDF DocumentPERSISTENCE AND LEVEL OF CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH GUSELKUMAB5PSQ-114
PDF DocumentDEPRESCRIBING LONG-TERM TREATMENTS WITH BIPHOSPHONATES. PHARMACEUTICAL INTERVENTION BRINGS VALUE.5PSQ-115
PDF DocumentPERSISTENCE OF INHIBITORS OF INTERLEUKIN-23 (anti-IL-23) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (msPs) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS.5PSQ-116
PDF DocumentEVALUATION OF CARDIOTOXICITY BY OSIMERTINIB IN CLINICAL PRACTICE5PSQ-117
PDF DocumentPATIENTS´ EXPERIENCE WITH SUBCUTANEOUS INJECTION SELF-ADMINISTRATION AND THE ROLE OF VIRTUAL REALITY5PSQ-118
PDF DocumentA NEW PHARMACEUTICAL CARE PROGRAMME FOR COVID-19 PATIENTS TREATED WITH PAXLOVID® : IMPLEMENTATION AND SAFETY OUTCOMES REPORTED5PSQ-119
PDF DocumentANALYSIS OF THE PHARMACEUTICAL INTERVENTIONS PERFORMED ON ONCOHEMATOLOGICAL PATIENTS THROUGH AN ONCOHEMATOLOGY PHARMACY CONSULTATION5PSQ-120
PDF DocumentCYTOKINE RELEASE SYNDROME RELATED TO THE TREATMENT WITH TECLISTAMAB: A CASE REPORT5PSQ-121
PDF DocumentCOVID-19 VACCINE VIGILANCE: COMPARATIVE STUDY BETWEEN HOSPITAL, REGIONAL AND NATIONAL DATA5PSQ-122
PDF DocumentIMPACT OF PHARMACOTHERAPEUTIC COMPLEXITY ON ADHERENCE TO ANTIRETROVIRAL TREATMENT IN OLDER ADULTS WITH HIV5PSQ-123
PDF DocumentEFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL TREATMENT SIMPLIFICATION TO DOLUTEGRAVIR+LAMIVUDINE OR DOLUTEGRAVIR+RILPIVIRINE IN OLDER ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS5PSQ-124
PDF DocumentBRIDGING ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER A TRANSURETHRAL RESECTION: PATIENT MANAGEMENT IS DONE APPROPRIATELY?5PSQ-125
PDF DocumentEFFICACY AND SAFETY OF OMALIZUMAB, MEPOLIZUMAB AND BENRALIZUMAB IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA5PSQ-126
PDF DocumentPHARMACOLOGICAL RISK FACTORS FOR DRUG-DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV: A SYSTEMATIC REVIEW5PSQ-127
PDF DocumentTHROMBOPROPHYLAXIS IN THE EMERGENCY DEPARTMENT. ADEQUACY OF THE PRESCRIPTION.5PSQ-128
PDF DocumentSWITCHING BETWEEN ANTI-CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN MIGRAINE5PSQ-129
PDF DocumentOFF-LABEL USE OF CIDOFOVIR INTRALESIONAL INJECTIONS IN EXTENSIVE ANOGENITAL CONDYLOMATOSIS: A CASE REPORT5PSQ-130
PDF DocumentLETERMOVIR, GANCICLOVIR AND IMMUNOGLOBULINS COMBINATION TREATMENT IN AN IMMUNOCOMPROMISED PATIENT WITH CYTOMEGALOVIRUS INFECTION: A CASE REPORT5PSQ-131
PDF DocumentPHARMACOGENETIC-GUIDED TREATMENT IN PATIENTS WITH DYHYDROPIRYMIDINE DEHYDROGENASE DEFICIENCY5PSQ-132
PDF DocumentPHARMACISTS – GENERAL PRACTIONERS (GPs) COLLABORATION TO IDENTIFY DRUG-RELATED PROBLEMS (DRPs) IN PATIENTS IN POLYTHERAPY5PSQ-133
PDF DocumentUNIT DOSE IN A CYBERATTACK SCENARIO5PSQ-134
PDF DocumentHAS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME HAD AN IMPACT ON THE ANTIBIOTIC CONSUMPTION?5PSQ-135
PDF DocumentANALYSIS OF ANTIRETROVIRAL THERAPY POTENCY IN HIV- NAÏVE PATIENTS5PSQ-136
PDF DocumentANALYSIS OF THE DPYD GENE MUTATIONS IN CANCER PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH FLUOROPYRIMIDINES5PSQ-137
PDF DocumentCHEMOTHERAPY ERRORS DETECTED DURING PHARMACEUTICAL VALIDATION5PSQ-138
PDF DocumentUSING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs)5PSQ-139
PDF DocumentFREQUENCY OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS UNDERGOING HOME TREATMENT WITH DIRECT-ACTING ORAL ANTICOAGULANTS (DOACs)5PSQ-140
PDF DocumentFALLS IN ELDERLY PATIENTS AND CHRONIC CONSUMPTION OF ANXIOLYTIC BENZODIAZEPINES.5PSQ-141
PDF DocumentEVALUATION OF ADEQUACY, ADHERENCE AND SAFETY OF HUMAN IMMUNODEFICIENCY VIRUS POST-EXPOSURE TREATMENT5PSQ-142
PDF DocumentTHE ROLE OF THE PHARMACIST IN INCREASING HEALTH VIGILANCE AMONG HEALTH PROFESSIONALS: QUINCKE’S EDEMA FOLLOWING THE ADMINISTRATION OF RITUXIMAB5PSQ-143
PDF DocumentELECTRONIC PATIENT-REPORTED OUTCOME (PROM) MEASUREMENT USING PRO-CTCAE®QUESTIONNAIRE TO IMPROVE QUALITY OF LIFE ASSESSMENT AND HEALTHCARE RESOURCES MANAGEMENT IN PATIENTS WITH LYMPHOMA RECEIVING INTRAVENOUS CHEMOTHERAPY5PSQ-144
PDF DocumentA PATIENT SATISFACTION SURVEY ON UNIT DOSE DRUG DISTRIBUTION IN HOSPITAL5PSQ-145

Section 6: Education and Research

PDF DocumentPoster TitlePoster Number
PDF DocumentEFFICACY AND SAFETY OF THE COMBINATION OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA: A CASE REPORT5PSQ-001
PDF DocumentPHARMACIST IN SECURING DRUG CIRCUIT : FROM PRESCRIPTION TO ADMINISTRATION (ANALYSIS AND ACTIONS)5PSQ-002
PDF DocumentPERFORMANCE OF A COLD MAINTENANCE DEVICE DURING THE IMPLEMENTATION OF A PNEUMATIC CIRCUIT5PSQ-003
PDF DocumentEPCLUSA RELATED SLEEPINESS: A CASE REPORT 5PSQ-004
PDF DocumentANALYSIS OF ANTI-ANGIOGENESIS-RELATED ADVERSE EVENTS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (VEGFR-TKIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA 5PSQ-005
PDF DocumentIMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: A 7-MONTHS ANALYSIS5PSQ-006
PDF DocumentIMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS’ KNOWLEDGE: WHAT’S NEW AND WHAT’S LEFT?5PSQ-007
PDF DocumentA DIGITAL ASSISTANT TO SUPPORT PATIENTS IN PREPARING MEDICATION RECONCILIATION: PATIENT EXPERIENCES.5PSQ-008
PDF DocumentEFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY SWITCHING IN MIGRAINE PATIENTS5PSQ-009
PDF DocumentDIGOXIN ADJUSTMENT: COMPARATIVE ANALYSIS OF THREE PHARMACOKINETIC SOFTWARE5PSQ-010
PDF DocumentPHARMACOKINETIC EVALUATION OF DRUGS WITH A NARROW THERAPEUTIC RANGE AND THEIR INFLUENCE ON CLINICAL DECISION5PSQ-011
PDF DocumentCASE REPORT: INHALED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR MILD-TO-MODERATE AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS – 24 MONTHS OF FOLLOW-UP5PSQ-012
PDF DocumentPALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: NEUTROPENIA MANAGEMENT IN CLINICAL PRACTICE.5PSQ-013
PDF DocumentIMPACT OF HISTAMINE-2 ANTAGONIST SHORTAGE ON THE INCIDENCE OF HYPERSENSITIVITY REACTIONS TO PACLITAXEL – TOWARDS CRISIS MANAGEMENT AND A PREMEDICATION RECONSIDERATION IN FRANCE (PACLIREACT STUDY)5PSQ-014
PDF DocumentPERSISTENCE OF TREATMENT WITH JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN PATIENTS ALREADY TREATED WITH THEM5PSQ-015
PDF DocumentHUMAN FACTORS ROLE IN MEDICATION ERRORS: DILUTING INTRAVENOUS MEDICATIONS AT HOSPITAL WARDS – A STUDY BASED ON INCIDENT REPORTS5PSQ-016
PDF DocumentIMMUNE-MEDIATED ADVERSE EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) THERAPY IN REAL LIFE POPULATION: WE CONTINUE TO LEARN.5PSQ-017
PDF DocumentPRESCRIBING ERRORS IN CHILDREN: WHAT IS THE IMPACT OF A COMPUTERIZED PHYSICIAN ORDER ENTRY?5PSQ-018
PDF DocumentANALYSIS OF THE USE OF IDARUCIZUMAB IN A TERTIARY HOSPITAL5PSQ-019
ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS TO INCREASE THE SAFETY AND ADEQUACY OF THEIR TREATMENT5PSQ-020
PDF DocumentAUTOMATION MEETS TRACEABILITY TO OPTIMIZE DRUGS AND MEDICAL DEVICES LOGISTICS GUARANTEEING PATIENT SAFETY AND HOSPITAL STAFF WELL-BEING5PSQ-021
PDF DocumentANALYSIS OF HEALTHCARE VISITS TO EMERGENCY SERVICES FROM PATIENTS WITH PAINFUL VASCULAR ULCERS TREATED WITH TOPICAL SEVOFLURANE5PSQ-022
PDF DocumentSEVERE PHOTOTOXICITY REACTION ASSOCIATED WITH VANDETANIB: A CASE REPORT5PSQ-023
PDF DocumentHAZARD VULNERABILITY ANALYSIS (HVA): EVALUATION OF RISK IN EXPERIMENTAL ONCOLOGICAL DRUGS COMPOUNDING5PSQ-024
PDF DocumentIMPACT AND EVALUATION OF PHARMACOKINETIC MONITORING IN PRIMARY CARE.5PSQ-025
PDF DocumentMEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND CDK4/6 INHIBITORS5PSQ-026
PDF DocumentAPPROPRIATENESS OF PRESCRIPTION OF TRICYCLIC ANTIDEPRESSANTS ACCORDING TO STOPP CRITERIA5PSQ-027
PDF DocumentCDK 4/6 INHIBITORS – ANALYSIS OF POTENTIAL DRUG INTERACTIONS5PSQ-028
PDF DocumentPERCEIVED EXPERIENCE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AFTER IMPLEMENTING A TELEPHARMACY PROGRAMME5PSQ-029
PDF DocumentSAFETY AND SECURITY OF CICLOSPORIN EYE DROPS IN PATIENTS WITH XEROPHTHALMIA5PSQ-030
PDF DocumentANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED5PSQ-031
PDF DocumentPHARMACIST INTEGRATION IN THE MULTIDISCIPLINARY EMERGENCY TEAM5PSQ-032
PDF DocumentANTIVIRAL TREATMENT DISCONTINUATION IN PATIENTS WITH HEPATITIS B5PSQ-033
PDF DocumentFIXED VS WEIGHT-BASED DOSING OF PEMBROLIZUMAB FOR PATIENTS UNDER 80 KG, BASED ON OBSERVED ADRS IN ONE CANCER SETTING5PSQ-034
PDF DocumentMASS UNIFORMITY OF HARD CAPSULES: ROYAL SPANISH PHARMACOPOEIA VS UNITED STATES PHARMACOPOEIA5PSQ-035
PDF DocumentMEDICATION ERRORS RELATED TO HIGH-ALERT MEDICATIONS IN A TERTIARY CARE PEDIATRIC HOSPITAL – AN ANALYSIS OF REGISTER-BASED DATA5PSQ-036
PDF DocumentIMPORTANCE AND IMPACT OF PHARMACEUTICAL RECONCILIATION AT DISCHARGE IN THE ELDERLY PATIENT WITH POLYMEDICATION5PSQ-037
PDF DocumentDRUG RELATED VISITS TO THE EMERGENCY DEPARTMENT IN NURSING HOME PATIENTS5PSQ-038
PDF DocumentRAF-KINASI PATHWAY INHIBITORS IN TREATMENT OF METASTATIC MELANOMA: WHEN COMPLIANCE DOESN’T MATCH WITH TOLERANCE.5PSQ-039
ANALYSIS OF THE IMPACT OF THE COVID-19 PANDEMIC ON PSYCHOTROPIC DRUG USE5PSQ-040
PDF DocumentSTERILE INTRAOCULAR INFLAMMATION AFTER INTRAVITREAL AFLIBERCEPT5PSQ-041
PDF DocumentPREVALENCE OF MEDICATION PRESCRIPTION WITH A POTENTIAL NEGATIVE EFFECT ON SWALLOWING IN OUTPATIENTS WITH COGNITIVE IMPAIRMENT AND A DIAGNOSIS OF DYSPHAGIA.5PSQ-042
UNSUPPORTED PRESCRIPTION OF POLYVALENT IMMUNOGLOBULINS IN A UNIVERSITY HOSPITAL CENTER: FREQUENCY AND COST5PSQ-043
PDF DocumentREAL-LIFE SAFETY AND SATISFACTION OF CFTR PROTEIN MODULATORS IN CYSTIC FIBROSIS5PSQ-044
PDF DocumentIMPACT OF PHARMACEUTICAL INTERVENTIONS IN CRITICAL PATIENTS5PSQ-045
PDF DocumentFMEA (FAILURE MODE AND EFFECT ANALYSIS) APPLICATION TO PARENTERAL NUTRITION BAGS MANUFACTURING PROCESS: ROLE OF HOSPITAL PHARMACIST5PSQ-046
PDF DocumentPRECAUTIONARY CANCELLATION: TOOL TO IMPROVE PATIENT SAFETY5PSQ-047
PDF DocumentWHAT DO ONCOLOGISTS AND PHARMACISTS THINK AND WANT FROM A CAHM-DRUG INTERACTION CHECKER? A BROADSCALE SURVEY TO ASSESS EXPECTATIONS.5PSQ-048
PDF DocumentASSESSMENT AND OPTIMISATION OF THE MANAGEMENT OF HIGH RISK MEDICINES IN A GENERAL HOSPITAL5PSQ-049
PDF DocumentANALYSIS OF THE USE OF USTEKINUMAB FOR CROHN DISEASE IN THE REAL CLINICAL PRACTICE5PSQ-050
PDF DocumentPARKINSONISM INDUCED BY TAKING TRAZODONE AS A HYPNOTIC: A CASE REPORT5PSQ-051
PDF DocumentCHANGES IN POLYMEDICATED PATIENTS’ PRESCRIPTIONS AFTER OUTPATIENT HOSPITAL CONSULTATIONS IN REAL LIFE SITUATIONS5PSQ-052
PDF DocumentDESIGN OF A PRIORIZATION SYSTEM BY COMPLEXITY OF THE REVIEW IN POLYMEDICATED PATIENTS: POTENTIAL INADECUACY INDEX5PSQ-053
PDF DocumentASSESSEMENT OF OCCUPATIONAL PRACTICES: ANALYSIS OF THE PRESCRIPTIONS OF TRANSCATHETER AORTICVALVE IMPLANTATION (TAVI)5PSQ-054
SAFETY TESTING ASSESSMENT FOR THE ADHERENCE OF DOSE REDUCTION IN ONCOLOGY TREATMENT FOLLOWING CLINICAL GUIDELINES RECOMMENDATIONS IN PATIENTS PRIOR RECEIVING FLUOROPYRIMIDINES (5-FLUOROURACIL, CAPECITABINE AND TEGAFUR)5PSQ-055
PDF DocumentHETEROGENEITY OF DEXMEDETOMIDINE TREATMENT EFFECT ON MORTALITY ACCORDING TO AGE5PSQ-056
PDF DocumentEFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF INFLAMMATORY FACIAL GRANULOMA SECONDARY TO SILICONE5PSQ-057
PDF DocumentMANAGEMENT OF SOLID ORAL PHARMACEUTICAL FORMS WITH UNIT DOSE5PSQ-058
PDF DocumentREAL-WORLD CLINICAL DATA OF PALBOCICLIB AND RIBOCICLIB IN BREAST CANCER PATIENT5PSQ-059
PDF DocumentGLUTEN IN MEDICINES. A PRESCRIPTION HELPING TOOL.5PSQ-060
PDF DocumentNEW-ONSET MULTIPLE SCLEROSIS ASSOCIATED WITH ADALIMUMAB TREATMENT: ABOUT TWO CASE REPORTS5PSQ-061
PDF DocumentREVIEW AND DEPRESCRIPTION OF MEDICATION IN POLYMEDICATED PATIENTS WITH PSYCHOACTIVE DRUGS.5PSQ-062
PDF DocumentA CROSS-SECTIONAL STUDY ON THE POTENTIALLY INAPROPIATE PRESCRIBED AND CONTRAINDICATED HIGH-RISK MEDICATION IN HOSPITALIZED CHRONIC COMPLEX PATIENTS5PSQ-063
PDF DocumentCONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT5PSQ-064
PDF DocumentBE A HUMAN, NOT A CASE REPORT! HOSPITAL PHARMACISTS MAKE THE DIFFERENCE5PSQ-065
PDF DocumentADEQUACY TO PROTOCOL OF USE OF TOCILIZUMAB FOR MANAGEMENT OF COVD-19 DISEASE5PSQ-066
TRACKING THE OVERAL IN USE AND STRESS STABILITY OF ROMIPLISTIM (N-PLATE®) BY THE EVALUATION OF A SELECTED SET OF CRITICAL QUALITY ATTRIBUTES5PSQ-067
PDF DocumentDIARRHEA OCCURRENCE ANALYSIS IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS5PSQ-068
PDF DocumentANALYSIS AND MONITORING OF ERRORS ASSOCIATED WITH ELECTRONIC PRESCRIPTION SYSTEMS: PRESCRIPTIONS WITH INCORRECT DRUG SCHEDULES.5PSQ-069
PDF DocumentPHARMACEUTICAL CARE IN AN ONCO-HEMATOLOGICAL CLINICAL TRIALS UNIT5PSQ-070
PDF DocumentANALYSIS OF MEDICATION PROVIDED BY PATIENTS5PSQ-071
PDF DocumentANALYSIS OF THE DURATION AND COMPLICATIONS ASSOCIATED WITH PERIPHERAL PARENTERAL NUTRITION: A COHORT STUDY.5PSQ-072
PDF DocumentIS THERE A SAFETY DIFFERENCE? JANUS KINASE INHIBITORS IN REAL CLINICAL PRACTICE5PSQ-073
PDF DocumentINTERACTIONS DETECTED WITH THE USE OF NIRMATRELVIR/RITONAVIR IN A TERTIARY HOSPITAL5PSQ-074
PDF DocumentPROPOSAL FOR THE ADJUSTMENT AND OPTIMISATION OF THE MEDICATION PROVIDED BY THE PATIENT5PSQ-075
PDF DocumentPATIENTS’ SATISFACTION AFTER CHANGING FROM 150MG TO 300MG SECUKINUMAB PEN PRESENTATION5PSQ-076
CYCLIN DEPENDENT KINASES 4 AND 6 INHIBITORS – REAL-WORLD DATA ANALYSIS5PSQ-077
PDF DocumentANALYSIS OF CASIRIVIMAB AND IMDEVIMAB USE IN OUTPATIENTS WITH COVID-195PSQ-078
PDF DocumentFONDAPARINUX IN AN INFANT WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA. A CASE REPORT.5PSQ-079
PDF DocumentIDENTIFICATION OF PHARMACOLOGICAL INTERACTIONS BETWEEN IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND DIETARY SUPPLEMENTS/HERBS IN PATIENTS WITH CYSTIC FIBROSIS IN AN OUTPATIENT PHARMACEUTICAL CARE UNIT5PSQ-080
PDF DocumentASSESSMENT OF THE IMPACT OF THE PHARMACEUTICAL INTERVENTION IN MEDICATION RECONCILIATION AT PATIENT ADMISSION IN A SURGICAL PRE-HOSPITALIZATION CLINIC5PSQ-081
GRAVIMETRIC CONTROL OF PARENTERAL NUTRITION IN NEONATOLOGY AND PEDIATRICS.5PSQ-082
PDF DocumentFOUR YEARS OF A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY5PSQ-083
PDF DocumentASSESSING QUALITY OF LIFE OF PATIENTS WITH SEVERE ASTHMA MEASURED BY PATIENT REPORTED OUTCOMES5PSQ-084
PDF DocumentMEDICATION ADMINISTRATION IN PATIENTS WITH DYSPHAGIA: SEARCHING FOR THE BEST PHARMACEUTICAL FORM5PSQ-085
PDF DocumentANALYSIS OF POTENCIALLY INAPPROPRIATE PRESCRIPTION IN A NURSING HOME5PSQ-086
PDF DocumentEVALUATION OF THE EFFECTIVENESS OF LAMIVUDINE IN THE PROPHYLAXIS OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL DISEASES5PSQ-087
PDF DocumentEXPLORING THE NEED FOR A CHECK OF COMPOUNDING APPROPRIATENESS SERVICE: EVALUATION OF SPONTANEOUS CHECKS BEFORE COMPOUNDING AT A LARGE TERTIARY CARE HOSPITAL5PSQ-088
CHRONIC NON-CANCER PAIN, WHAT ABOUT THIS PATIENTS?5PSQ-089
PDF DocumentSTUDY OF THE USE OF RESTRICTED ANTIBIOTICS DURING COVID-19 PANDEMIC: CEFTAROLINE, CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM.5PSQ-090
PDF DocumentTRIFECTA™ BIOPROSTHESES : EVALUATION OF THE SAFETY BASED ON THE STUDY OF DEGENERATIONS ACCORDING TO THE VARC-3 CLASSIFICATION5PSQ-091
PDF DocumentPHARMACOVIGILANCE OF BIOLOGICAL THERAPIES FROM THE OUTPATIENT DEPARTMENT5PSQ-092
PDF DocumentPHARMACEUTICAL INTERVENTION AFTER INAPPROPRIATE PRESCRIPTION OF ZOLPIDEM5PSQ-093
PDF DocumentTOXICITY IN PATIENTS TREATED WITH VENETOCLAX. A SAFETY STUDY IN REAL-WORLD PRACTICE5PSQ-094
CARDIAC CONDUCTION DISORDERS ASSOCIATED WITH THE USE OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY5PSQ-095
PDF DocumentA PROSPECTIVE OBSERVATIONAL STUDY OF MEDICATION PRESCRIBING ERRORS IN AN EMERGENCY DEPARTMENT.5PSQ-096
PDF DocumentHEALTH ALERT OF TOFACITINIB AND PHARMACEUTICAL INTERVENTION5PSQ-097
PDF DocumentSAFETY AND PERSISTENCE OF ANTI-FIBROTIC DRUGS IN INTERSTITIAL LUNG DISEASES5PSQ-098
PDF DocumentADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARS-CoV-2 INFECTION IN A UNIVERSITY HOSPITAL5PSQ-099
PDF DocumentUTILITY OF SOCIAL MEDIA AS A SOURCE OF PAEDIATRIC DRUG SAFETY, A SYSTEMATIC REVIEW5PSQ-100
ANALYSIS OF HIP PROSTHESES OVER A YEAR5PSQ-101
PDF DocumentSAFETY EVALUATION OF MIDLINE CATHETERS USED FOR ANTIBIOTIC THERAPY5PSQ-102
PDF DocumentPARENTAL UNMET NEEDS ON PAEDIATRIC DRUGS EXPRESSED IN FORUMS5PSQ-103
PDF DocumentERRORS IN ACENOCOUMAROL RECONCILIATION IN PATIENTS ADMITTED FROM THE EMERGENCY DEPARTMENT5PSQ-104
PDF DocumentDEVELOPMENT OF HYPOMAGNESEMIA IN CRITICAL PATIENTS TREATED WITH ISAVUCONAZOLE5PSQ-105
PDF DocumentSAFETY PERCEIVED BY PROFESSIONALS AFTER THE INNOVATION OF THE MEDICATION USE CIRCUIT IN A NEONATAL INTENSIVE CARE UNIT5PSQ-106
PDF DocumentSAFETY ASSESSMENT OF ERENUMAB AND GALCANEZUMAB IN CLINICAL PRACTICE5PSQ-107
PDF DocumentCOMPUTERIZED PHYSICIAN ORDER ENTRY WITH CLINICAL DECISION SUPPORT IN PREVENTING WRONG DOSE ERRORS IN PEDIATRIC MEDICATION ORDERS: A SYSTEMATIC REVIEW5PSQ-108
PDF DocumentRANSOMWARE ATTACK ON A CYTOTOXIC PREPARATION UNIT (CPU): WHAT NOW?5PSQ-109
IMPACT OF THE USE OF TRANSPARENT ADHESIVE DRESSINGS ON INFECTIONS IN PERITONEAL DIALYSIS5PSQ-110
PDF DocumentMEDICATION ERRORS, THEIR PERCEPTION, ANALYSIS, AND PROPOSAL OF SOLUTIONS IN A PUBLIC HOSPITAL5PSQ-111
PDF DocumentRELATIONSHIP BETWEEN EFFECTIVENESS AND IMMUNE-MEDIATED TOXICITY OF IMMUNE CHECK-POINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER5PSQ-112
PDF DocumentREAL-LIFE EFFECTIVENESS, SAFETY AND ADHERENCE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS5PSQ-113
PDF DocumentPERSISTENCE AND LEVEL OF CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH GUSELKUMAB5PSQ-114
PDF DocumentDEPRESCRIBING LONG-TERM TREATMENTS WITH BIPHOSPHONATES. PHARMACEUTICAL INTERVENTION BRINGS VALUE.5PSQ-115
PDF DocumentPERSISTENCE OF INHIBITORS OF INTERLEUKIN-23 (anti-IL-23) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (msPs) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS.5PSQ-116
PDF DocumentEVALUATION OF CARDIOTOXICITY BY OSIMERTINIB IN CLINICAL PRACTICE5PSQ-117
PDF DocumentPATIENTS´ EXPERIENCE WITH SUBCUTANEOUS INJECTION SELF-ADMINISTRATION AND THE ROLE OF VIRTUAL REALITY5PSQ-118
PDF DocumentA NEW PHARMACEUTICAL CARE PROGRAMME FOR COVID-19 PATIENTS TREATED WITH PAXLOVID® : IMPLEMENTATION AND SAFETY OUTCOMES REPORTED5PSQ-119
PDF DocumentANALYSIS OF THE PHARMACEUTICAL INTERVENTIONS PERFORMED ON ONCOHEMATOLOGICAL PATIENTS THROUGH AN ONCOHEMATOLOGY PHARMACY CONSULTATION5PSQ-120
PDF DocumentCYTOKINE RELEASE SYNDROME RELATED TO THE TREATMENT WITH TECLISTAMAB: A CASE REPORT5PSQ-121
PDF DocumentCOVID-19 VACCINE VIGILANCE: COMPARATIVE STUDY BETWEEN HOSPITAL, REGIONAL AND NATIONAL DATA5PSQ-122
PDF DocumentIMPACT OF PHARMACOTHERAPEUTIC COMPLEXITY ON ADHERENCE TO ANTIRETROVIRAL TREATMENT IN OLDER ADULTS WITH HIV5PSQ-123
PDF DocumentEFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL TREATMENT SIMPLIFICATION TO DOLUTEGRAVIR+LAMIVUDINE OR DOLUTEGRAVIR+RILPIVIRINE IN OLDER ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS5PSQ-124
PDF DocumentBRIDGING ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER A TRANSURETHRAL RESECTION: PATIENT MANAGEMENT IS DONE APPROPRIATELY?5PSQ-125
PDF DocumentEFFICACY AND SAFETY OF OMALIZUMAB, MEPOLIZUMAB AND BENRALIZUMAB IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA5PSQ-126
PDF DocumentPHARMACOLOGICAL RISK FACTORS FOR DRUG-DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV: A SYSTEMATIC REVIEW5PSQ-127
PDF DocumentTHROMBOPROPHYLAXIS IN THE EMERGENCY DEPARTMENT. ADEQUACY OF THE PRESCRIPTION.5PSQ-128
PDF DocumentSWITCHING BETWEEN ANTI-CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN MIGRAINE5PSQ-129
PDF DocumentOFF-LABEL USE OF CIDOFOVIR INTRALESIONAL INJECTIONS IN EXTENSIVE ANOGENITAL CONDYLOMATOSIS: A CASE REPORT5PSQ-130
PDF DocumentLETERMOVIR, GANCICLOVIR AND IMMUNOGLOBULINS COMBINATION TREATMENT IN AN IMMUNOCOMPROMISED PATIENT WITH CYTOMEGALOVIRUS INFECTION: A CASE REPORT5PSQ-131
PDF DocumentPHARMACOGENETIC-GUIDED TREATMENT IN PATIENTS WITH DYHYDROPIRYMIDINE DEHYDROGENASE DEFICIENCY5PSQ-132
PDF DocumentPHARMACISTS – GENERAL PRACTIONERS (GPs) COLLABORATION TO IDENTIFY DRUG-RELATED PROBLEMS (DRPs) IN PATIENTS IN POLYTHERAPY5PSQ-133
PDF DocumentUNIT DOSE IN A CYBERATTACK SCENARIO5PSQ-134
PDF DocumentHAS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME HAD AN IMPACT ON THE ANTIBIOTIC CONSUMPTION?5PSQ-135
PDF DocumentANALYSIS OF ANTIRETROVIRAL THERAPY POTENCY IN HIV- NAÏVE PATIENTS5PSQ-136
PDF DocumentANALYSIS OF THE DPYD GENE MUTATIONS IN CANCER PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH FLUOROPYRIMIDINES5PSQ-137
PDF DocumentCHEMOTHERAPY ERRORS DETECTED DURING PHARMACEUTICAL VALIDATION5PSQ-138
PDF DocumentUSING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs)5PSQ-139
PDF DocumentFREQUENCY OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS UNDERGOING HOME TREATMENT WITH DIRECT-ACTING ORAL ANTICOAGULANTS (DOACs)5PSQ-140
PDF DocumentFALLS IN ELDERLY PATIENTS AND CHRONIC CONSUMPTION OF ANXIOLYTIC BENZODIAZEPINES.5PSQ-141
PDF DocumentEVALUATION OF ADEQUACY, ADHERENCE AND SAFETY OF HUMAN IMMUNODEFICIENCY VIRUS POST-EXPOSURE TREATMENT5PSQ-142
PDF DocumentTHE ROLE OF THE PHARMACIST IN INCREASING HEALTH VIGILANCE AMONG HEALTH PROFESSIONALS: QUINCKE’S EDEMA FOLLOWING THE ADMINISTRATION OF RITUXIMAB5PSQ-143
PDF DocumentELECTRONIC PATIENT-REPORTED OUTCOME (PROM) MEASUREMENT USING PRO-CTCAE®QUESTIONNAIRE TO IMPROVE QUALITY OF LIFE ASSESSMENT AND HEALTHCARE RESOURCES MANAGEMENT IN PATIENTS WITH LYMPHOMA RECEIVING INTRAVENOUS CHEMOTHERAPY5PSQ-144
PDF DocumentA PATIENT SATISFACTION SURVEY ON UNIT DOSE DRUG DISTRIBUTION IN HOSPITAL5PSQ-145

26th Congress of the EAHP

National Poster Prize Winners

PDF DocumentPoster TitlePoster Number
PDF DocumentThe appropriateness review FOR HOSPITAL MEDICATION ORDERS IN FINLANDNP-01
PDF DocumentUsage of falls-risk-increasing drugs among patients with high risk of falls in the nursing ward of Tartu University HospitalNP-02
PDF DocumentFrom basic to advanced computerized IV to oral switch for paracetamol and antibiotics: an interrupted time series analysisNP-03
PDF DocumentMONITORING OF GRAM-NEGATIVE (G-) MULTIDRUG RESISTANT (MDR) PATIENS AT POLICLINICO UMBERTO I OF ROME WITH THE AIM OF CONTROLLING HEALTHCARE ASSOCIATED INFECTIONS, COUNTERACTING THE PHENOMENON OF ANTIMICROBIAL RESISTANCE AND…NP-04
PDF DocumentINTRAVESICAL EPIRUBICIN ADMINISTRATION IN A UROLOGY DEPARTMENTNP-05
PDF DocumentRELATIONSHIP BETWEEN SERUM VEDOLIZUMAB CONCENTRATIONS IN INDUCTION PHASE AND EARLY AND SUSTAINED RESPONSE ON PATIENTS WITH ULCERATIVE COLITISNP-06
PDF DocumentIntegrating pharmacogenetic information into medication reviews – an interprofessional challengeNP-08

Section 1: Introductory Statements and Governance

PDF DocumentPoster TitlePoster Number
PDF DocumentIMPACT OF TELEPHARMACY AND COMMUNITY PHARMACY REMOTE-DISPENSING ON PATIENTS ON ORAL ANTINEOPLASTIC AGENTS1ISG-003
PDF DocumentASSESSMENT OF CUSTOMER SATISFACTION WITH HOSPITAL PHARMACY SERVICES IN ESTONIA1ISG-004
ESTIMATION OF DRUG COST AVOIDANCE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER1ISG-006
PDF DocumentECONOMIC SAVINGS FROM WEIGHT-BASED DOSING OF PEMBROLIZUMAB: WHAT IS THE IMPACT IN A TERTIARY HOSPITAL?1ISG-007
PDF DocumentOPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA1ISG-008
PDF DocumentIMPLEMENTATION AND EVALUATION OF TELEPHARMACY DURING COVID-19 PANDEMIC IN AN ACADEMIC MEDICAL CITY : PAVING THE WAY FOR TELEPHARMACY1ISG-009
PDF DocumentECONOMIC EVALUATION OF DOSE BANDING IN INMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB1ISG-012
PDF DocumentUsers’ expectations and opinions on a computerised physician order entry (CPOE) system before and after its implementation1ISG-013

Section 2: Selection, Procurement and Distribution

PDF DocumentPoster TitlePoster Number
PDF DocumentHOW CAN WE BEST MANAGE SUPPLY SHORTAGES OF EXCLUSIVELY HUMAN MOLECULES FOR SUBSTITUTION ? THE EXAMPLE OF IMMUNOGLOBULINS2SPD-001
PDF DocumentTELEPHARMACY IN ONCO-HEMATOLOGIC PATIENTS: A SEVEN MONTH EXPERIENCE2SPD-003
PDF DocumentSIGNIFICANT DISCONTINUATION RATES IN PATIENTS INITIATING OR SWITCHING FROM CT-P13: A RETROSPECTIVE COHORT STUDY IN A UNIVERSITY HOSPITAL2SPD-005
PDF DocumentDEVELOPMENT OF A PRIORITATION PROTOCOL FOR THE USE OF IMMUNOGLBULINS IN VIEW OF THE GLOBAL SUPPLY PROBLEM2SPD-006
PDF DocumentNETWORK META-ANALYSIS OF IMMUNOTHERAPIES IN UNTREATED ADVANCED OR METASTARIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA2SPD-008
PDF DocumentRIVAROXABAN VERSUS ENOXAPARIN IN TRAUMATOLOGY: A PHARMACO-ECONOMIC STUDY2SPD-011
PDF DocumentIMMUNOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY IN REAL LIFE2SPD-012​
PDF DocumentINCREASE IN HEALTHCARE COSTS WITH FIDAXOMICIN INSTEAD OF VANCOMYCINFOR CLOSTRIDIUM DIFFICLIE TREATMENT2SPD-013
PDF DocumentAPPROPRIATENESS OF USTEKINUMAB THERAPY PRESCRIPTION AND REAL-LIFE CONDITION USE IN CROHN’S DISEASE2SPD-014
PDF DocumentLOGISTICS AUTOMATION AND PROCESS REENGINEERING: IMPACT ON INTER-HOSPITAL LOAN MANAGEMENT2SPD-015
PDF DocumentAPPLICATION OF FAILURE MODE AND EFFECT ANALYSIS TO IMPROVE CYTOSTATIC DRUG STOCK MANAGEMENT2SPD-016
PDF DocumentANALYSIS AND MONITORING OF THE WORKLOAD AND FINANCIAL BURDEN OF DISPENSING HIGHCOST MEDICINES WITH ITEM-BASED REIMBURSEMENT IN HUNGARIAN HOSPITAL PHARMACIES2SPD-017​
PDF DocumentINVENTORY MANAGEMENT DURING THE COVID-19 PANDEMIC: OUR CASE FOR THE THIRD WAVE2SPD-019
PDF DocumentINTRODUCTION OF A NEW PRESENTATION OF HYALURONIC ACID FOR INTRAARTICULAR INFILTRATION2SPD-020
PDF DocumentASSESSMENT OF FORECAST ACCURACY FOR CONTRACTUAL PURCHASES2SPD-021
PDF DocumentRELEVANCE OF UNIVERSAL KIT COMPOSITION AND ECONOMIC VALUE OF NON-USED MEDICAL DEVICES2SPD-022
PDF DocumentCHOOSING THE RIGHT FORECASTING METHOD: WHICH PRACTICE IS BEST FOR OUR CASE?2SPD-023
PDF DocumentRETROSPECTIVE EVALUATION OF THE SAFETY STOCK LEVEL DETERMINED FOR THE PANDEMIC IN TERMS OF SERVICE LEVEL2SPD-024
PDF DocumentACALABRUTINIB + OBINUTUZUMAB VERSUS IBRUTINIB + OBINUTUZUMAB AS FIRST LINEIN CHRONIC LYMPHOCYTIC LEUKEMIA2SPD-025
PDF DocumentMedication storage temperatures inside emergency vehicles A pilot study in a temperate climate country2SPD-027
PDF DocumentSTABILITY OF NIVOLUMAB SOLUTIONS AFTER TRANSPORT THROUGH PNEUMATIC TUBE SYSTEMS2SPD-029
PDF DocumentHow to assess the impact of medicines shortages in the European Union?2SPD-030
PDF DocumentTHE ECONOMIC IMPACT OF ANTIMICROBIAL SHORTAGES IN ANTIMICROBIAL STEWARDSHIP PROGRAMMES2SPD-031
PDF DocumentDRUG EXCHANGE NETWORK2SPD-032
PDF DocumentMaking the case for Prefilled Syringes (PFS): Development and utilisation of an economic model2SPD-033
PDF DocumentMETHODOLOGICAL ANALYSIS OF PHARMACOECONOMIC STUDIES IN CAR-T: A SYSTEMATIC REVIEW2SPD-034
PDF DocumentCOST MINIMISATION ANALYSIS IN CLINICAL PRACTICE OF RIBOCICLIB VERSUS PALBOCICLIB IN THE TREATMENT OF METASTASTIC BREAST CANCER2SPD-035

Section 3: Production and Compounding

PDF DocumentPoster TitlePoster Number
PDF DocumentCHOLESTEROL 2%/SIMVASTATIN 1% OINTMENT FOR THE TREATMENT OF POROKERATOSIS PTYCHOTROPICA: A CASE REPORT3PC-001​
PDF DocumentGLASS AMPOULES AND DRUG FILTRATION: ¿HOW MUCH DO WE KNOW ABOUT IT?3PC-002
SODIUM THIOSULPHATE GEL 25% FOR THE TREATMENT OF CALCIPHYLAXIS3PC-003
PDF DocumentINSULIN EYE DROP FORMULATION: EFFECTIVENESS, SAFETY AND PATIENT SATISFACTION3PC-004
PDF DocumentSELECTION OF AN OSMOLARITY VALIDATION MODEL FOR NOMINATIVE PARENTERAL NUTRITION3PC-005
PDF DocumentEVALUATION OF PARENTERAL NUTRITION COMPOUNDING THROUGH A CHECKLIST3PC-006
PDF DocumentTIMES AND ERRORS FOR DISPENSING NARCOTICS DRUGS IN AUTOMATED SYSTEM VERSUS MANUAL SYSTEM3PC-008
PDF DocumentSTANOZOLOL RAPID HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) QUANTIFICATION METHOD FOR QUALITY CONTROL3PC-009
PDF DocumentAssessment of Chemfort (OnGuard, US) Syringe Adaptor Lock Fitted With Luer Lock Syringes to Container Integrity Standards (NHS, UK) Supporting Dose Banding of Cytotoxic Drugs3PC-010
PDF DocumentSTUDY OF THE CONTAINERCONTENT INTERACTION BETWEEN ETOPOPHOS POLYVINYL CHLORIDE (PVC) PERFUSION3PC-011
PDF DocumentIMPACT OF PRELIMINARY WIPING OF EQUIPMENT INTRODUCED INTO A CLEANROOM ON THE CONTROL OF THE ENVIRONMENT3PC-012
PDF DocumentPHARMACEUTICAL COMPOUNDING IN PAEDIATRIC PATCH TESTING: ARE WE SURE ABOUT THE ACTUAL ACTIVE INGREDIENT CONCENTRATION?3PC-013
PDF DocumentEVALUATION OF THE MICROBIOLOGICAL QUALITY OF NONSTERILE DRUGS PREPARED IN A HOSPITAL PHARMACY3PC-014
PDF DocumentVANCOMYCIN EYE DROPS AT 50 MG/ML : PHYSICOCHEMICAL STABILITY, IMPACT OF PACKAGING AND STORAGE CONDITIONS3PC-016
PDF DocumentAssessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days3PC-017
PDF DocumentCOMPATIBILITY AND 30-DAY STABILITY OF FOUR INTRAVENOUS MIXTURES FOR MULTIMODAL ANALGESIA3PC-018
PDF DocumentEVALUATION OF THE IMPACT OF MACHINE-AIDED DEBLISTERING IN UNIT DOSE BLISTER PRODUCTION ON THE FUNCTIONALITY OF TABLET COATING3PC-019
PDF DocumentCHEMICAL STABILITY AND PHYSICAL COMPATIBILITY OF INSULIN EYE DROPS USED IN CLINICAL PRACTICE3PC-020
PDF DocumentDESIGN AND ELABORATION OF METRONIDAZOLE 1% TOPICAL SOLUTION FOR TREATMENT OF ULCERS INFECTED BY ANAEROBIC BACTERIA3PC-021
PH STABILITY OF TETRACAINE SOLUTIONS FOR SURFACE ANAESTHESIA3PC-022
PDF DocumentInvestigation of Leachable Compounds In water for injection used in hospital pharmacy3PC-023
IMPACT OF PH MODIFICATION ON THE AGGREGATION OF NIVOLUMAB (OPDIVO) IN CLINICAL SOLUTIONS AT 1 AND 5 MG/ML MEASURED BY DYNAMIC LIGHT SCATTERING (DLS) AND SIZEEXCLUSION HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-DIODE ARRAY DETECTION (SE/HPLC-DAD)3PC-024
PDF DocumentRainer Trittler, Brigitte Altmann, Manuel Garcia-Käufer, Richard Gminski, Martin J. Hug3PC-026
PDF DocumentDIGITALIZATION SUPPORT SYSTEM FOR INTRAVENOUS MIXTURES ELABORATION IN A BIOLOGICAL SAFETY CABINET3PC-027
PDF DocumentPHARMACEUTICAL INTERVENTIONS IN PAEDIATRIC PARENTERAL NUTRITION3PC-028
PDF DocumentSTUDY OF PSMA11-68GA ADSORPTION ON MEDICAL DEVICES USED FOR RADIOSYNTHESIS AND MEDIA FILL TEST3PC-029
PDF DocumentDifferent substrates for orodispersible films: You have the choice!3PC-030
PDF DocumentPHYSICOCHEMICAL STABILITY OF helen.linxweiler@unimedizin-mainz.de DILUTED ‘THIOTEPA RIEMSER’ INFUSION SOLUTIONS IN PREFILLED 5% GLUCOSE INFUSION BAGS3PC-031
PDF DocumentOptimising Analgosedation in the Intensive Care Unit during the SARS-COV-2 Pandemic3PC-032
PDF DocumentY-site Compatibility of Intravenous Nefopam with Medications Commonly Used in Intensive Care Units3PC-033
PDF DocumentDEVELOPMENT AND VALIDATION OF A METHOD FOR THE DETERMINATION OF VANCOMYCIN EYE DROPS BY ULTRAVIOLET-VISIBLE SPECTROPHOTOMETRY3PC-034
PDF DocumentMinimising Waste In Oncology3PC-035

Section 4: Clinical Pharmacy Services

PDF DocumentPoster TitlePoster Number
PDF DocumentCOVID-19 HOSPITAL VACCINATION CENTER: PATIENT AND NURSE SATISFACTION4CPS-002
OUTPATIENT-REPORTED EXPERIENCE IN HOSPITAL PHARMACY AMBULATORY CARE DURING THE COVID19 PANDEMIC4CPS-003
PDF DocumentIMPACT OF THE SARS-COV PANDEMIC ON THE TRAINING OF HOSPITAL PHARMACY RESIDENTS4CPS-004
Evaluating pharmaceutical logistics automated technologies in the hospital setting: a Health Technology Assessment (HTA) approach4CPS-005
PDF DocumentEVALUATION STUDY OF THE CHAGE IN ADMINISTRATION TIMING OF FIXED COMBINATION: NETUPITANT AND PALONOSETRON IN ONCOHEMATOLOGIC PATIENTS WITH HIGH DOSES OF CARBOPLATIN4CPS-006​
PDF DocumentThe role of the pharmacist in the management of Intravenous fluids & electrolytes in adult patients4CPS-008
PDF DocumentASSESSMENT OF KNOWLEDGE, ATTITUDES AND PRACTICES REGARDING ANTIBIOTIC RECONSTITUTION AMONG HEALTHCARE PROFESSIONALS IN 12 SOUTHEASTERN EUROPEAN HOSPITALS: A MULTICENTRE CROSS-SECTIONAL STUDY4CPS-011
PDF DocumentMERGING THE MEDICATION RECONCILIATION AND THE HOSPITALIZATION REPORT TO FORM THE LIAISON LETTER IN A DEPARTMENT OF OTOLARYNGOLOGY4CPS-013
PDF DocumentCLINICAL RELEVANCE OF PHARMACISTS’ INTERVENTIONS IN THE ACUTE WARD4CPS-014
PDF DocumentSATISFACTION AND INDIRECT IMPACT OF AN OUTPATIENTS’ TELEPHARMACY PROGRAMME4CPS-015
PDF DocumentFactors influencing the attitudes and opinions of Czech physicians and citizens toward influenza vaccination in Czech pharmacies4CPS-016
PDF DocumentTHE DECISION-MAKING PROCESS IN HEALTH POLICY IMPACTS CLINICAL PRACTICES: A QUALITATIVE STUDY4CPS-017
PDF DocumentPerceptions of young people regarding pharmaceutical care provided by pharmacists4CPS-018
PDF DocumentREACTOGENICITY OF THE BNT162B2 (PFIZERBIONTECH) MRNA VACCINE AGAINST COVID-19 IN TERTIARY HOSPITAL WORKERS4CPS-019
PDF DocumentCOMPARISON OF DEPRESCRIBING STRATEGIES: LESSCHRON CRITERIA VERSUS THE GOOD PALLIATIVEGERIATRIC ALGORITHM IN A NURSING HOME4CPS-020
PDF DocumentPOST-STERNOTOMY MEDIASTINITIS: A MEDICOECONOMIC STUDY COMPARING TWO PREVENTIVE STRATEGIES IN CARDIAC SURGERY4CPS-021
PDF DocumentTo vaccinate or not to vaccinate : Impact of a public health action on vaccine hesitancy4CPS-022
PDF DocumentINDIVIDUALIZATION OF TREATMENT WITH TOCILIZUMAB IN GRAVES ORBITHOPATHY4CPS-023
PDF DocumentPHARMACEUTICAL INTERVIEWS DEDICATED TO VACCINATION: WHAT ROLE FOR THE CLINICAL PHARMACIST IN MONITORING THE VACCINATION COVERAGE OF AT-RISK PATIENTS ?4CPS-024
PDF DocumentAdequacy of hepatitis B reactivation prophylaxis in patients treated with rituximab4CPS-025
PDF DocumentOPTIMISATION OF DIRECT ORAL ANTICOAGULANT TREATMENTS: ANALYSIS OF PRESCRIPTIONS AND PHARMACEUTICAL INTERVIEWS (PI)4CPS-026
PDF DocumentDESENSITISATION PROTOCOL FOR LIPOSOMAL AMPHOTHERICIN B: A CASE REPORT4CPS-027
PDF DocumentEFFECTIVENESS AND SAFETY OF CENOBAMATE: EXPERIENCE IN A THIRD-LEVEL HOSPITAL4CPS-028
PDF DocumentPEMBROLIZUMAB, NIVOLUMAB AND ATEZOLIZUMAB: INCREMENTAL COST-EFFECTIVENESS RATIO4CPS-029
PDF DocumentSELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT IN PREVENTING VENTILATOR-ASSOCIATED PNEUMONIA IN AN INTENSIVE CARE UNIT4CPS-030
PDF DocumentEFFICACY AND SAFETY OF HIGH-DOSE TWICE WEEKLY SEBELIPASE ALFA IN SEVERE-ONSET WOLMAN DISEASE: A CASE REPORT4CPS-031
PDF DocumentMedication errors in prescribing antithrombotics for patients admitted to the hospital in the weekend. A pilot-study4CPS-032
PDF DocumentDevelopment and evaluation of an amitriptyline topical form for the treatment of cancer-related neuropathy4CPS-033
PDF DocumentDEPRESCRIBING ORAL IRON IN ELDERLY PATIENTS: EXPERIENCE FROM A NURSING HOME ASSOCIATED WITH A THIRD LEVEL HOSPITAL4CPS-034
PDF DocumentPHARMACIST-LED MEDICATION RECONCILIATION AT DISCHARGE SHALL NOT BE SUFFICIENT TO REDUCE UNPLANNED HEALTHCARE UTILIZATION: HEAR THE PATIENT EXPERIENCE!4CPS-035
PDF DocumentIS OUR PROTOCOL FOR THE USE OF TOCILIZUMAB IN COVID PATIENTS ADEQUATE?4CPS-036​
PDF DocumentThe 5P-study: Patient and healthcare Provider Perspectives on Potential Preventability of hospital admission for acute exacerbations of Chronic Obstructive Pulmonary Disease4CPS-037
PDF DocumentIntrapleural colistin for pleural empyema caused by extensively drug-resistant Pseudomonas aeruginosa: A case report4CPS-038
PDF DocumentEFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE TREATMENT OF MIGRAINE4CPS-039
PDF DocumentINTERINDIVIDUAL VARIABILITY OF LINEZOLID IN CRITICALLY ILL PATIENTS4CPS-040
PDF DocumentSACUBITRIL/ VALSARTAN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE4CPS-041
PDF DocumentPHARMACOKINETIC MONITORING OF TACROLIMUS IN RENAL TRANSPLANT PATIENTS4CPS-042
PDF DocumentEFFECTIVENESS, SAFETY AND ADHERENCE OF GUSELKUMAB IN MODERATE TO SEVERE PSORIASIS4CPS-043
PDF DocumentPATIENTS’ PERCEPTIONS OF HEALTHCARE ASSOCIATED-INFECTIONS AND USE OF ANTIBIOTICS IN SURGICAL CONTEXT4CPS-044
PDF DocumentHEALTHCARE EVALUATION OF HOSPITAL PHARMACY SERVICES BY PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A MULTICENTRE STUDY4CPS-045​
PDF DocumentCARDIOVASCULAR RISK OF HIV PATIENTS4CPS-046
PDF DocumentIMPROVING SAFETY IN THE USE OF MONOCLONAL ANTIBODIES IN PATIENTS WITH MIGRAINE: AN INTERDISCIPLINARY STUDY4CPS-048
PDF DocumentMANAGEMENT OF PAN-RESISTANT STENOTROPHOMONAS MALTOPHILIA4CPS-049
PDF DocumentUSE OF GALCANEZUMAB IN PATIENTS WITH MIGRAINE IN A TERTIARY HOSPITAL: HEALTH RESULTS4CPS-050
PDF DocumentPHARMACOKINETICS ALTERATIONS IN TWO CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL4CPS-051
PDF DocumentGALCANEZUMAB IN PROPHYLAXIS OF REFRACTORY HIGH-FREQUENCY EPISODIC MIGRAINE IN CLINICAL PRACTICE4CPS-053
PDF DocumentANALYSIS OF REAL-WORLD DATA FOR ERENUMAB UTILISATION AND PATIENT-RELATED OUTCOMES4CPS-054
PDF DocumentSUCCESSFUL SOFOSBUVIR/VELPATASVIR TREATMENT IN A HEPATITIS C PATIENT RECEIVING CHRONIC ANTIEPILEPTIC THERAPY: A CASE REPORT4CPS-055
PDF DocumentPOLYPHARMACY AND POTENTIALLY INAPPROPIATE MEDICATIONS IN OLDER PEOPLE LIVING WITH HIV4CPS-056
PDF DocumentDISCONTINUATION OF PROTON PUMP INHIBITORS DURING HOSPITALISATION: A RANDOMISED CONTROLLED TRIAL4CPS-057
PDF DocumentREAL-WORLD EXPERIENCE WITH PROLONGED TEDIZOLID TREATMENT: EFFECTIVENESS AND SAFETY4CPS-058
PDF DocumentCASE REPORT OF SEVERE HYPERBILIRRUBINEMIA IN A PATIENT CARRYING POLYMORPHISMS IN CES1P1, CDA, SLC22A7 AND ENOSF1 TREATED WITH FLUOROPYRIMIDINES4CPS-059
PDF DocumentINFLUENCE OF GENETIC POLYMORPHISMS ON THE RESPONSE AND TOXICITY OF CAPECITABINE THERAPY IN PATIENTS WITH BREAST CANCER4CPS-060​
PDF DocumentIMPACT OF PHARMACOGENETICS ON THE TOXICITY OF HIGH-DOSE METHOTREXATE IN A PAEDIATRIC POPULATION4CPS-061​
PDF DocumentRITUXIMAB PHARMACOKINETICS CHARACTERIZATION IN PLASMA AND URINE IN A PATIENT WITH NEPHOTIC SYNDROME4CPS-062
PDF DocumentERENUMAB VERSUS GALCANEZUMAB, EFFECTIVENESS IN REAL-LIFE EXPERIENCE4CPS-063
PDF DocumentQUALITY OF LIFE STUDY: GALCANEZUMAB IN THE TREATMENT OF MIGRAINE4CPS-064
PDF DocumentSAFETY OF BEVACIZUMAB BIOSIMILAR IN CLINICAL PRACTICE IN NEW AND SWITCHED TREATMENTS4CPS-065
PDF DocumentPHARMACIST INTERVENTIONS IN SEQUENTIAL ANTIMICROBIAL THERAPY INSIDE AN ANTIMICROBIAL STEWARDSHIP PROGRAMME (ASP)4CPS-067
PDF DocumentIMPACT OF PHARMACOGENETICS IN SEVERE ALLERGIC ASTHMA PATIENTS TREATED WITH OMALIZUMAB4CPS-068
PDF DocumentINFLUENCE OF GENETIC VARIANTS IN THE VITAMIN D HYDROXYLATION PATHWAY AS A RESPONSE FACTOR TO PLATINUM-BASED CHEMOTHERAPY IN NONSMALL CELL LUNG CANCER4CPS-069
PDF DocumentSTUDY OF CARDIOVASCULAR TOXICITY ASSOCIATED WITH IBRUTINIB TREATMENT4CPS-070
PDF DocumentCYP27B1 GENETIC VARIANTS’ INFLUENCE IN NEPHROTOXICITY DUE TO PLATINUMBASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER4CPS-071
PDF DocumentBEZLOTOXUMAB FOR THE PREVENTION OF CLOSTRIDIOIDES DIFFICILE RECURRENCE: STUDY IN THE REAL WORLD4CPS-072
PDF DocumentDESENSITISATION TO IBRUTINIB IN A PATIENT WITH SERIOUS LATE REACTION: A CASE REPORT4CPS-073
PDF DocumentEVALUATION OF THE COST OF MANAGING ADVERSE EVENTS RELATED TO CYTOTOXIC DRUGS IN CHILDREN4CPS-075
PDF DocumentGENETICVARIANTSAFFECTINGBISOPROLOL RESPONSEINCARDIOVASCULARDISEASES4CPS-077
PDF DocumentMOTIVATIONAL INTERVIEWING IN CLINICAL PHARMACIST INTERVENTIONS: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS4CPS-078
PDF DocumentANALYSIS OF CURRENT RESEARCH IN WEAREABLES : TOWARD A MORE DIGITAL HEALTH4CPS-079
EFFICACY AND SAFETY OF THE CONTINUOUS INFUSION OF VANCOMYCIN IN PAEDIATRIC PATIENTS: A SYSTEMATIC REVIEW4CPS-080
PDF DocumentSUBCUTANEOUS FUROSEMIDE INFUSION USING ELASTOMERIC INFUSION PUMPS IN A TERTIARY HOSPITAL4CPS-081
ENVIRONMENTAL POLLUTION WITH QUINOLONES IN SPAIN4CPS-082
PDF DocumentCost-effectiveness analysis of adalimumab and its clinical alternatives in immunemediated inflammatory diseases in Spain4CPS-083
PDF DocumentSTABILITY OF MEROPENEM AND PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION FOR HOME ADMINISTRATION4CPS-085
PDF DocumentInhaled sedation with halogenated agents in the Intensive Care Unit: A literature mini-review4CPS-086
PDF DocumentTHE USE OF PATIENT-REPORTED OUTCOME INSTRUMENTS IN IMMUNE CHECKPOINT INHIBITOR THERAPY FOR CANCER IN CLINICAL PRACTICE: A SYSTEMATIC REVIEW4CPS-087
PDF DocumentINDIRECT COMPARISON OF NIVOLUMAB, PEMBROLIZUMAB AND CAMRELIZUMAB IN PATIENTS WITH UNRESECTABLE AND/OR ADVANCED SQUAMOUS CELL CARCINOMA OF ESOPHAGUS IN SECOND-LINE SETTING4CPS-088
PDF DocumentRISANKIZUMAB IN REFRACTORY HIDRADENITIS SUPPURATIVA TO ANTI-TNFa A CASE REPORT4CPS-089
PDF DocumentEFFICACY AND SAFETY OF PANGENOTYPS TREATMENTS IN HCV PATIENTS4CPS-090​
PDF DocumentANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO HIGH-RISK-DRUGS IN THE EMERGENCY DEPARTMENT4CPS-091
PDF DocumentBIOLOGICAL THERAPIES FOR THE TREATMENT OF PSORIASIS: EFFECTIVENESS, SAFETY AND ECONOMIC IMPACT OF OPTIMISATION STRATEGIES4CPS-092
PDF DocumentDRUG-INDUCED SOMNOLENCE IN FRAILTY PATIENTS ATTENDED IN AN EMERGENCY DEPARTMENT4CPS-093
PDF DocumentAPPROPRIATENESS OF EMPIRICAL ANTIBIOTIC THERAPY FOR CERVICITIS AND URETHRITIS PRESCRIBED AT THE EMERGENCY DEPARTMENT4CPS-095
PDF DocumentCLINICALLY RELEVANT DRUG-DRUG INTERACTION EVENTS IN PATIENTS WITH ABIRATERONE, ENZALUTAMIDE OR APALUTAMIDE TREATMENT4CPS-099
PDF DocumentINTRADIALYTIC PARENTERAL NUTRITION EFFECTS ON ALBUMIN LEVELS IN MALNOURISHED HAEMODIALYSIS PATIENTS4CPS-100
PDF DocumentBIOLOGIC AGENTS IN RHEUMATOLOGICAL DISEASES: IMPACT OF ‘TREAT TO TARGET’ IN CLINICAL PRACTICE4CPS-101
PDF DocumentDrug-related hospital admissions in older adults: comparison of the Naranjo algorithm and an adjusted version of the Kramer algorithm4CPS-102
PDF DocumentIMPROVING MEDICATION RECONCILIATION REPORTS: EVALUATION THROUGH QUALITY AUDITS4CPS-103
PDF DocumentPERSISTENCE WITH DISEASE-MODIFYING THERAPY IN MULTIPLE SCLEROSIS PATIENTS4CPS-104
PDF DocumentCARDIOVASCULAR RISK FACTORS IN PATIENTS WITH HIV INFECTION WITH ANTIRETROVIRAL TREATMENT4CPS-105
PDF DocumentSAFETY OF ADJUVANT TRASTUZUMAB EMTANSINA FOR RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER4CPS-106
PDF DocumentIMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA: EFFECTIVENESS AND SAFETY IN CLINICAL PRACTICE4CPS-107
PDF DocumentBIOMARKERS EVOLUTION IN PATIENTS WITH SARSCOV-2 PNEUMONIA TREATED WITH BARICITINIB4CPS-108
PDF DocumentDESCRIPTIVE ANALYSIS OF PATIENTS CO-INFECTED WITH HIV AND HEPATITIS C VIRUS (HCV) TREATED WITH ANTIVIRALS FOR HCV AND ITS EFFICACY IN A PRISON FROM 2002 TO 20204CPS-109
PDF DocumentINITIAL EXPERIENCE OF THE USE OF CEFIDEROCOL FOR MULTIDRUG RESISTANT INFECTIONS IN A UNIVERSITY HOSPITAL4CPS-110
PDF DocumentRUXOLITINIB FOR REFRACTORY GRAFT-VERSUS-HOST DISEASE IN PAEDIATRIC PATIENTS4CPS-111​
PDF DocumentVORICONAZOLE THERAPEUTIC DRUG MONITORING: RELATIONSHIP WITH LIVER TOXICITY4CPS-112
PDF DocumentREAL-LIFE DATA ON THE USE OF ABIRATERONE/ ENZALUTAMIDE IN CASTRATION-RESISTANT PROSTATE CANCER4CPS-113
PDF DocumentINTEGRATION OF A PHARMACIST INTO A GERIATRIC DEPARTMENT4CPS-114
PDF DocumentNABPACLITAXEL PLUS GEMCITABINE VERSUS FOLFIRINOX IN METASTATIC PANCREATIC CANCER: REAL WORLD DATA EXPERIENCE4CPS-115
ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE4CPS-116
PDF DocumentAPPROPRIATENESS OF ANTIBIOTIC PRESCRIPTIONS IN A LONG-TERM CARE FACILITY4CPS-117
PDF DocumentREAL-WORLD EXPERIENCE WITH PCSK9 INHIBITORS PROTOCOL FOR HYPERCHOLESTEROLEMIA4CPS-119
PDF DocumentADVERSE DRUG REACTION (ADR) NOTICATIONS’ IMPACT ON PATIENTS FOLLOWED AT AN AMBULATORY CARE PHARMACY UNIT4CPS-120
PDF DocumentCLINICAL PHARMACIST INTERVENTIONS IN THE EMERGENCY DEPARTMENT AND THEIR IMPACT ON PREVENTABLE ADVERSE DRUG EVENTS4CPS-121
PDF DocumentOVERVIEW OF THE IMPACT OF PENICILLIN ALLERGY LABELS ON ANTIBIOTIC USE IN THE EMERGENCY DEPARTMENT4CPS-122​
PDF DocumentPERFORMANCE OF MOST COMMONLY USED EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN CRITICALLY ILL PATIENTS4CPS-123
PDF DocumentCOST OPTIMISATION PLAN IN IMMUNOTHERAPY4CPS-124
PDF DocumentSINGLE-AGENT BEVACIZUMAB IN OFF-LABEL TREATMENT OF RECURRENT OR REFRACTORY GLIOMA4CPS-125
PDF DocumentREAL-WORLD PERSISTENCE WITH FAMPRIDINE AMONG MULTIPLE SCLEROSIS PATIENTS4CPS-126
PDF DocumentTHERAPEUTIC DRUG MONITORING WITH BIOLOGICAL DRUGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE4CPS-127
PDF DocumentADJUST DOSES OF ANTIBIOTICS IN PATIENTS WITH RENAL INSUFFICIENCY4CPS-129
PDF DocumentAnalysis of the Different Cardioversion Strategies in the Emergency Department in a Secondary Hospital4CPS-130
PDF DocumentSWITCHING AND DISCONTINUATION OF DISEASE-MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS: EXPERIENCE IN AN UNIVERSITY HOSPITAL4CPS-131
PDF DocumentANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT4CPS-133
PDF DocumentOPTIMIZATION OF DENOSUMAB PRESCRIPTION IN OSTEOPOROSIS PATIENTS4CPS-134​
PDF DocumentPERSISTENCE OF FIRST-LINE BIOLOGICAL THERAPY IN PATIENTS WITH CROHN’S DISEASE4CPS-136
PDF DocumentProspective analysis of clinical pharmacist interventions for QT drug-drug interactions alongside clinical decision support4CPS-137
PDF DocumentTHERAPEUTIC DRUG MONITORING OF INTRAVENOUSBUSULFANINPAEDIATRICPATIENTS4CPS-138
ANTIMICROBIAL STEWARDSHIP PROGRAM IN ONCOLOGY PATIENTS THROUGH A MULTIDISCIPLINARY TEAM4CPS-140​
PDF DocumentASSESSMENT OF TEDIZOLID FOR USE IN GRAM-POSITIVE BACTERIAL INFECTIONS BACKGROUND: REAL WORLD DATA4CPS-141
PDF DocumentEFFECTIVENESS AND SAFETY OF ATEZOLIZUMAB IN METASTATIC UROTHELIAL CARCINOMA4CPS-142
PDF DocumentEFFECTIVENESS AND SAFETY OF BARICITINIB AND TOFACITINIB IN REUMATOID ARTHRITIS IN CLINICAL PRACTICE4CPS-145
PDF DocumentDevelopment and validation of a rapid High Performance Liquid Cromatography method (HPLC) for the determination of triazoles in human plasma4CPS-146
PDF DocumentEXPERIENCE OF USE OF BIOLOGICAL ANTIMIGRAINE TREATMENTS IN CLINICAL PRACTICE4CPS-147
PDF DocumentUse of remdesivir in severe Sars-CoV-2 pneumonia in critically and non-critically ill patients4CPS-148
PDF DocumentHOSPITAL AT HOME COVID UNIT: MULTIDISCIPLINARY STRATEGIES4CPS-149
PDF DocumentAbility to assess acute kidney injury in patients admitted to hospital4CPS-150
PDF DocumentCHARACTERIZATION OF A COMPOUNDED VORICONAZOLE SOLUTION FOR NEBULIZATION AND DESCRIPTION OF ITS USE IN THE CLINICAL SETTING4CPS-152
PDF DocumentSTEVENS–JOHNSON SYNDROME IN A PREGNANT WOMAN CAUSED BY PYRIMETHAMINE AND SULFADIZINE4CPS-154
PDF DocumentAPPROPRIATENESS OF PHARMACOTHERAPY IN NURSING HOMES: PHARMACY AND GERIATRICS SERVICES COORDINATION PROJECT4CPS-155​
PDF DocumentANTIMICROBIAL STEWARDSHIP PROGRAMME IN A GENERAL SURGERY SERVICE: ROLE OF THE PHARMACIST4CPS-156
PDF DocumentIMPACT OF COVID-19 PANDEMIC ON PATIENTS TREATED WITH BIOLOGICAL DRUGS AND ENZYME REPLACEMENT THERAPIES4CPS-157
PDF DocumentBUDGETARY IMPACT OF PCSK9I DOSES REGIMEN OPTIMISATION4CPS-161
PDF DocumentCYTOKINE RELEASE SYNDROME IN ONCOHAEMATOLOGICAL PATIENTS TREATED WITH TOCILIZUMAB4CPS-162
PDF DocumentEARLY EXPERIENCES IN SWITCHING BETWEEN MONOCLONAL ANTIBODIES IN CHRONIC MIGRAINE PREVENTIVE THERAPY4CPS-163
PDF DocumentDURABILITY OF ORAL DUAL ANTIRETROVIRAL THERAPY IN HIV PATIENTS4CPS-164
PDF DocumentHAS COVID AFFECTED THE TREATMENT OF ONCOLOGY PATIENTS?: A DESCRIPTIVE STUDY OF TREATMENTS FROM 2019 TO 20214CPS-165
PDF DocumentASSOCIATION BETWEEN IMMUNE-RELATED EFFECTS AND EFFECTIVENESS OF FIRST-LINE PEMBROLIZUMAB IN ADVANCED NON-SMALL CELL LUNG CANCER4CPS-166​
PDF DocumentSODIUM AND MAGNESIUM ALTERATIONS IN THE CRITICAL PATIENT WITH SARS-CoV-2 AND PARENTERAL NUTRITION4CPS-167
PDF DocumentReview of new biomarkers that predict the pharmacokinetics of biologic drugs in inflammatory bowel disease4CPS-170
PDF DocumentEFFECT OF LIPIDIC COMPOSITION OF PARENTERAL NUTRITION ON THE DEVELOPMENT OF HYPERTRIGLYCERIDAEMIA AND CHOLESTASIS4CPS-171​
PDF DocumentPOSACONAZOL THERAPEUTIC DRUG MONITORING IN A PAEDIATRIC TERTIARY HOSPITAL4CPS-172
PDF DocumentPHARMACEUTICAL INTERVENTION IN BROAD-SPECTRUM ANTIBIOTIC PRESCRIPTION IN HOSPITALIZED PATIENTS4CPS-173
EFFECTIVENESS OF OBETICOLIC ACID TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS E4CPS-174
PDF DocumentMEDICATION REGIMEN COMPLEXITY INDEX AMONG SOLID ORGAN TRANSPLANT PATIENTS4CPS-175
PDF DocumentORAL IVERMECTIN EFFECTIVENESS IN THE TREATMENT OF PERMETHRIN-RESISTANT SCABIES: A DESCRIPTIVE AND RETROSPECTIVE OBSERVATIONAL STUDY4CPS-176
PDF DocumentA QUALITATIVE STUDY ON PHARMACIST PRESCRIBING FOR PATIENTS WITH CHRONIC KIDNEY DISEASE4CPS-177
PDF DocumentTHERAPEUTIC DRUG MONITORINGOF GENTAMICIN AFTER PRE-DIALYSIS ADMINISTRATION4CPS-178
PDF Document“Description and Follow-up of the Use of Emtricitabin/ Tenofovir for HIV Pre-Exposure Prophylaxis4CPS-179
PDF DocumentINCREASE IN THE PRESCRIPTION OF BENZODIAZEPINES IN THE CONTEXT OF THE SARSCOV-2 PANDEMIC4CPS-182
PDF DocumentPrevention of coronavirus contamination from the environment using an air-cleaning closed system drug-transfer device4CPS-183
PDF DocumentA toll for Hospital Pharmacist Interventions optimization4CPS-185​
PDF Document2020 ANTIMICROBIAL CONSUMPTION INDICATORS: ANALYSIS COMPARED WITH PREVIOUS YEARS4CPS-186
PDF DocumentPharmacist-clinician Collaborative Study for Prospective Identification of Drug Interactions on HIV Patients4CPS-187
PDF DocumentTELEPHARMACY: A PILOT EXPERIENCE IN TIMES OF COVID-19 IN A TERTIARY HOSPITAL4CPS-190
PDF DocumentSWITCH TO BENRALIZUMAB FOR SEVERE EOSINOPHILIC ASTHMA4CPS-191
PDF DocumentIMPACT OF THE SARS-COV-2 PANDEMIC ON THE USE OF ANTIFUNGALS IN AN INTENSIVE CARE UNIT IN A THIRD-LEVEL HOSPITAL4CPS-192
PDF DocumentSelection of clinical rules for the screening of high-risk situations in paediatric medicine4CPS-193
PDF DocumentCLINICAL IMPACT OF A PHARMACIST-LED DISCHARGE MEDICATION REVIEW SERVICE: AN ANALYSIS OF PREVALENCE AND ACCEPTANCE OF INTERVENTIONS4CPS-194
PDF DocumentMedication-related readmissions: documentation and communication to the next healthcare providers and patients4CPS-195
PDF DocumentEvaluation of adherence to cystic fibrosis transmembrane conductance protein modulator drugs4CPS-197
PDF DocumentTHE IMPACT OF A PHARMACIST-LED MEDICATION REVIEW ON THE MEDICINE RISK SCORE: A NONRANDOMISED CONTROLLED STUDY4CPS-198
PDF DocumentEVALUATION OF FREMANEZUMAB RESPONSE IN MIGRAINE PROPHYLAXIS4CPS-199
PDF DocumentEFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE PREVENTION OF MIGRAINE4CPS-200
PDF DocumentAudit on the prescription and administration of Parkinson’s Disease medication on admission to hospital4CPS-201
PDF DocumentOPTIMISATION OF SUBCUTANEOUS BIOLOGICAL THERAPIES IN RHEUMATIC AND DERMATOLOGICAL DISEASES4CPS-202
PDF DocumentCOMPARISON OF PIRFENIDONE VERSUS NINTENDANIB IN IDIOPATHIC PULMONARY FIBROSIS4CPS-203
PDF DocumentAN EXPLORATION OF PATIENTS’ PERCEPTIONS OF COLORECTAL CANCER AND ITS MANAGEMENT: A QUALITATIVE STUDY AT INITIATION OF TREATMENT WITH CHEMOTHERAPY4CPS-204
PDF DocumentRIBOCICLIB AS FIRST LINE FOR METASTASIC BREAST CANCER: ANALISIS OF USE AND SECURITY4CPS-206​
PDF DocumentIMPROVING THE SAFETY OF PHARMACOTHERAPY IN PAEDIATRIC HAEMATO-ONCOLOGY BY CLINICAL PHARMACY SERVICES4CPS-207
PDF DocumentBenefit of Medication Reviews by a Renal Pharmacist in the Setting of a Computerized Physician Order Entry System4CPS-209
PDF DocumentIMPACT OF THE ANTIBIOTIC THERAPY USED DURING THE SARS-COV-2 PANDEMIC ON THE INCIDENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION4CPS-210
PDF DocumentReduction of flushing volume and incompatibilities by a clinical pharmacist in a paediatric intensive care unit4CPS-211
PDF DocumentINSTRUCTIONS GIVEN BY THE ANAESTHETIST ON THE MANAGEMENT OF CHRONIC TREATMENTS PREOPERATIVELY: WHAT DOES THE PATIENT REALLY UNDERSTAND AND RETAIN? AN OBSERVATIONAL STUDY4CPS-212
PDF DocumentA COMPARATIVE RISK ANALYSIS COMPARING THE CONVENTIONAL AND FULLY AUTOMATED MANAGEMENT OF CLINICAL TRIALS IN AN ONCOLOGY PHARMACY4CPS-213
PDF DocumentEXPERIENCE OF USE OF CANNABIDIOL IN PAEDIATRIC PATIENTS4CPS-214
PDF DocumentPERSISTENCE AND THERAPEUTIC ADHERENCE TO FIRST GENERATION JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS4CPS-215
PDF DocumentCLINICAL, ECONOMIC AND ORGANISATIONAL IMPACT OF PHARMACISTS’ INTERVENTIONS IN ONCOLOGICAL CARE PATIENTS4CPS-217
PDF DocumentEVALUATION OF THE IMPACT OF INCORPORATING A PHARMACIST INTO A HOSPITAL EMERGENCY DEPARTMENT4CPS-218
PDF DocumentPOTENTIALLY INAPPROPRIATE MEDICINES IN OLDER PATIENTS4CPS-221
PDF DocumentADHERENCE IN POLYMEDICATED ELDERLY PATIENTS ADMITTED TO A TRAUMA WARD4CPS-222
PDF DocumentADHERENCE TO ABIRATERONE AND CORTICOID IN PATIENTS WITH PROSTATE CANCER4CPS-223
PDF DocumentIMPACT OF PROACTIVE MEDICATION RECONCILIATION PRIOR TO PRE-ANAESTHESIC CONSULTATION4CPS-224
PDF DocumentIntegration of a clinical pharmacist in a therapeutic education team for diabetic patients: an initiative that is worth gold!4CPS-225
PDF DocumentTHE ROLE OF THE CLINICAL PHARMACIST IN THE SCREENING OF CANDIDATES FOR ONCOHAEMATOLOGICAL CLINICAL TRIALS4CPS-226
PDF DocumentFeedback from a French region on the use of e – Therapeutic Patient Education during the health crisis: high-speed interviews!4CPS-227
PDF DocumentImplementation of an interprofessional pre-operative medication management program in cardiac surgery – a pre post quality improvement study4CPS-229
PDF DocumentARE WE SUSTAINABLE? A BASELINE QUESTIONNAIRE REGARDING THE ENVIRONMENTAL IMPACT OF PHARMACY PRACTICE ACROSS THE COUNTRY4CPS-231
Pharmacist-led medication review unveiled more medication-related problems in possibly medication-related hospitalisations than in unlikely medication-related hospitalisations in elderly patients4CPS-232
PDF DocumentTHERAPEUTIC SWITCH OF ANTIRETROVIRAL TREATMENTS: EFFICACY, TOLERABILITY AND REASON FOR CHANGE4CPS-233
PDF DocumentIMPACT OF AN INTENSIVE MONITORING PROGRAM ON METHOTREXATE ELIMINATION4CPS-234
PDF DocumentPROFILE OF USE OF PHARMACOTHERAPY IN PSORIASIS, BIOLOGICAL DRUGS AND BIOSIMILARS4CPS-235
PDF DocumentMEASURING ADHERENCE TO ANTIRETROVIRAL TREATMENT: CORRELATION AND CONCORDANCE BETWEEN TWO INDIRECT METHODS4CPS-237
PDF DocumentIMPACT OF KNOWLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION ON THE QUALIY OF LIFE OF PEOPLE LIVING WITH HIV4CPS-239
PDF DocumentDEVELOPMENT OF A 25% BENZYL BENZOATE LOTION FOR A CASE OF RESISTANT NORWEGIAN SCABIES4CPS-240
PDF DocumentEffectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Tenofovir alafenamide, Emtricitabine and Bictegravir in a Real-Life Cohort of HIV-Infected Adults4CPS-241
PDF DocumentHUMAN IMMUNODEFICIENCY VIRUS PRE-EXPOSURE PROPHYLAXIS: ANALYSIS, FOLLOW-UP AND PANDEMIC EFFECT4CPS-242
PDF DocumentINFLUENCE OF VENOVENOUS EXTRACORPOREAL MEMBRANE OXYGENATION ON THE PHARMACOKINETICS OF VANCOMYCIN IN ADULTS: CAN AN OPTIMAL PHARMACODYNAMIC TARGET BE ACHIEVED?4CPS-243
PDF DocumentCARDIOVASCULAR, RENAL AND BONE EVALUATION OF A HIV POPULATION OVER 60 YEARS OLD4CPS-244
PDF DocumentINAPPROPRIATE ANTIBIOTIC DOSAGE ADJUSTMENTS IN PATIENTS WITH RENAL IMPAIRMENT: A CROSS-SECTIONAL ANALYSIS4CPS-245
PDF DocumentMEDICATION-RELATED ADMISSION WAS MORE FREQUENT IN ELDERLY PATIENTS HOSPITALISED IN AN ORTHOPEDIC UNIT THAN IN AN EMERGENCY DEPARTMENT IN TWO FRENCH HOSPITALS4CPS-246
PDF DocumentEVALUATION OF THE CLINICAL IMPACT OF MEDICATION RECONCILIATION ON ADMISSION USING THE CLEO TOOL4CPS-247
PDF DocumentELTROMBOPAG FOR TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA ASSOCIATED WITH COVID-19 VACCINE: A CASE REPORT4CPS-249
PDF DocumentHOME DELIVERY FOR OUTPATIENTS WITH IMMUNEMEDIATED DISEASES: EXPERIENCE AND PATIENT SATISFACTION4CPS-250
PDF DocumentINFLUENCE OF POLYPHARMACY AND COMORBIDITIES IN THE QUALITY OF LIFE OF PATIENTS WHO SUFFER HIP FRACTURE4CPS-251
PDF DocumentORAL AND INTRAVENOUS IRON IN THE TREATMENT OF PERIOPERATIVE ANAEMIA4CPS-252
PDF DocumentDIFFERENCES BETWEEN PHARMACEUTICAL INTERVENTIONS PERFORMED ON ANTIMICROBIALS IN MEDICAL AND SURGICAL SERVICES4CPS-253
PDF DocumentEFFECTIVENESS AND SAFETY OF NINTEDANIB AND PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS4CPS-257​
PDF DocumentACTIVATION, ADHERENCE AND HEALTH OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH BIOLOGICAL DRUGS4CPS-258
PDF DocumentANALYSIS OF THE ANTICHOLINERGIC LOAD IN POLYMEDICATED ELDERLY PATIENTS WHO HAVE SUFFERED A FALL4CPS-259
PDF DocumentPERSISTENCE AND SAFETY OF CALCITONIN GENERELATED PEPTIDE INHIBITORS IN CHRONIC MIGRAINE4CPS-260
PDF DocumentEVALUATION OF DRY EYE SEVERITY AND THERAPEUTIC ADHERENCE OF PATIENTS ON AUTOLOGOUS SERUM EYE DROPS4CPS-262
PDF DocumentEVALUATION OF THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS TOCILIZUMAB4CPS-263
PDF DocumentANALYSIS OF MEDICAL TREATMENT, RISK FACTORS AND RECURRENCE OF CLOSTRIDIOIDES DIFFICILE NOSOCOMIAL DIARRHOEA4CPS-264
PDF DocumentCHRONIC COMPLEX PALLIATIVE PAEDIATRIC PATIENT AT-HOME CARE UNIT: PHARMACOTHERAPEUTIC PROFILE AND ANALYSIS OF SIALORRHEA TREATMENT4CPS-265
PDF DocumentDetection and follow-up of drug related problems for patients with cardiovascular disease: A study of the Medicine Start Service in hospital pharmacies4CPS-266
PDF DocumentDesign, implementation, and evaluation of a medication counselling service provided by pharmacists using teach-back at hospital discharge4CPS-267
PDF DocumentANALYSIS OF RECURRENCES AND RISK FACTORS IN INFECTION BY CLOSTRIDIUM DIFFICILE4CPS-269
PDF DocumentInvestigating the Use of Patient Frailty to Guide Pharmacist-led Medication Review4CPS-270
PDF DocumentADHERENCE TO MEPOLIZUMAB AND BENRALIZUMAB IN REAL CLINICAL PRACTICE4CPS-271
PDF DocumentINTEGRATION OF THE HOSPITAL PHARMACIST INTO A MULTIDISCIPLINARY DYSPHAGIA SCREENING TEAM IN AN INTERMEDIATE AND LONG STAY HOSPITAL4CPS-272
PDF DocumentIMPACT OF A SPECIALIST PHARMACIST ON HEPATOPANCREATICO-BILIARY (HPB) SURGICAL WARD ROUNDS AT A LARGE TERTIARY LIVER CENTRE4CPS-273
PDF DocumentEvaluation of pharmaceutical interventions documented by a pharmacy technician: Where do pharmacy technicians have the biggest impact to avoid drug-related problems?4CPS-274
PDF DocumentASSOCIATION BETWEEN THE DEVELOPMENT OF IMMUNE-RELATED ADVERSE EVENTS AND THE EFFECTIVENESS OF IPILIMUMAB IN ADVANCED MELANOMAACPS-189

Section 5: Patient Safety and Quality Assurance

PDF DocumentPoster TitlePoster Number
PDF DocumentADVERSE EVENTS REPORTED AFTER ADMINISTRATION OF BNT162B2 AND MRNA-1273 COVID-19 VACCINES AMONG HEALTHCARE-WORKERS5PSQ-002
PDF DocumentDEVELOPMENT AND APPLICABILITY OF THE MEDHIPPRO-Q: A QUESTIONNAIRE ASSESSING MEDICAL DOCTORS’ EXPERIENCE WITH MEDICATION MANAGEMENT IN THE HIP FRACTURE PATIENT PATHWAY5PSQ-003
PDF DocumentANALYSIS OF ADVERSE DRUG REACTIONS OF DISEASE -MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS5PSQ-004
PDF DocumentDOSING LOW MOLECULAR WEIGHT HEPARINS IN RENAL IMPAIRMENT: A NATIONWIDE SURVEY5PSQ-006
PDF DocumentASSESSMENT OF PATIENTCONTROLLED ANALGESIA (PCA) PRACTICES IN A PUBLIC HOSPITAL5PSQ-008
PDF DocumentPatient Safety and Medication Safety Culture in a Hospital Pharmacy Department: A Mixed Methods Study5PSQ-009
PDF DocumentIdentification of incorrect dosing of direct oral anticoagulants: an important intervention to improve patient safety5PSQ-010
PDF DocumentINTRAVENOUS POTASSIUM CHLORIDE: HOSPITALWIDE EVALUATION AND BENEFITS OF A VIDEO COURSE5PSQ-011
PDF DocumentARE 12 MONTHS OF TREATMENT WITH MONOCLONAL ANTIBODIES SUFFICIENT FOR MIGRAINE ATTACK PREVENTION?5PSQ-012
PDF DocumentANTINEOPLASTIC DRUGS AND THROMBOSIS: ANALYSIS OF A COHORT OF PATIENTS WITH CANCER-ASSOCIATED THROMBOSIS5PSQ-013
PDF DocumentSAFETY AND TOLERANCE PROFILE OF NIVOLUMAB AND PEMBROLIZUMAB5PSQ-014
PDF DocumentANTIBIOTIC DESENSITIZATION IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH POTENTIALLY ALLERGY-TRIGGERING MOLECULES5PSQ-015
PDF DocumentACE INHIBITORS AND ARBs AS RISK FACTORS FOR COVID-19 INFECTION: FAKE NEWS OR EVIDENCE-BASED MEDICINE?5PSQ-016
PDF DocumentMAPPING OF PHARMACOLOGICAL RISK FACTORS AND COMORBIDITY IN PATIENTS WITH SEVERE COVID-19: A RETROSPECTIVE OBSERVATIONAL CASE-CONTROL STUDY5PSQ-017
PDF DocumentANALYSIS OF THE USE OF FONDAPARINUX IN SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA5PSQ-018
PDF DocumentASSESSMENT OF THE LEVEL OF KNOWLEDGE AND MOTIVATION IN A HOSPITAL CENTER STAFF FOR GETTING VACCINATED AGAINST SARS-CoV-25PSQ-019
PDF DocumentPatient´s and physician´s acceptance of a pharmacist-led intervention to reduce anticholinergic burden5PSQ-021
PDF DocumentDESENSITISATION PROTOCOL FOR ADALIMUMAB IN ARTHROPATHIC PSORIASIS: A CASE REPORT5PSQ-022
PDF DocumentNeutropenia as an indicator of trifluridinetipiracil efficacy in metastatic colorectal cancer5PSQ-023
PDF DocumentEffectiveness and safety of durvalumab in the treatment of unresectable locally advanced non small cell lung cancer (LANSCLC)5PSQ-024
PDF DocumentANTICHOLINERGIC RISK IN OLDER PEOPLE LIVING WITH HIV5PSQ-025
PDF DocumentCLINICAL IMPORTANCE OF GENETIC VARIANTS IN CAPECITABINE BIOACTIVATION PATHWAY FOR THE PREDICTION OF RESPONSE IN COLORECTAL CANCER PATIENTS5PSQ-026
PDF DocumentMisuse assesment and risks of NSAIDs prescriptions for elderly patients in surgical units5PSQ-027
PDF DocumentASSESSMENT OF SUSPICION OF ALLERGY TO CORONAVIRUS DISEASE 2019 VACCINE BY SKIN TESTING: RESULTS FROM A MONOCENTRIC COHORT5PSQ-028
PDF DocumentEVALUATION OF THE EFFICACY AND SAFETY OF ERENUMAB IN THE PROFILAXIS OF CHRONIC AND EPISODIC MIGRAINE5PSQ-029
PDF DocumentUSE OF CEFIDEROCOL FOR MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII IN PATIENTS WITH SARS-COV-2: TWO CASE REPORTS5PSQ-030
PDF DocumentEVALUATION OF THE SAFETY AND TOLERANCE OF THE COMMERCIAL PRESENTATION OF CICLOSPORINE 0.1% COLLYRIUM5PSQ-031
PDF DocumentCOMPLIANCE ANALYSIS OF PEDIATRIC ANTICANCER DRUG DOSING5PSQ-032
PDF DocumentPositive Impact of an Implemented Ward Pharmacist in a Multiprofessional Cancer Care Team in Germany5PSQ-033
PDF DocumentHOMOGENEITY OF OPINION EXPERT ON CLEO SCALE WHEN APPLIED TO 50 MODELED PHARMACEUTICAL INTERVENTIONS5PSQ-034
PDF DocumentINTENSIFICATING THERAPY WITH USTEKINUMAB IN NON-FIRST LINE CROHN’S DISEASE: CLINICAL EXPERIENCE, SAFETY AND EFFECTIVENESS IN THE “REAL WORLD”5PSQ-035
PDF DocumentIMPROVEMENT IN POSTOPERATIVE PAIN CONTROL BY THE INTRODUCTION OF ELASTOMETRIC LOCAL ANAESTHESIC LEVOBUPIVACAINE PUMPS IN PATIENTS UNDERGOING ARTHROPLASTY5PSQ-036
PDF DocumentDEPRESCRIBING INTERVENTIONS PERFORMED BY HOSPITAL PHARMACISTS REDUCE POTENTIALLY INAPPROPRIATE MEDICATION AT HOSPITAL DISCHARGE5PSQ-038
PDF DocumentPHARMACEUTICALS IN HOSPITAL WASTEWATER: A REVIEW5PSQ-040
PDF DocumentSAFETY AND EFFICACY OF HIGH DOSES OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FOLFIRI SCHEME BASED ON UGT1A1 GENOTYPE: A SYSTEMATIC REVIEW5PSQ-041
PDF DocumentTOXICITY OF REMDESIVIR AS TREATMENT OF NON-CRITICALLY ILL COVID-19 PATIENTS5PSQ-042
PDF DocumentBENZODIAZEPINES AND HYPNOTIC ANTIPSYCHOTICS IN A PSYCHIATRIC HOSPITAL5PSQ-043
PDF DocumentCONCILIATION AND PHARMACEUTICAL CARE ON DISCHARGE IN THE PSYCHIATRIC PATIENT5PSQ-044
PDF DocumentANALYSIS OF ANTIPSYCHOTIC POLYTHERAPY IN A PSYCHIATRIC HOSPITAL5PSQ-045
PDF DocumentIMPACT OF THE COVID-19 PANDEMIC ON A NOTIFICATION AND LEARNING SYSTEM FOR PATIENT SAFETY IN A PSYCHIATRIC HOSPITAL5PSQ-046
PDF DocumentANALYSIS OF THE UNIT DOSE SYSTEM OF MEDICATION DISTRIBUTION IN MENTAL HEALTH PHARMACY5PSQ-048
PDF DocumentSTARTING POINT TO PROMOTE A POTENTIALLY INAPPROPRIATE PRESCRIPTION ASSESSMENT PROJECT5PSQ-049
PDF DocumentCOST-EFFECTIVENESS OF A PRESURGICAL PHARMACEUTICAL CARE CONSULTATION5PSQ-051
PDF DocumentINFLUENCE OF AUGMENTED RENAL CLEARANCE IN THE LOWER INCIDENCE OF LINEZOLID-RELATED HAEMATOLOGICAL TOXICITY5PSQ-053​
PDF DocumentENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH ANTIANGIOGENIC DRUGS: A RARE BUT SERIOUS COMPLICATION5PSQ-054
PDF DocumentLONG-TERM EFFECTIVENESS OF ADALIMUMAB IN SECONDLINE OF BIOLOGICAL THERAPY IN ULCERATIVE COLITIS AND INFLUENCE OF THE FIRST-LINE TREATMENT5PSQ-055
PDF DocumentLOT QUALITY ASSURANCE SAMPLING (LQAS) OF A TELEPHARMACY PROGRAMME FROM THE HOSPITAL PHARMACY TO THE OUTPATIENT THROUGH THE COMMUNITY PHARMACY5PSQ-056
PDF DocumentACTIVE PHARMACOVIGILANCE OF PATIROMER IN A CENTRAL HOSPITAL PHARMACEUTICAL CONSULTATION SETTING5PSQ-057
PDF DocumentEFFICACY AND MARGINAL COST OF TREATMENT WITH TOCILIZUMAB IN COVID-19 PATIENTS5PSQ-058
PDF DocumentCHARACTERISATION OF MEDICATION ERRORS IN A PUBLIC HOSPITAL5PSQ-059
PDF DocumentLONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE5PSQ-060​
PDF DocumentREAL CLINICAL PRACTICE RESULTS OF INTERLEUKIN23 BLOCKERS IN REFRACTORY PSORIASIS5PSQ-062
PDF DocumentPERSISTENCE OF TYROSINE KINASE INHIBITORS IN ADVANCED RENAL CELL CARCINOMA5PSQ-063
PDF DocumentINMUNOTHERAPY: RECOGNISING AND TREATING ADVERSE EFFECTS5PSQ-065
PATIENT OUTCOMES AFTER THE IMPLEMENTATION OF A HUMANISED ENHANCED RECOVERY AFTER KNEE JOINT REPLACEMENT SURGERY PROGRAMME5PSQ-066
ARE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS WELL TOLERATED BY OUR PATIENTS? A SAFETY STUDY IN REAL-WORD PRACTICE5PSQ-067​
PDF DocumentINCIDENCE OF POST-ARTESUNATE-INDUCED HAMOLYSIS AFTER SEVERE MALARIA5PSQ-068​
PDF DocumentDOES THE TREATMENT LINE HAVE AN IMPACT ON THE TOXICITY PRODUCED BY OFF-LABEL ONCOLOGICAL TREATMENTS?5PSQ-069
PDF DocumentUSEFULNESS OF PHARMACEUTICAL VALIDATION IN CHEMOTHERAPY PRESCRIPTION5PSQ-070
PDF DocumentREAL-WORLD RESULTS OF EFFECTIVENESS AND SECURITY OF ERENUMAB AND GALCANEZUMAB IN MIGRAINE PATIENTS5PSQ-071​
PDF DocumentCOVID-19 VACCINES: ADVERSE EVENTS AFTER A SECOND DOSE OF PFIZER OR ASTRAZENECA VACCINES IN HEALTHCARE WORKERS WHO RECEIVED A FIRST DOSE OF ASTRAZENECA VACCINE5PSQ-074
PDF DocumentEVALUATION AND MONITORING OF BIOCHEMICAL PARAMETERS IN PATIENTS ON PARENTERAL NUTRITION5PSQ-076
PDF DocumentBEVACIZUMAB BIOSIMILARUSE IN OPHTHALMOLOGY5PSQ-077
PDF DocumentTHROMBOEMBOLIC PROPHYLAXIS IN PATIENTS TREATED WITH ORAL IMMUNOMODULATORS IN MULTIPLE MYELOMA5PSQ-078
PDF DocumentERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING5PSQ-080
PDF DocumentIMPACT OF PHARMACY INTERVENTION ON REDUCTION OF MEDICATION-RELATED PROBLEMS IN ELDERLY PATIENTS IN A NURSING HOME5PSQ-081
PDF DocumentEFFECTIVENESS IN REAL LIFE OF BIOLOGICAL DRUGS USED IN MIGRAINE PROPHYLAXIS5PSQ-082​
PDF DocumentUSE OF ISAVUCONAZOLE IN PATIENTS WITH COVID19 IN AN INTENSIVE CARE UNIT5PSQ-083
PDF DocumentHOME DELIVERY AND TELEPHARMACY PROGRAMME: SATISFACTION OF PATIENTS5PSQ-084
PDF DocumentREAL-WORLD SAFETY AND TOLERABILITY OF PALBOCICLIB AS FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER5PSQ-085
PDF DocumentEVALUATION OF THE EFFECTIVENESS OF BEZLOTOXUMAB ON PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION5PSQ-086
PDF DocumentLONG-TERM DUAL ANTIPLATELET THERAPY: CONTROVERSY CONTINUES5PSQ-087
PDF DocumentANTI SARS-CoV-2 MONOCLONAL ANTIBODIES: FROM CLINICAL TRIAL TO REAL WORLD EVIDENCE5PSQ-088
PDF DocumentUSE OF MONOCLONAL ANTIBODIES AGAINST THE CALCITONIN GENERELATED PEPTIDE PATHWAY IN CHRONIC MIGRAINE IN CLINICAL PRACTICE5PSQ-090
PDF DocumentDALBAVANCIN ADMINISTRATION IN OUTPATIENTS TO REDUCE HOSPITAL STAY IN SELECTED PATIENTS5PSQ-091
PDF DocumentTREATMENT OF METASTATIC HER2+ BREAST CANCER: USE OF TRASTUZUMAB BIOSIMILARS IN COMBINATION WITH PERTUZUMAB5PSQ-092
PDF DocumentPERSISTENCE OF TREATMENT WITH INTERLEUKIN -17 INHIBITORS IN SKIN DISORDERS5PSQ-093
PDF DocumentREASONS FOR DISCONTINUATION OF SELECTIVE IMMUNOSUPPRESSIVE BIOLOGICAL TREATMENTS AGAINST PSORIASIS5PSQ-094
PDF DocumentCOMPARISON BETWEEN THE MAXIMUM RECOMMENDED DOSE OF AZATHIOPRINE ACCORDING TO THE ENZYMATIC ACTIVITY OF THIOPURINE METHYLTRANSFERASE AND 6-THIOGUANINE LEVELS WITH THE MAXIMUM TOLERATED DOSE5PSQ-095
PDF DocumentUSE AND PERSISTENCE OF FIRST-LINE BIOLOGICAL TREATMENTS FOR PSORIASIS5PSQ-097
PDF DocumentEXPERIENCE IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION5PSQ-098
PDF DocumentMEDICATION ERRORS IN UNIT-DOSE DRUG DISTRIBUTION SYSTEM: QUALITY CONTROL5PSQ-101
PDF DocumentDEVELOPMENT AND TESTING OF A SMARTPHONEBASED SOLID ORAL DOSAGE FORM IMAGE RECOGNITION SYSTEM BY MACHINE LEARNING TO SUPPORT THE IDENTIFICATION OF DISPENSING ERRORS5PSQ-103
PDF DocumentVOLUNTARY ELECTRONIC REPORTING OF MEDICATION ERRORS AND ADVERSE DRUGS EVENTS DURING THE FIRST YEAR OF THE COVID-19 PANDEMIC5PSQ-104
PDF DocumentINSULIN PERFUSION IN NEONATOLOGY. WHICH ONE IS THE SAFEST?5PSQ-105
PDF DocumentIMPLEMENTATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) RECONSTITUTION IN A UNIVERSITY TEACHING HOSPITAL IN FRANCE : PROPOSAL OF A DECISION-MAKING ALGORITHM5PSQ-106
PDF DocumentSECURIZING OF TISAGENLECLEUCEL THAWING AND DELIVERING5PSQ-107
PDF DocumentSECURIZING OF TISAGENLECLEUCEL (KYMRIAH®) STORAGE5PSQ-108
PDF DocumentOMEPRAZOLE DEPRESCRIPTION PROJECT IN A SOCIAL HEALTH CENTER WITH A DEPOSIT OF MEDICINES ASSOCIATED WITH A HOSPITAL PHARMACY SERVICE5PSQ-110
PDF DocumentPHARMACEUTICAL INTERVENTION: AVOIDING INTERACTIONS BETWEEN ANTIRETROVIRALS AND VITAMIN SUPPLEMENTS/ ANTIACIDS5PSQ-111
PDF DocumentHIDDEN HARM? ASSESSING MAGNITUDE AND COSTS OF INTRAVENOUS THERAPY ADMINISTRATION ERRORS VIA SMART PUMP REPORTS5PSQ-112
PDF DocumentANALYSIS OF MEDICATION ERRORS INVOLVING HIGH-RISK PATIENTS IN THE PERIOPERATIVE SETTING5PSQ-115​
PDF DocumentMedication-related follow-up of older patients after hospital discharge: a multicentre retrospective chart review5PSQ-116
PDF DocumentDETERMINATION OF GENETIC POLYMORPHISMS IN THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN A PATIENT WITH GASTRIC ADENOCARCINOMA TREATED WITH FLUOROPYRIMIDINES: A CASE REPORT5PSQ-117
PDF DocumentLITHIUM THERAPY ON HOSPITAL ADMISSION5PSQ-118
PDF DocumentIMPACT OF THE COVID-19 PANDEMIC ON THE USE OF ANTIMICROBIALS IN PRIMARY AND HOSPITAL CARE5PSQ-120
PDF DocumentIMPORTANCE OF CONCILIATION IN IMMUNOSUPPRESSANT TREATMENT5PSQ-121
PDF DocumentEXPERIENCE OF BARICITINIB-REMDESIVIR USE IN PATIENTS WITH SARS-COV-2 INFECTION5PSQ-122
PDF DocumentORPHAN OFF-LABEL DRUG: IS IT REALLY COMMON PRACTICE?5PSQ-123
PDF DocumentTHE ROLE OF THE CLINICAL PHARMACIST AVOIDING MEDICATION ERRORS IN A CLINICAL RESEARCH ONCO-HEMATOLOGIC UNIT5PSQ-124
PDF DocumentTHE IDENTIFICATION OF HEALTH CONSEQUENCES ASSOCIATED WITH COUNTERFEIT MEDICINE AND ILLEGAL HEALTH PRODUCT APPLICATION USING PHARMACOVIGILANCE DATA5PSQ-125​
PDF DocumentCLINICAL INTERVENTIONS IN THE AREA OF INPATIENT PRESCRIPTIONS PERFORMED BY HOSPITAL PHARMACY RESIDENT5PSQ-128
PDF DocumentDOSE BANDING OF INTRAVENOUS 5-FLUOROURACIL, OXALIPLATIN, PACLITAXEL AND GEMCITABIN: EVALUATION OF EFFICIENCY AND SAFETY SUBSEQUENT TO AN IMPLEMENTATION PROGRAMME5PSQ-130
PDF DocumentPARENTERAL NUTRITION IN ACUTE PANCREATITIS: A REVIEW OF APPROPRIATENESS5PSQ-131
PDF DocumentANALYSIS OF CHEMICAL CONTAMINATION BY HAZARDOUS DRUGS WITH SEMIQUANTITATIVE SYSTEM IN A TERTIARY HOSPITAL5PSQ-132
PDF DocumentANALYSIS OF REAL-LIFE DATA: OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL OF NIVOLUMAB AND ATEZOLIZUMAB IN NOT SMALL CELLS LUNG CANCER5PSQ-133
PDF DocumentPATIENTS’ SATISFACTION TOWARD PHARMACEUTICAL CARE AT A UNIVERSITY HOSPITAL5PSQ-134
PDF DocumentNEW SECURITY WARNINGS FOR TOFACITINIB: ANALYSIS OF PATIENTS IN RISK5PSQ-135
PDF DocumentMEDICATION ERRORS RELATING TO ISOAPPEARANCES IN THE EMERGENCY ROOM5PSQ-137
PDF DocumentIMPACT OF HIGH TEMPERATURE, SHAKING AND LIGHT ON QUALITY OF THE THERAPEUTIC PEPTIDE TEDUGLUTIDE (REVESTIVE®) EVALUATED BY LC/MS/MS (ORBITRAP) PEPTIDE MAPPING ANALYSIS AND STRESS5PSQ-138
PDF DocumentANTICHOLINERGIC RISK EVALUATION IN HOSPITALISED PATIENTS5PSQ-139
PDF DocumentPATIENT SAFETY CLIMATE IN A HOSPITAL PHARMACY DEPARTMENT5PSQ-140
PDF DocumentPersonalized therapy for interstitial lung diseases in caused by ABCA3 mutations5PSQ-141
Development and validation of clinical rules to address risk prescriptions5PSQ-144
PDF DocumentMEDICINAL PLANTS USE AMONG TUNISIAN PATIENTS: PREVALENCE AND PERCEPTION5PSQ-145
PDF DocumentRISK MAPPING OF DRUG MANAGEMENT IN A PRISON5PSQ-146
PDF DocumentA SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO THE MEDICAL DEVICES MANAGEMENT PROCESS IN A HOSPITAL PHARMACY5PSQ-147
TANDEM PROJECT: TRANSITIONS OF CARE AND MEDICATION RECONCILIATION IN HIGH-RISK PATIENTS5PSQ-148
DURVALUMAB FOR THE TREATMENT OF NONSMALL CELL LUNG CANCER: REAL-WORLD EXPERIENCE5PSQ-149
PDF DocumentImplementation of a Programme for Optimising the Use of Antibiotics (PROA) in the Paediatrics Emergency Care Unit of a third level hospital5PSQ-150
PDF DocumentOPTIMIZATION OF THE SUBCUTANEOUS ADMINISTRATION OF DARATUMUMAB5PSQ-151
PDF DocumentEFFECTIVENESS AND SAFETY OF ERENUMAB IN MIGRAINE PROPHYLAXIS5PSQ-152
PDF DocumentPERSISTENCE AND REASONS FOR DISCONTINUATION OF TREATMENT WITH APREMILAST IN DERMATHOLOGICAL DISEASES5PSQ-153
PDF DocumentImpact of the COVID-19 Pandemic on Antimicrobial Consumption and Antimicrobial Resistance5PSQ-154
PDF DocumentHOW IS CHEMOTHERAPY USED AT THE END OF LIFE IN A SECONDARY HOSPITAL?5PSQ-155
PDF DocumentREASONS FOR SECUKINUMAB TREATMENT DISCONTINUATION5PSQ-156
PDF DocumentSEVERE NEUROTOXICITY OF ORAL IVERMECTIN: A SYSTEMATIC REVIEW OF CASES AND CASE SERIES5PSQ-157
PDF DocumentFood and drink management as part of medicaton administration safety5PSQ-158​

Section 6: Education and Research

PDF DocumentPoster TitlePoster Number
PDF DocumentADVERSE EVENTS REPORTED AFTER ADMINISTRATION OF BNT162B2 AND MRNA-1273 COVID-19 VACCINES AMONG HEALTHCARE-WORKERS5PSQ-002
PDF DocumentDEVELOPMENT AND APPLICABILITY OF THE MEDHIPPRO-Q: A QUESTIONNAIRE ASSESSING MEDICAL DOCTORS’ EXPERIENCE WITH MEDICATION MANAGEMENT IN THE HIP FRACTURE PATIENT PATHWAY5PSQ-003
PDF DocumentANALYSIS OF ADVERSE DRUG REACTIONS OF DISEASE -MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS5PSQ-004
PDF DocumentDOSING LOW MOLECULAR WEIGHT HEPARINS IN RENAL IMPAIRMENT: A NATIONWIDE SURVEY5PSQ-006
PDF DocumentASSESSMENT OF PATIENTCONTROLLED ANALGESIA (PCA) PRACTICES IN A PUBLIC HOSPITAL5PSQ-008
PDF DocumentPatient Safety and Medication Safety Culture in a Hospital Pharmacy Department: A Mixed Methods Study5PSQ-009
PDF DocumentIdentification of incorrect dosing of direct oral anticoagulants: an important intervention to improve patient safety5PSQ-010
PDF DocumentINTRAVENOUS POTASSIUM CHLORIDE: HOSPITALWIDE EVALUATION AND BENEFITS OF A VIDEO COURSE5PSQ-011
PDF DocumentARE 12 MONTHS OF TREATMENT WITH MONOCLONAL ANTIBODIES SUFFICIENT FOR MIGRAINE ATTACK PREVENTION?5PSQ-012
PDF DocumentANTINEOPLASTIC DRUGS AND THROMBOSIS: ANALYSIS OF A COHORT OF PATIENTS WITH CANCER-ASSOCIATED THROMBOSIS5PSQ-013
PDF DocumentSAFETY AND TOLERANCE PROFILE OF NIVOLUMAB AND PEMBROLIZUMAB5PSQ-014
PDF DocumentANTIBIOTIC DESENSITIZATION IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH POTENTIALLY ALLERGY-TRIGGERING MOLECULES5PSQ-015
PDF DocumentACE INHIBITORS AND ARBs AS RISK FACTORS FOR COVID-19 INFECTION: FAKE NEWS OR EVIDENCE-BASED MEDICINE?5PSQ-016
PDF DocumentMAPPING OF PHARMACOLOGICAL RISK FACTORS AND COMORBIDITY IN PATIENTS WITH SEVERE COVID-19: A RETROSPECTIVE OBSERVATIONAL CASE-CONTROL STUDY5PSQ-017
PDF DocumentANALYSIS OF THE USE OF FONDAPARINUX IN SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA5PSQ-018
PDF DocumentASSESSMENT OF THE LEVEL OF KNOWLEDGE AND MOTIVATION IN A HOSPITAL CENTER STAFF FOR GETTING VACCINATED AGAINST SARS-CoV-25PSQ-019
PDF DocumentPatient´s and physician´s acceptance of a pharmacist-led intervention to reduce anticholinergic burden5PSQ-021
PDF DocumentDESENSITISATION PROTOCOL FOR ADALIMUMAB IN ARTHROPATHIC PSORIASIS: A CASE REPORT5PSQ-022
PDF DocumentNeutropenia as an indicator of trifluridinetipiracil efficacy in metastatic colorectal cancer5PSQ-023
PDF DocumentEffectiveness and safety of durvalumab in the treatment of unresectable locally advanced non small cell lung cancer (LANSCLC)5PSQ-024
PDF DocumentANTICHOLINERGIC RISK IN OLDER PEOPLE LIVING WITH HIV5PSQ-025
PDF DocumentCLINICAL IMPORTANCE OF GENETIC VARIANTS IN CAPECITABINE BIOACTIVATION PATHWAY FOR THE PREDICTION OF RESPONSE IN COLORECTAL CANCER PATIENTS5PSQ-026
PDF DocumentMisuse assesment and risks of NSAIDs prescriptions for elderly patients in surgical units5PSQ-027
PDF DocumentASSESSMENT OF SUSPICION OF ALLERGY TO CORONAVIRUS DISEASE 2019 VACCINE BY SKIN TESTING: RESULTS FROM A MONOCENTRIC COHORT5PSQ-028
PDF DocumentEVALUATION OF THE EFFICACY AND SAFETY OF ERENUMAB IN THE PROFILAXIS OF CHRONIC AND EPISODIC MIGRAINE5PSQ-029
PDF DocumentUSE OF CEFIDEROCOL FOR MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII IN PATIENTS WITH SARS-COV-2: TWO CASE REPORTS5PSQ-030
PDF DocumentEVALUATION OF THE SAFETY AND TOLERANCE OF THE COMMERCIAL PRESENTATION OF CICLOSPORINE 0.1% COLLYRIUM5PSQ-031
PDF DocumentCOMPLIANCE ANALYSIS OF PEDIATRIC ANTICANCER DRUG DOSING5PSQ-032
PDF DocumentPositive Impact of an Implemented Ward Pharmacist in a Multiprofessional Cancer Care Team in Germany5PSQ-033
PDF DocumentHOMOGENEITY OF OPINION EXPERT ON CLEO SCALE WHEN APPLIED TO 50 MODELED PHARMACEUTICAL INTERVENTIONS5PSQ-034
PDF DocumentINTENSIFICATING THERAPY WITH USTEKINUMAB IN NON-FIRST LINE CROHN’S DISEASE: CLINICAL EXPERIENCE, SAFETY AND EFFECTIVENESS IN THE “REAL WORLD”5PSQ-035
PDF DocumentIMPROVEMENT IN POSTOPERATIVE PAIN CONTROL BY THE INTRODUCTION OF ELASTOMETRIC LOCAL ANAESTHESIC LEVOBUPIVACAINE PUMPS IN PATIENTS UNDERGOING ARTHROPLASTY5PSQ-036
PDF DocumentDEPRESCRIBING INTERVENTIONS PERFORMED BY HOSPITAL PHARMACISTS REDUCE POTENTIALLY INAPPROPRIATE MEDICATION AT HOSPITAL DISCHARGE5PSQ-038
PDF DocumentPHARMACEUTICALS IN HOSPITAL WASTEWATER: A REVIEW5PSQ-040
PDF DocumentSAFETY AND EFFICACY OF HIGH DOSES OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FOLFIRI SCHEME BASED ON UGT1A1 GENOTYPE: A SYSTEMATIC REVIEW5PSQ-041
PDF DocumentTOXICITY OF REMDESIVIR AS TREATMENT OF NON-CRITICALLY ILL COVID-19 PATIENTS5PSQ-042
PDF DocumentBENZODIAZEPINES AND HYPNOTIC ANTIPSYCHOTICS IN A PSYCHIATRIC HOSPITAL5PSQ-043
PDF DocumentCONCILIATION AND PHARMACEUTICAL CARE ON DISCHARGE IN THE PSYCHIATRIC PATIENT5PSQ-044
PDF DocumentANALYSIS OF ANTIPSYCHOTIC POLYTHERAPY IN A PSYCHIATRIC HOSPITAL5PSQ-045
PDF DocumentIMPACT OF THE COVID-19 PANDEMIC ON A NOTIFICATION AND LEARNING SYSTEM FOR PATIENT SAFETY IN A PSYCHIATRIC HOSPITAL5PSQ-046
PDF DocumentANALYSIS OF THE UNIT DOSE SYSTEM OF MEDICATION DISTRIBUTION IN MENTAL HEALTH PHARMACY5PSQ-048
PDF DocumentSTARTING POINT TO PROMOTE A POTENTIALLY INAPPROPRIATE PRESCRIPTION ASSESSMENT PROJECT5PSQ-049
PDF DocumentCOST-EFFECTIVENESS OF A PRESURGICAL PHARMACEUTICAL CARE CONSULTATION5PSQ-051
PDF DocumentINFLUENCE OF AUGMENTED RENAL CLEARANCE IN THE LOWER INCIDENCE OF LINEZOLID-RELATED HAEMATOLOGICAL TOXICITY5PSQ-053​
PDF DocumentENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH ANTIANGIOGENIC DRUGS: A RARE BUT SERIOUS COMPLICATION5PSQ-054
PDF DocumentLONG-TERM EFFECTIVENESS OF ADALIMUMAB IN SECONDLINE OF BIOLOGICAL THERAPY IN ULCERATIVE COLITIS AND INFLUENCE OF THE FIRST-LINE TREATMENT5PSQ-055
PDF DocumentLOT QUALITY ASSURANCE SAMPLING (LQAS) OF A TELEPHARMACY PROGRAMME FROM THE HOSPITAL PHARMACY TO THE OUTPATIENT THROUGH THE COMMUNITY PHARMACY5PSQ-056
PDF DocumentACTIVE PHARMACOVIGILANCE OF PATIROMER IN A CENTRAL HOSPITAL PHARMACEUTICAL CONSULTATION SETTING5PSQ-057
PDF DocumentEFFICACY AND MARGINAL COST OF TREATMENT WITH TOCILIZUMAB IN COVID-19 PATIENTS5PSQ-058
PDF DocumentCHARACTERISATION OF MEDICATION ERRORS IN A PUBLIC HOSPITAL5PSQ-059
PDF DocumentLONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE5PSQ-060​
PDF DocumentREAL CLINICAL PRACTICE RESULTS OF INTERLEUKIN23 BLOCKERS IN REFRACTORY PSORIASIS5PSQ-062
PDF DocumentPERSISTENCE OF TYROSINE KINASE INHIBITORS IN ADVANCED RENAL CELL CARCINOMA5PSQ-063
PDF DocumentINMUNOTHERAPY: RECOGNISING AND TREATING ADVERSE EFFECTS5PSQ-065
PATIENT OUTCOMES AFTER THE IMPLEMENTATION OF A HUMANISED ENHANCED RECOVERY AFTER KNEE JOINT REPLACEMENT SURGERY PROGRAMME5PSQ-066
ARE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS WELL TOLERATED BY OUR PATIENTS? A SAFETY STUDY IN REAL-WORD PRACTICE5PSQ-067​
PDF DocumentINCIDENCE OF POST-ARTESUNATE-INDUCED HAMOLYSIS AFTER SEVERE MALARIA5PSQ-068​
PDF DocumentDOES THE TREATMENT LINE HAVE AN IMPACT ON THE TOXICITY PRODUCED BY OFF-LABEL ONCOLOGICAL TREATMENTS?5PSQ-069
PDF DocumentUSEFULNESS OF PHARMACEUTICAL VALIDATION IN CHEMOTHERAPY PRESCRIPTION5PSQ-070
PDF DocumentREAL-WORLD RESULTS OF EFFECTIVENESS AND SECURITY OF ERENUMAB AND GALCANEZUMAB IN MIGRAINE PATIENTS5PSQ-071​
PDF DocumentCOVID-19 VACCINES: ADVERSE EVENTS AFTER A SECOND DOSE OF PFIZER OR ASTRAZENECA VACCINES IN HEALTHCARE WORKERS WHO RECEIVED A FIRST DOSE OF ASTRAZENECA VACCINE5PSQ-074
PDF DocumentEVALUATION AND MONITORING OF BIOCHEMICAL PARAMETERS IN PATIENTS ON PARENTERAL NUTRITION5PSQ-076
PDF DocumentBEVACIZUMAB BIOSIMILARUSE IN OPHTHALMOLOGY5PSQ-077
PDF DocumentTHROMBOEMBOLIC PROPHYLAXIS IN PATIENTS TREATED WITH ORAL IMMUNOMODULATORS IN MULTIPLE MYELOMA5PSQ-078
PDF DocumentERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING5PSQ-080
PDF DocumentIMPACT OF PHARMACY INTERVENTION ON REDUCTION OF MEDICATION-RELATED PROBLEMS IN ELDERLY PATIENTS IN A NURSING HOME5PSQ-081
PDF DocumentEFFECTIVENESS IN REAL LIFE OF BIOLOGICAL DRUGS USED IN MIGRAINE PROPHYLAXIS5PSQ-082​
PDF DocumentUSE OF ISAVUCONAZOLE IN PATIENTS WITH COVID19 IN AN INTENSIVE CARE UNIT5PSQ-083
PDF DocumentHOME DELIVERY AND TELEPHARMACY PROGRAMME: SATISFACTION OF PATIENTS5PSQ-084
PDF DocumentREAL-WORLD SAFETY AND TOLERABILITY OF PALBOCICLIB AS FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER5PSQ-085
PDF DocumentEVALUATION OF THE EFFECTIVENESS OF BEZLOTOXUMAB ON PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION5PSQ-086
PDF DocumentLONG-TERM DUAL ANTIPLATELET THERAPY: CONTROVERSY CONTINUES5PSQ-087
PDF DocumentANTI SARS-CoV-2 MONOCLONAL ANTIBODIES: FROM CLINICAL TRIAL TO REAL WORLD EVIDENCE5PSQ-088
PDF DocumentUSE OF MONOCLONAL ANTIBODIES AGAINST THE CALCITONIN GENERELATED PEPTIDE PATHWAY IN CHRONIC MIGRAINE IN CLINICAL PRACTICE5PSQ-090
PDF DocumentDALBAVANCIN ADMINISTRATION IN OUTPATIENTS TO REDUCE HOSPITAL STAY IN SELECTED PATIENTS5PSQ-091
PDF DocumentTREATMENT OF METASTATIC HER2+ BREAST CANCER: USE OF TRASTUZUMAB BIOSIMILARS IN COMBINATION WITH PERTUZUMAB5PSQ-092
PDF DocumentPERSISTENCE OF TREATMENT WITH INTERLEUKIN -17 INHIBITORS IN SKIN DISORDERS5PSQ-093
PDF DocumentREASONS FOR DISCONTINUATION OF SELECTIVE IMMUNOSUPPRESSIVE BIOLOGICAL TREATMENTS AGAINST PSORIASIS5PSQ-094
PDF DocumentCOMPARISON BETWEEN THE MAXIMUM RECOMMENDED DOSE OF AZATHIOPRINE ACCORDING TO THE ENZYMATIC ACTIVITY OF THIOPURINE METHYLTRANSFERASE AND 6-THIOGUANINE LEVELS WITH THE MAXIMUM TOLERATED DOSE5PSQ-095
PDF DocumentUSE AND PERSISTENCE OF FIRST-LINE BIOLOGICAL TREATMENTS FOR PSORIASIS5PSQ-097
PDF DocumentEXPERIENCE IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION5PSQ-098
PDF DocumentMEDICATION ERRORS IN UNIT-DOSE DRUG DISTRIBUTION SYSTEM: QUALITY CONTROL5PSQ-101